WO2007001448A2 - Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals - Google Patents

Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals Download PDF

Info

Publication number
WO2007001448A2
WO2007001448A2 PCT/US2005/040100 US2005040100W WO2007001448A2 WO 2007001448 A2 WO2007001448 A2 WO 2007001448A2 US 2005040100 W US2005040100 W US 2005040100W WO 2007001448 A2 WO2007001448 A2 WO 2007001448A2
Authority
WO
WIPO (PCT)
Prior art keywords
poly
composition
polymer
core
interactions
Prior art date
Application number
PCT/US2005/040100
Other languages
French (fr)
Other versions
WO2007001448A3 (en
Inventor
Sangyong Jon
Omid C. Farokhazd
Robert S. Langer
Jianjun Cheng
Original Assignee
Massachusetts Institute Of Technology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Massachusetts Institute Of Technology filed Critical Massachusetts Institute Of Technology
Priority to US11/666,908 priority Critical patent/US9492400B2/en
Publication of WO2007001448A2 publication Critical patent/WO2007001448A2/en
Publication of WO2007001448A3 publication Critical patent/WO2007001448A3/en
Priority to US15/349,681 priority patent/US20170112776A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin

Definitions

  • This invention pertains to drug delivery vehicles, and, more particularly, to controlled release particles coated with a mucoadhesive material.
  • the serum levels of the drug will not be continuous. Serum levels will spike shortly after administration and then tail off in a non-linear fashion. While there may be an optimal serum concentration, a patient will only experience this optimum concentration briefly, as the concentration of the drug decreases from the initial spike. While the average concentration over time may be correct, the actual serum concentration of the drug will practically always be greater or less than optimal. Another factor that tends to impede a patient's receipt of the proper quantity of a drug is patient compliance. Many patients are unwilling or unable to comply with a physician's instructions describing how often to take a drug. It is inconvenient and confusing to take several drugs at different times during the day and painful to inject protein drugs such as insulin.
  • Controlled release polymer systems can be designed to provide a drug level in the optimum range over a longer period of time than other drug delivery methods, thus increasing both the efficacy of the drug and patient compliance.
  • Biodegradable particles have been developed as sustained release vehicles used in the administration of small molecule drugs as well as protein and peptide drugs and nucleic acids (Langer, Science, 249:1527-1533, 1990; Mulligan, Science, 260:926-932, 1993; Eldridge, MoI Immunol, 28:287-294, 1991; the entire teaching of each of the foregoing references is incorporated herein by reference).
  • the drugs are typically encapsulated in a polymer matrix which is biodegradable and biocompatible. As the polymer is degraded or dissolved and/or as the drug diffuses out of the polymer, the drug is released into the body.
  • polymers used in preparing these particles are polyesters such as poly(glycolide-co-lactide) (PLGA), polyglycolic acid, poly- ⁇ -hydroxybutyrate, and polyacrylic acid ester. These particles have the additional advantage of protecting the drug from degradation by the body.
  • PLGA poly(glycolide-co-lactide)
  • polyglycolic acid polyglycolic acid
  • poly- ⁇ -hydroxybutyrate polyacrylic acid ester
  • controlled-release system that can be used for oral administration of substances that are not normally stable in the gastrointestinal tract or that are difficult to transport across the intestinal mucosa into the bloodstream.
  • Oral delivery is expected to result in enhanced patient compliance, resulting in improved clinical outcomes, largely due to ease of drug administration as compared to subcutaneous or intravenous injection.
  • An appropriate delivery system that can 1) encapsulate protein and other labile drugs, 2) protect the drugs while in transit through the gastrointestinal (GI) tract, 3) efficiently transport the drugs across the intestinal mucosa, and 4) efficiently release the drugs in the systemic circulation may result in high bioavailability of protein drugs after oral administration. Even for drugs that are stable in the GI tract, a delivery system that can transport them across the intestinal mucosa and release them directly into the bloodstream can enhance bioavailability.
  • the invention is a composition for delivering an active agent to a patient.
  • the composition includes a polymer core encapsulating a predetermined amount of the active agent and a mucoadhesive coating disposed about the core to form a coated particle.
  • the polymer includes covalently linked poly(alkylene glycol) chains.
  • the mucoadhesive coating is retained on the core through one or more of covalent interactions, electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions.
  • a molecular weight and cross-link density of the biodegradable polymer is selected such that the polymer core will decompose over a predetermined time interval.
  • the mucoadhesive coating is selected to facilitate transfer of the particle through the intestinal mucosa.
  • the fraction of the predetermined amount entering the systemic circulation during the predetermined time interval is between about 0.25% and about 25%, for example, between about 5% and about 20% or between about 10% and about 15%.
  • the composition may further include a targeting agent disposed under the mucoadhesive coating and, optionally, an intermediate layer disposed between the targeting agent and the mucoadhesive coating.
  • the intermediate layer may include a first material while the mucoadhesive coating includes a second material, and the first material and the second material may have opposing electrostatic charges at pH 2, but not at pH 7.4.
  • the intermediate layer may include a biodegradable polymer, and the targeting agent may be disposed at a surface portion of the polymer core, an interior portion of the polymer core, or both.
  • the targeting agent may be one or more of nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences, for example, RGD.
  • the core may include PEGylated poly (lactic acid).
  • the coating may be a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions.
  • the active agent may be a biomolecule, bioactive agent, small molecule, drug, protein, vaccine, or polynucleotide.
  • the poly(alkylene glycol) may be carboxylated and may be selected from poly(ethylene glycol) and poly(propylene glycol).
  • the poly(alkylene glycol) may have a molecular weight between about 100 and about 7000 Daltons, for example, between about 100 and about 1000 Daltons, between about 1000 Daltons and 3500 Daltons, between 3500 Daltons and about 7000 Daltons, or more.
  • the coating may include one or more of chitosan, poly(lysine), poly(ethylene imine), lecithin, lectin, polycarboxylic acids, poly(acrylic acids), polysaccharides, hydrogels, monosaccharides, oligosaccharides, oligopeptides, polypeptides, and copolymers of these.
  • the invention is a composition for administering an active agent to a patient.
  • the composition includes a plurality of particles, each particle including a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core to form a coated particle, and a pharmaceutically acceptable carrier combined with the plurality of particles.
  • the pharmaceutically acceptable carrier is edible or inhalable.
  • the invention is a method for administering an active agent to a patient. The method includes orally administering to the patient a composition comprising a plurality of particles. Each particle includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core to form a coated particle.
  • the composition further includes a pharmaceutically acceptable edible carrier.
  • Bioavailability refers to the rate at which and extent to which an active agent is absorbed or is otherwise available to a treatment site in the body.
  • bioavailability also depends on the extent to which the active agent is released from the polymer and/or carrier into the bloodstream.
  • Biomolecules refers to molecules (e.g., proteins, amino acids, peptides, polynucleotides, nucleotides, carbohydrates, sugars, lipids, nucleoproteins, glycoproteins, lipoproteins, steroids, etc.) whether naturally-occurring or artificially created (e.g., by synthetic or recombinant methods) that are commonly found in cells and tissues.
  • molecules e.g., proteins, amino acids, peptides, polynucleotides, nucleotides, carbohydrates, sugars, lipids, nucleoproteins, glycoproteins, lipoproteins, steroids, etc.
  • biomolecules include, but are not limited to, enzymes, receptors, neurotransmitters, hormones, cytokines, cell response modifiers such as growth factors and chemotactic factors, antibodies, vaccines, haptens, toxins, interferons, ribozymes, anti-sense agents, plasmids, DNA, and RNA.
  • Biocompatible The term “biocompatible”, as used herein is intended to describe compounds that are not toxic to cells. Compounds are “biocompatible” if their addition to cells in vitro results in less than or equal to 20 % cell death, and their administration in vivo does not induce significant inflammation or other such significant adverse effects.
  • Biodegradable As used herein, “biodegradable” polymers are polymers that degrade fully (i.e., down to monomeric species) under physiological or endosomal conditions. In preferred embodiments, the polymers and polymer biodegradation byproducts are biocompatible. Biodegradable polymers are not necessarily hydrolytically degradable and may require enzymatic action to fully degrade.
  • composition is the process by which a material is broken down under physiological conditions into components that may be metabolized by the body.
  • biodegradable polymers are degraded to monomeric species.
  • Non-biodegradable polymers may be dissolved and removed from the bloodstream by the kidneys.
  • the material or its components may be metabolized by the liver.
  • Endosomal conditions The phrase “endosomal conditions”, as used herein, relates to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered within endosomal vesicles.
  • chemical e.g., pH, ionic strength
  • biochemical e.g., enzyme concentrations
  • endosomal pH ranges from about 5.0 to 6.5.
  • physiological conditions relate to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered in the intracellular and extracellular fluids of tissues.
  • chemical e.g., pH, ionic strength
  • biochemical e.g., enzyme concentrations
  • Polynucleotide refers to a polymer of nucleotides.
  • a polynucleotide comprises at least two nucleotides. DNAs and RNAs are polynucleotides.
  • the polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2- aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5 bromouridine, C5 fluorouridine, C5 iodouridine, C5 methylcytidine, 7 deazaadenosine, 7 deazaguanosine, 8 oxoadenosine, 8 oxoguanosine, 0(6) methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g.,
  • Nucleic acids also include nucleic acid-based therapeutic agents, for example, nucleic acid ligands, siRNA, short hairpin RNA, antisense oligonucleotides, ribozymes, aptamers, and SPIEGELMERSTM, oligonucleotide ligands described in Wlotzka, et al., Proc. Nat'l. Acad. Sci. USA, 2002, 99(13):8898, the entire contents of which are incorporated herein by reference.
  • nucleic acid ligands for example, nucleic acid ligands, siRNA, short hairpin RNA, antisense oligonucleotides, ribozymes, aptamers, and SPIEGELMERSTM, oligonucleotide ligands described in Wlotzka, et al., Proc. Nat'l. Acad. Sci. USA, 2002, 99(13):8898, the entire contents of which are incorporated herein by reference
  • Polypeptide “peptide”, or “protein”: According to the present invention, a “polypeptide”, “peptide”, or “protein” comprises a string of at least three amino acids linked together by peptide bonds.
  • the terms “polypeptide”, “peptide”, and “protein”, may be used interchangeably.
  • Peptide may refer to an individual peptide or a collection of peptides. Inventive peptides preferably contain only natural amino acids, although non natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and/or amino acid analogs as are known in the art may alternatively be employed.
  • one or more of the amino acids in a peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc.
  • the modifications of the peptide lead to a more stable peptide (e.g., greater half-life in vivo). These modifications may include cyclization of the peptide, the incorporation of D-amino acids, etc. None of the modifications should substantially interfere with the desired biological activity of the peptide.
  • "Polysaccharide”, “carbohydrate” or “oligosaccharide” The terms
  • polysaccharide refers to a polymer of sugars.
  • a polysaccharide comprises at least two sugars.
  • the polymer may include natural sugars (e.g., glucose, fructose, galactose, mannose, arabinose, ribose, and xylose) and/or modified sugars (e.g., 2'-fluororibose, T- deoxyribose, and hexose).
  • “Mucoadhesive” As used herein, the term “mucoadhesive” is used to indicate that a moiety has an affinity for a component of the intestinal wall.
  • the affinity may be specific, for example, a specific affinity for a protein or sugar found in the membrane of a cell, for example, an M cell or intestinal epithelial cell, or nonspecific, for example, a tendency to non-covalently bind to the mucosa.
  • Small molecule As used herein, the term “small molecule” is used to refer to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight. In some embodiments, small molecules are monomeric and have a molecular weight of less than about 1500 g/mol. Preferred small molecules are biologically active in that they produce a local or systemic effect in animals, preferably mammals, more preferably humans. Small molecules include, but are not limited to, radionuclides and imaging agents. In certain embodiments, the small molecule is a drug. Preferably, though not necessarily, the drug is one that has already been deemed safe and effective for use by the appropriate governmental agency or body.
  • drugs for human use listed by the FDA under 21 C.F.R. ⁇ 330.5, 331 through 361, and 440 through 460; drugs for veterinary use listed by the FDA under 21 C.F.R. ⁇ 500 through 589, incorporated herein by reference, are all considered acceptable for use in accordance with the present invention.
  • Known naturally-occurring small molecules include, but are not limited to, penicillin, erythromycin, taxol, cyclosporin, and rapamycin.
  • Known synthetic small molecules include, but are not limited to, ampicillin, methicillin, sulfamethoxazole, and sulfonamides.
  • Bioactive agents As used herein, “bioactive agents” is used to refer to compounds or entities that alter, inhibit, activate, or otherwise affect biological or chemical events.
  • bioactive agents may include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants, anti-viral substances, enzyme inhibitors, including but not limited to protease and reverse transcriptase inhibitors, fusion inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, an enzyme inhibitors
  • the bioactive agent is a drug.
  • bioactive agents and specific drugs suitable for use in the present invention may be found in "Pharmaceutical Substances: Syntheses, Patents, Applications” by Axel Kleemann and Jurgen Engel, Thieme Medical Publishing, 1999; the “Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", Edited by Susan Budavari et al, CRC Press, 1996, and the United States Pharmacopeia-25/National Formulary-20, published by the United States Pharmcopeial Convention, Inc., Rockville MD, 2001, all of which are incorporated herein by reference.
  • pharmaceutically active agent refers collectively to biomolecules, small molecules, and bioactive agents.
  • Figure 1 is a schematic diagram of a particle according to an embodiment of the invention.
  • Figures 2A&B are graphs showing the transport yields of nanoparticles (A) and micorparticles (B) across monolayers of Caco-2 cells with and without a mucoadhesive coating.
  • Figures 3A&B are graphs showing the absorption yields of nanoparticles (A) and micorparticles (B) into mice.
  • Figure 4A is a graph showing the whole blood absorption of 125 I-insulin delivered to balb/C mice by PEGylated and non-PEGylated PLA nanoparticles.
  • Fibure 4B is a graph comparing the whole blood absorption of 125 I-insulin delivered to balb/C mice by PEGylated PLA nanoparticles and microparticles
  • Figure 5 is a graph illustrating the decrease in plasma glucose over time after administration of insulin encapsulated in PLA-PEG-COOH and PLGA-PEG-COOH nanoparticles.
  • Figure 6 is a graph illustrating the reduction in plasma glucose after intravenous administration of Humulin R (0.5U/kg)
  • Figure 7 is a graph illustrating the linear relationship between absorbance and plasma insulin concentration
  • Figure 8 is a graph illustrating the serum insulin concentration with respect to time after intravenous and intraperitoneal administration of Humulin-R
  • Figure 9 is a graph illustrating the serum insulin concentration with respect to time after administration of encapsulated Humulin with various surface coatings.
  • a delivery device for biopharmaceuticals and other substances that are not easily transported from the gastrointestinal tract to the circulatory system or that are not stable in the gastrointestinal tract includes a polymer encapsulating an active agent and a mucoadhesive surface.
  • the device is a plurality of microparticles or nanoparticles 10 having a core 12 in which a pharmaceutical is encapsulated by a controlled-release polymer and a mucoadhesive coating 14 disposed about the core ( Figure 1).
  • the controlled-release polymer may be biodegradable, and the coating may be biodegradable as well.
  • the coating is affixed to the core by covalent or non-covalent interactions. The coating may remain in place as the core material decomposes. Such particles may be ingested by a patient.
  • the particles may be nanoparticles, having a size between about 10 and about 1000 nm, for example, between about 10 and aboutlOO nm, between 100 and about 500 nm, or between about 500 and about 1000 nm.
  • the particles may be microparticles having a size between about 1 and about 100 micrometers, for example, between about 1 and about 10 micrometers, between about 10 and about 50 micrometers, or between about 50 and about 100 micrometers.
  • the particles adhere to the intestinal lining and gradually pass through the lining into the circulatory system, where they gradually release the active agent at a rate determined by the decomposition rate of the core.
  • the core material may also include a mucoadhesive, obviating a coating.
  • Materials for use in encapsulating pharmaceuticals for use with the invention may be biodegradable.
  • a variety of biodegradable polymers are well known to those skilled in the art.
  • Exemplary synthetic polymers suitable for use with the invention include but are not limited to poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, poly(vinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(
  • U.S. Patents that describe the use of polyanhydrides for controlled delivery of substances include U.S. Pat. No. 4,857,311 to Domb and Langer, U.S. Pat. No. 4,888,176 to Langer, et al., and U.S. Pat. No. 4,789,724 to Domb and Langer.
  • Naturally-occurring polymers such as polysaccharides and proteins, may also be employed.
  • Exemplary polysaccharides include alginate, starches, dextrans, celluloses, chitin, chitosan, hyaluronic acid and its derivatives;
  • exemplary proteins include collagen, albumin, and gelatin.
  • Polysaccharides such as starches, dextrans, and celluloses may be unmodified or may be modified physically or chemically to affect one or more of their properties such as their characteristics in the hydrated state, their solubility, or their half-life in vivo.
  • the polymer includes polyhydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), their copolymers poly(lactic-co- glycolic acid) (PLGA), and mixtures of any of these.
  • PLA polylactic acid
  • PGA polyglycolic acid
  • PLGA poly(lactic-co- glycolic acid)
  • copolymerization of PLA and PGA offers the advantage of a large spectrum of degradation rates from a few days to several years by simply varying the copolymer ratio of glycolic acid to lactic acid, which is more hydrophobic and less crystalline than PGA and degrades at a slower rate.
  • Non-biodegradable polymers may also be employed for use with the invention.
  • Exemplary non-biodegradable, yet biocompatible polymers include polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly( vinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, nonbiodegradable polyurethanes, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilmes, polythiophene, and poly(ethylene oxide), Any of the above polymers may be functionalized with a poly(alkylene glycol), for example, poly(ethylene glycol) (PEG) or poly (propyleneglycol) (PPG), or may have a particular terminal functional group, e.g., poly(lactic acid) modified to have a terminal carboxyl group.
  • PEG poly(ethylene glycol)
  • PPG
  • Exemplary PEGylated polymers include but are not limited to PEGylated ⁇ oly(lactic acid), PEGylated poly(lactic-co-glycolic acid), PEGylated poly(ca ⁇ rolactone), PEGylated poly(ortho esters), PEGylated polylysine, and PEGylated poly(ethylene imine).
  • Poly(alkylene glycols) are known to increase the bioavailability of many pharmacologically useful compounds, partly by increasing the gastrointestinal stability of derivatized compounds. Poly(alkylene glycols) chains may be as short as about 100 Daltons or have a molecular weight of about 1000, about 3000, about 5000, about 7000 Daltons, or more.
  • the poly(alkylene glycol) chain may also be modified to have a charged endgroup or other group selected to engage in a particular interaction with the coating material.
  • carboxylated PEG will engage in electrostatic interactions with positively charged coating materials such as chitosan.
  • Co-polymers, mixtures, and adducts of any of the above modified and unmodified polymers may also be employed.
  • amphiphilic block copolymers having hydrophobic regions and anionic or otherwise hydrophilic regions may be employed.
  • Block co-polymers having regions that engage in different types of non-covalent or covalent interactions may also be employed.
  • a block co-polymer may have one block that is optimized to interact with an active agent being encapsulated and another block optimized to interact with the bioadhesive coating (see below).
  • polymers may be chemically modified to have particular functional groups.
  • polymers may be functionalized with hydroxyl, amine, carboxy, maleimide, thiol, N-hydroxy- succinimide (NHS) esters, or azide groups. These groups may be used to render the polymer hydrophilic or to achieve particular interactions with coating materials as described below.
  • the molecular weight and the degree of cross-linking may be adjusted to control the decomposition rate of the polymer and thus the release rate of the pharmaceutical.
  • Methods of controlling molecular weight and cross-linking to adjust release rates are well known to those skilled in the art.
  • particles in which active agents are encapsulated are well known to those skilled in the art.
  • a double emulsion technique may be used to combine a polymer and active agent in particles.
  • particles may be prepared by spray-drying.
  • Positively charged biocompatible materials such as chitosan, poly(L-lysine), and poly(ethylene imines) are suitable for coating particles for use with the invention.
  • Lectins may also be used to coat particles. Lectins may particularly target M cells in Peyer's patches in the intestine, enhancing the affinity of the particles for the intestinal wall. Lectins are produced by a wide variety of plants; one skilled in the art will recognize that not all lectins are appropriate for use in pharmaceutical compositions. A wide variety of lectins are available from Sigma- Aldrich, which also provides information on the toxicity and mutagenicity of commercially available lectins.
  • bioadhesive materials also include, without limitation, lecithin, polycarboxylic acids, poly(acrylic acids), polysaccharides, monosaccharides, oligosaccharides, oligopeptides, polypeptides, and co-polymers of two or more mucoadhesive materials.
  • mucoadhesive or non-mucoadhesive polymers may be modified with mucoadhesive materials.
  • sugars may be covalently linked to poly aery lates.
  • Polymers having regions adapted to bind the coating to the core material and regions adapted to be mucoadhesive may also be employed.
  • a block co-polymer of a polycation and a hydrogen bond donor can be used to coat a core containing a polymer that acts as a hydrogen bond receptor.
  • Additional bioadhesive molecules that may be used with the invention include but are not limited to hydrophilic and amphiphilic polymers, hydrogels, and the polymers disclosed in U.S. Patents Nos. 6,217,908, 6,297,337; 6,514,535; and 6,284,235 the contents of which are incorporated herein by reference.
  • Bioadhesive molecules may be PEGylated or otherwise modified as described above.
  • the particles are provided with a double coating.
  • the particles may include a targeting agent that helps direct the particles to a specific tissue once they enter the blood stream.
  • exemplary targeting agents include nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences such as RGD.
  • Nucleic acid aptamers selective for a particular target may be known from the literature or may be identified using any method known to those skilled in the art, for example, the methods disclosed in U.S. Patents Nos. 5,270,163, 5,475,096, and 6,114,120, the contents of which are incorporated herein by reference.
  • Aptamers for certain tissues may also be obtained commercially, for example, from Archemix Corp. These targeting agents may be attached to the surface of the particle or may be attached to the polymer itself before the particles are formed.
  • the particles are then coated with a negatively charged material, e.g., a negatively charged polymer.
  • a negatively charged material e.g., a negatively charged polymer.
  • Exemplary polymers include carboxymethylcellulose, polyacrylic acid, polymethacrylic acid, polystyrenesulfonate, and polymers including carboxylate, sulfonate, sulfate, phosphate, or nitrate groups.
  • a positively charged mucoadhesive material is then coated over the negatively charged material.
  • the environmental pH increases from about 2-3 to about 7.4.
  • the pKa of the negative coating it may become neutrally charged, reducing its affinity for the positively charged mucoadhesive coating.
  • the negatively charged coating may also be biodegradable, for example, through hydrolysis or enzymatic mechanisms.
  • the pKa of the negatively charged coating is such that it will become neutrally charged after entering the bloodstream, the degradation of the coating will dislodge the outer mucoadhesive coating from the particle.
  • the two coatings protect both the agent being delivered and the targeting agent from degradation in the digestive system while allowing the targeting agent to be exposed at the surface of the particles after they enter the bloodstream.
  • the active agents to be incorporated in the controlled release polymer system of the present invention may be therapeutic, diagnostic, prophylactic or prognostic agents. Any chemical compound to be administered to an individual may be delivered using the conjugates of the invention.
  • the active agent may be a small molecule, organometallic compound, nucleic acid, protein, peptide, metal, an isotopically labeled chemical compound, drug, vaccine, immunological agent, etc.
  • Exemplary active agents include small molecules, biomolecules, and bioactive agents as defined herein.
  • the agents are organic compounds with pharmaceutical activity.
  • the agent is a small molecule that is a clinically used drug.
  • the drug is an antibiotic, anti-viral agent, anesthetic, steroidal agent, anti-inflammatory agent, anti-neoplastic agent, antigen, vaccine, antibody, decongestant, antihypertensive, sedative, birth control agent, progestational agent, anti-cholinergic, analgesic, anti-depressant, anti- psychotic, adrenergic blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non-steroidal anti-inflammatory agent, nutritional agent, etc. While many small molecule drugs are already available for oral administration, some are not sufficiently soluble to be orally administered and may benefit from the techniques described herein.
  • the agent is a protein drug, such as an antibody, an antibody fragment, a recombinant antibody, a recombinant protein, a purified protein, a peptide, an amino acid and combinations thereof.
  • protein drugs include but are not limited to biologically active macromolecules such as enzyme inhibitors, colony-stimulating factors, plasminogen activators, polypeptide hormones, insulin, myelin basic protein, collagen S antigen, calcitonin, angiotensin, vasopressin, desmopressin, LH-RH (luteinizing hormone-releasing hormone), somatostatin, glucagon, somatomedin, oxytocin, gastrin, secretin, h-ANP (human atrial natriuretic polypeptide), ACTH (adrenocorticotropic hormone), MSH (melanocyte stimulating hormone), beta-endorphin, muramyl dipeptide, enkephalin, neurotensin, bombesin, VIP
  • Exemplary growth factors include but are not limited to activin A (ACT), retinoic acid (RA), epidermal growth factor, bone morphogenetic protein, platelet derived growth factor, hepatocyte growth factor, insulin-like growth factors (IGF) I and II, hematopoietic growth factors, peptide growth factors, erythropoietin, angiogenic factors, anti-angiogenic factors, interleukins, tumor necrosis factors, interferons, colony stimulating factors, t-PA (tissue plasminogen activator), G-CSF (granulocyte colony stimulating factor), heparin binding growth factor (HBGF), alpha or beta transforming growth factor ( ⁇ - or ⁇ -TGF), fibroblastic growth factors, epidermal growth factor (EGF), vascular endothelium growth factor (VEGF), nerve growth factor (NGF) and muscle morphogenic factor (MMP).
  • ACT activin A
  • RA retinoic acid
  • epidermal growth factor e growth factor
  • the active agent delivered using the techniques of the invention is a nucleic acid based drug, such as DNA, RNA, modified DNA, modified RNA, antisense oligonucleotides, expression plasmid systems, nucleotides, modified nucleotides, nucleosides, modified nucleosides, nucleic acid ligands (e.g. aptamers), intact genes, a promoter complementary region, a repressor complementary region, an enhancer complementary region, and combinations thereof.
  • nucleic acid based drug such as DNA, RNA, modified DNA, modified RNA, antisense oligonucleotides, expression plasmid systems, nucleotides, modified nucleotides, nucleosides, modified nucleosides, nucleic acid ligands (e.g. aptamers), intact genes, a promoter complementary region, a repressor complementary region, an enhancer complementary region, and combinations thereof.
  • a promoter complementary region, a repressor complementary region, or an enhancer complementary region can be fully complementary or partially complementary to the DNA promoter region, repressor region, an enhancer region of a gene for which it is desirable to modulate expression. For example, it may be at least 50% complementary, at least 60% complementary, at least 70% complementary, at least 80% complementary, at least 90% complementary, or at least 95% complementary.
  • nucleic acid based drugs can be encapsulated with anionic polymers or other hydrophilic polymers that do not have cationic groups.
  • polymers modified with short poly(cytosine) tags may be used to encapsulate genetic material.
  • Other examples include but are not limited to polysebacic anhydride (PSA) and poly(lactic acid). These polymers may be modified to carry a more negative charge, for example, a terminal carboxylic acid group can be added to poly(lactic acid).
  • the controlled release polymer systems may deliver a diagnostic or prognostic agent used for long term diagnosis of a patient's health.
  • kidney function is determined by delivering an agent, such as creatinine, to the bloodstream that is cleared solely by the glomerulus and then measuring the concentration of the agent in the blood or urine over time.
  • the controlled release particles of the invention can be used to provide a steady state concentration of the clearance agent in the bloodstream for an extended period of time, and periodic assays of the concentration of the agent in the patient's urine can be used to determine the rate of clearance of the agent by the kidneys.
  • Alternative clearance agents for example, agents that are cleared from the body through other mechanisms, e.g, by the liver or through other metabolic processes, may also be encapsulated and delivered using the controlled release polymer systems described herein.
  • Prophylactic agents that can be delivered to a patient by exploiting the invention include, but are not limited to, antibiotics and nutritional supplements.
  • the techniques of the invention may be used to deliver nutrients to patients experiencing a deficiency or who are unable to produce or store such substances themselves.
  • vitamin D may be delivered to patients who are unable to synthesize it.
  • Vaccines and antigens are additional prophylactic agents that may be administered to a patient using the techniques of the invention. Some vaccines require extended exposure to the immune system to stimulate the desired immune response. Micro- or nanoparticles containing a vaccine or antigen may be suspended in a fluid or charged into a capsule and ingested, allowing patients to receive their vaccine orally instead of as an injection. A single administration of a dose of particles produced according to the invention may substitute for multiple injections or reduce the number of administrations. Of course, fast-decomposing particles may be fabricated to encapsulate vaccines that do not require extended exposure. Formulation of the vaccine as a capsule, pill, or ingestible liquid may also improve the shelf life of the vaccine, easing delivery of vaccines to rural or impoverished areas.
  • Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, dead organisms and viruses, genetically altered organisms or viruses, and cell extracts.
  • Prophylactic agents may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant, etc.
  • Prophylactic agents include antigens of such bacterial organisms as Streptococccus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans, Pseudomonas aeruginosa, Salmonella typhi, Haemophilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio cholerae, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Lepto
  • antigens may be in the form of whole killed organisms, peptides, proteins, glycoproteins, carbohydrates, or combinations thereof. While practically any bioactive agent, small molecule, or drug may benefit from the teachings herein, certain pharmaceutical compositions will find particular utility in the inventive compositions. Proteins such as insulin that are not generally stable in the gastrointestinal system may be encapsulated using the techniques of the invention. For example, diabetics could swallow a capsule containing microparticles or nanoparticles having encapsulated insulin. The particles would adhere to the mucosa and pass through the mucosal layer into the blood stream, where they would gradually release insulin. Peptides and small molecules may be delivered in the same manner. Other biomolecules involved in metabolic disorders may also be delivered using the techniques of the invention.
  • phenylalanine hydroxylase and/or tyrosine may be administered to phenylketonurics.
  • Nutritional and enzymatic supplements may be provided to patients with maple syrup urine disease.
  • the techniques of the invention may be exploited to provided enzyme replacement therapy to treat a host of metabolic diseases including but not limited to Gaucher disease, Fabry disease, Niemann-Pick disease, cystic fibrosis, mucopolysaccharidosis, Tay- Sachs disease, Hurler syndrome, many forms of muscular dystrophy, including Pompe disease, and lysosomal storage disorders (see, for example, Sly, "Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice," Mo Med. 2004 Mar-Apr;101(2):100-4; Desnick, et al, "Enzyme replacement and enhancement therapies: lessons from lysosomal disorders," Nat Rev Genet. 2003 Feb;4(2):157).
  • the compositions of the invention can reduce the frequency with which patients have to take the drug. For example, a patient could take a pill once a week or once a month instead of daily.
  • controlled release particles produced using the invention may be used to deliver contraceptive drugs to patients. Instead of taking a pill every day, the formulations of the invention may be used to provide a weekly or monthly dose regimen.
  • Estrogen replacement therapy may be administered in the same manner.
  • female reproductive hormones for example, estrogen and progesterone, may be formulated as particles using the techniques of the invention.
  • the agent to be delivered may be a mixture of agents.
  • an antibiotic may be combined with an inhibitor of the enzyme commonly produced by bacteria to inactivate the antibiotic (e.g., penicillin and clavulanic acid).
  • different active agents may be compounded into particles, and then mixtures of different particles may be combined with a delivery vehicle in specific ratios using the techniques described below to provide different combinations of active agents to patients.
  • cyclic contraceptives work by providing a different ratio of reproductive hormones to patients over the course of three weeks, simulating the manner in which the ratio of estrogen and other hormones vary over the course of a menstrual cycle. Rather than preparing particles with different ratios of estrogen and progesterone, different ratios of particles encapsulating estrogen and progesterone may be compounded into single dosage units.
  • the techniques of the invention provide improved bioavailability to the compounds delivered thereby. Less of the compound will be lost in the digestive tract than if it were delivered without the protection of the encapsulating material and the PEG tag.
  • the mucoadhesive facilitates increased transfer of the active agent across the intestinal mucosa.
  • between 0.25 and 25%, for example, between 10 and 15%, of the active agent delivered in a dosage unit can be made available to the patient through release in the bloodstream.
  • the bioavailability of the active agent may be determined using standard pharmacokinetic techniques known to those skilled in the art. For example, the concentration of the active agent in the bloodstream or of the agent or its derivatives in urine may be measured periodically and used to calculate AUC (area under the curve).
  • Coatings may be immobilized on the particles using a variety of chemical interactions.
  • positively charged coatings such as chitosan will form electrostatic bonds with negatively charged PLA or PLGA. This interaction prevents the coating from being stripped off the particle as it passes into the bloodstream.
  • negatively charged coatings may be employed with positively charged cores.
  • the electrostatic interaction allows for easy fabrication of the particles and facilitates release of the active agent.
  • Layer-by-layer deposition techniques may be used to coat the particles. For example, particles may be suspended in a solution containing the coating material, which then simply adsorbs onto the surface of the particles.
  • the coating is not a thick or tight layer but rather allows the active agent to diffuse from the polymer core into the bloodstream.
  • the coating allows enzymes to diffuse from the blood into the particle. Even though the coating can remain intact as the active agent is released, it is itself susceptible to decomposition, and the particle can be fully metabolized.
  • other non-covalent interactions may also be used to immobilize a coating. Exemplary non-covalent interactions include but are not limited to the following:
  • biotin may be attached to the surface of the controlled release polymer core and streptavidin may be attached to the coating material; or conversely, biotin may be attached to the coating material and the streptavidin may be attached to the surface of the controlled release polymer core.
  • the biotin group and streptavidin are typically attached to the controlled release polymer system or to the coating via a linker, such as an alkylene linker or a polyether linker. Biotin and streptavidin bind via affinity interactions, thereby retaining the coating on the controlled release polymer core.
  • a polyhistidine may be attached to the coating material, and a nitrilotriacetic acid can be attached to the surface of the controlled release polymer core.
  • a metal such as Ni +2 , will chelate the polyhistidine and the nitrilotriacetic acid, thereby binding the coating to the controlled release polymer core.
  • a hydrophobic tail such as polymethacrylate or an alkyl group having at least about 10 carbons
  • the hydrophobic tail will adsorb onto the surface of a hydrophobic controlled release polymer, such as a polyorthoester, polysebacic anhydride, unmodified poly(lactic acid),or polycaprolactone, thereby binding the coating to the controlled release polymer core.
  • a hydrophobic controlled release polymer such as a polyorthoester, polysebacic anhydride, unmodified poly(lactic acid),or polycaprolactone
  • a macrocyclic host such as cucurbituril or cyclodextrin
  • a guest group such as an alkyl group, a polyethylene glycol, or a diaminoalkyl group
  • the host group may be attached to the coating material and the guest group may be included in the controlled release polymer core.
  • the host and/or the guest molecule may be attached to the coating material or the controlled release polymer system via a linker, such as an alkylene linker or a polyether linker.
  • an oligonucleotide having a particular sequence may be attached to the surface of the controlled release polymer core, and an essentially complementary sequence may be attached to the coating material.
  • the coating material will then bind to the controlled release polymer core via complementary base pairing with the oligonucleotide attached to the controlled release polymer system.
  • Two oligonucleotides are essentially complimentary if about 80% of the nucleic acid bases on one oligonucleotide form hydrogen bonds via an oligonucleotide base pairing system, such as Watson-Crick base pairing, reverse Watson-Crick base pairing, Hoogsten base pairing, etc., with a base on the second oligonucleotide.
  • an oligonucleotide sequence attached to the controlled release polymer system may form at least about 6 complementary base pairs with a complementary oligonucleotide attached to the nucleic acid ligand.
  • a poly(cytosine) tag may be attached to the controlled release polymer core and a poly(guanine) tag may be attached to the coating material.
  • sugars may be used as a mucoadhesive coating. The hydroxyl groups on sugars such as glucose and galactose will hydrogen bond with polar moieties on polymers such as poly (vinyl alcohol). Sugar dimers or oligomers may be used as well.
  • the core and the coating may also be linked via covalent interactions.
  • PLGA may be modified with a carboxylate group and employed as a core material. Chitosan or another aminated coating material can be coupled to the core using a coupling reagent such as EDC or DCC.
  • PLGA may be modified to have an activated NHS ester which can then be reacted with an amine group on the coating material.
  • Either coating or core materials may be modified to include reactive groups such as hydroxyl, amine, carboxyl, maleimide, thiol, NHS ester, azide, or alkyne. Standard coupling reactions may then be used to couple the modified material to a second material having a complementary group (e.g., a carboxyl modified core coupled to an aminated coating material).
  • inventive particles may be combined with pharmaceutical acceptable carriers to form a pharmaceutical composition. While the composition may be injectable or administrable as a suppository, it is preferable that the composition be orally administrable, either through ingestion or as an inhalant. To this end, the particles produced using the techniques described herein may be sufficiently small to traverse the intestinal mucosa or the alveolar wall. Enhanced uptake may be achieved for larger particles by the use of mucoadhesive coatings, as described herein. The size of the particle may be optimized for stability and increased uptake. One skilled in the art will recognize that the optimum particle size may vary depending on the nature of the drug being delivered. The studies described below may be used to determine the optimal particle size.
  • the term "pharmaceutically acceptable carrier” means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type.
  • materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEENTM 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as
  • compositions of the invention can be administered to a patient by any means known in the art including oral and parenteral routes.
  • patient refers to humans as well as non-humans, including, for example, mammals, birds, reptiles, amphibians, and fish.
  • the non-humans are mammals (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig).
  • Non-edible compositions may be administered by injection (e.g., intravenous, subcutaneous or intramuscular, intraperitoneal injection), rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).
  • injection e.g., intravenous, subcutaneous or intramuscular, intraperitoneal injection
  • rectally rectally
  • vaginally topically
  • topically as by powders, creams, ointments, or drops
  • inhalation as by sprays.
  • Powders and sprays can contain, in addition to the inventive particles of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures thereof.
  • Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
  • compositions for oral administration can be liquid or solid.
  • Liquid dosage forms suitable for oral administration of inventive particles include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs.
  • the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof.
  • inert diluents commonly used in the art such
  • the oral compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
  • adjuvant refers to any compound which is a nonspecific modulator of the immune response.
  • the adjuvant stimulates the immune response. Any adjuvant may be used in accordance with the present invention.
  • a large number of adjuvant compounds is known in the art (Allison Dev. Biol. Stand. 92:3-11, 1998; Unkeless et al. Annu. Rev. Immunol. 6 :251 -281 , 1998 ; and Phillips et al. Vaccine 10:151- 158,1992).
  • Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
  • the encapsulated or unencapsulated particle is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example,
  • Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
  • the solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
  • the exact dosage of the inventive particle is chosen by the individual physician in view of the patient to be treated. In general, dosage and administration are adjusted to provide an effective amount of the desired active agent to the patient being treated.
  • the "effective amount" of a substance refers to the amount necessary to elicit the desired biological response.
  • the effective amount of encapsulated active agent may vary depending on such factors as the desired biological endpoint, the active agent to be delivered, the target tissue, the route of administration, etc.
  • the effective amount of inventive particles containing an anti-cancer drug might be the amount that results in a reduction in tumor size by a desired amount over a desired period of time. Additional factors which may be taken into account include the severity of the disease state; age, weight and gender of the patient being treated; diet, time and frequency of administration; drug combinations; reaction sensitivities; and tolerance/response to therapy.
  • the particles of the invention are preferably compounded with a carrier in dosage unit form for ease of administration and uniformity of dosage.
  • dosage unit form refers to a physically discrete unit of conjugate appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment.
  • the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans.
  • Therapeutic efficacy and toxicity of particle materials and the drugs delivered thereby can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED 50 (the dose is therapeutically effective in 50% of the population) and LD 50 (the dose is lethal to 50% of the population).
  • the dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD 5 o/ED 50 .
  • Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. Examples
  • Example 1 In vitro and in vivo evaluation of insulin release from nano- or microspheres with or without bioadhesive polymer coats
  • Poly(D,L-lactic acid)- ⁇ /oc£-poly(ethylene glycol)-COOH (PLA-PEG 3400 - COOH) was synthesized by ring opening polymerization with minor modifications in anhydrous toluene using stannous octoate as catalyst.
  • D,L-Lactide (1.6 g, 11.1 mmol) and COOH-PEG 3400 -OH (290 mg, 0.085 mmol) in anhydrous toluene (10 mL) containing anhydrous Na 2 SO 4 (200 mg) were heated to reflux temperature at 120 0 C, after which the polymerization was initiated by adding tin(II) 2-ethylhexanoate (20 mg, 0.049 mmol).
  • 1 H NMR (400 MHz) spectra were recorded on a Bruker instrument (Avance DPX 400).
  • Aqueous phase GPC was performed by American Polymer Standards (Mentor, OH) using Ultrahydrogels L and 120A columns in series (Waters Corporation, Milford, MA). Water (1% acetic acid, 0.3 M NaCl) was used as the eluent at a flow rate of 1.0 mL/min. Data were collected using a Knauer differential refractometer and processed using an IBM/PC GPC-PRO 3.13 software package (Viscotek Corporation, Houston, TX).
  • Drug encapsulated nanoparticles were prepared using the water-in-oil-in-water (W/O/W) solvent evaporation procedure (double emulsion method) employed elsewhere.
  • W/O/W water-in-oil-in-water
  • 50 ⁇ l of the 125 I-lableled Insulin solution (1 mg/mL in aqueous 2 wt % trehalose) was emulsified in a 1 mL solution of the polymer (PLA-COOH or PLA-PEG-COOH) (50 mg) in dichloromethane using a probe sonicator (1OW for 15- 20s).
  • Chitosan-coated nanoparticles were prepared as follows. The 125 I-Insulin encapsulated nanoparticles (1 mL, ca. 10 mg) were added dropwise to chitosan solution (10 mL, 0.2 wt% in distilled water, pH 5.5) with gentle stirring. After 10 min, the resulting suspension was then centrifuged at 10,000 rpm for 10 min. The remained nanoparticles were washed with aqueous trehalose (2% w/v, 20 mL) and finally suspended in aqueous trehalose (2% w/v, 2 mL).
  • Nanoparticles encapsulating 5 I-labeled were prepared by the procedure above, centrifuged, and then the radioactivity in the supernatant was measured by liquid scintillation analyzer (Packard Instrument Company, Downers Grove, IL). The encapsulation efficiency was calculated by the difference between the total amount of radioactivity in the initial solution and the remained amount in the supernatant. lhe nanoparticles before and after chitosan coating were characterized using several standard analytical means.
  • Samples (0.1 mL, ca. 1 mg) were diluted with 3 mL of distilled water. Particle sizes were measured at 25 °C.
  • Correlation functions were collected at a scattering angle of 90°, and particle sizes were calculated using the MAS option of the company's particle sizing software (version 2.30) under the viscosity and refractive index of pure water at 25 °C. Particle sizes expressed as effective diameters assuming a log-normal distribution.
  • Electrophoretic mobilities were measured at 25 °C using BIC PALS zeta potential analysis software, and zeta potentials were calculated using the Smoluchowsky model.
  • Surface morphology and size were characterized by high-resolution scanning electron microscopy (JEOL 6320FV). All samples were coated with 75 A Au/Pd prior to analysis.
  • Atom composition of the nanoparticles was analyzed using a Kratos AXIS Ultra Imaging X-ray Photoelectron Spectrometer with a monochromatized Al K X-ray source and a 160 mm concentric hemispherical energy analyzer for acquisition of spectra and scanned images, lateral resolution down to 20 ⁇ m. The spot size was 300 by 700 ⁇ m.
  • Table 1 summarizes the size, zeta potential, and drug encapsulation efficiency of the nanoparticles.
  • 125 Iodine-labeled insulin was encapsulated by PLA-COOH and PLA-PEG-COOH polymer system with efficiency of 65 % and 71%, respectively.
  • Both polymer particles showed large negative zeta potentials, indicating the presence of the negatively charged carboxylic acid group on the particle surface.
  • a much larger negative charge was developed on the surface of PEGylated particles compared to PLA particles. This may be attributed to the presence of the hydrophilic PEG block interposed between PLA and COOH.
  • COOH Upon exposure to aqueous media, COOH is sequestered at the particle surface.
  • Chitosan coating was carried out by simply adding the negatively charged particle ' s to chitosan solution at pH 5.5. Highly positive zeta potential values are observed after chitosan coating, suggesting successful coating of the cationic chitosan onto the negatively charged nanoparticles. As expected, there were slight increases in particle sizes after chitosan coating.
  • a chitosan layer on the particle surface was further confirmed by X-ray photoelectron spectroscopy (XPS).
  • XPS X-ray photoelectron spectroscopy
  • Table 2 High resolution XPS C(Is) composition of nanoparticles a
  • each nanoparticle (5 mg) encapsulating FITC-labeled insulin (as a model protein) was incubated at 37 °C in simulated digestive fluid (5 mL) with gentle stirring using a magnetic bar. Aliquots (33 ⁇ L) were removed at appropriate time intervals and mixed with 967 ⁇ L of lactate detection kit (0.5 mL lactate dehydrogenase, 2 vials nicotinamide adenine dinucleotide, 12 mL glycine buffer). After incubation at 37 0 C for 15 min, the absorbance of the solution was measured at 340 nm.
  • lactate detection kit 0.5 mL lactate dehydrogenase, 2 vials nicotinamide adenine dinucleotide, 12 mL glycine buffer.
  • Particle stability was determined by measuring lactate concentration in solution after neutralization using a lactate detection kit. As shown in Table 3, in gastric fluid, 3% and 2% of the PLA in PLA-COOH and PLA-PEG-COOH particles, respectively, degraded. In intestinal fluid, the degradation percentage was ca. 15% and 10%, respectively. As expected, the presence of PEG increased stability as compared to simple PLA, presumably due to the enzyme repelling properties of PEG. The chitosan coating rendered the corresponding nanoparticles more stable than the uncoated equivalents in intestinal fluid (15% versus 9% degradation for PLA-COOH and 10% versus 6% degradation for PLA-PEG-COOH nanoparticles, respectively).
  • Caco-2 cell line was purchased from the American Type Culture Collection (Manassas, VA) and grown at 37 0 C, 5% CO 2 in Dulbecco's modified Eagle's medium (DMEM), 90%; fetal bovine serum, 10%; penicillin, 100 units/mL; streptomycin, 100 ⁇ g/mL; apo-transferrin, 10 ⁇ g/mL.
  • DMEM Dulbecco's modified Eagle's medium
  • Costar transwells (12 well/plate) were obtained from Corning, Inc.
  • the Caco-2 cells were seeded at 1.7 x 10 5 cells/mL in 12 well/plate transwells (Costar, pore size of 3 ⁇ m) and grown for 12-24 days.
  • Costar transwells had a membrane insert size of 12 mm and a pore size of 3 ⁇ m, with an apical chamber volume of 0.75 mL and a basal chamber volume of 2 mL. Cells generally reached confluence within 10 days.
  • Transepithelial resistance measurements were made of monolayers and only cultures with greater than 250 ohms/cm 2 were used for experiments representing a "tight monolayer" with closed gap junctions.
  • Enhanced transport by chitosan coating may be attributed to either increased interaction of positively charged chitosan with partially negatively charged epithelial cell layers or chitosan-facilitated paracellular transport.
  • chitosan can open tight junctions
  • PEGylated polymer particles exhibited much higher (at least 60%) transport than non-PEGylated systems with and without chitosan coating. Therefore, the chitosan-coated PEGylated nanoparticle appears to have the most satisfactory transport profile in this experimental model.
  • Male BALA/c mice (10 weeks old, 22-25 g weight) were obtained from Taconic (Germantown, NY) and allowed access to food and water.
  • Half of the mice (n — 4) were sacrificed, then samples of blood (0.2 mL) were taken by cardiac puncture.
  • the absorption yield of insulin into blood was denoted as % original dose.
  • the chitosan-coated particles exhibited approximately 80% increased insulin-absorption at Ih and 40% increased absorption when measured at 6h with respect to their uncoated equivalent. Much less absorption was observed for microparticles than for nanoparticles, but they both still exhibited enhanced insulin uptake after chitosan coating. Chitosan coating of nanoparticles resulted in at least 2 times higher absorption of insulin into the blood than corresponding microparticles.
  • the absorption yield of chitosan-coated nanoparticles (14%) indicates an efficiency several times higher than reported literature values of 2- 3%.
  • Example 2 In vivo absorption of 125 I-insulin and Humulin R
  • NH 2 -PEG 500 o-COOH and HO- PEG 5000 -COOH were purchased from Nektar Therapeutics.
  • 125 I-labeled insulin was purchased from Amersham Bioscience (Piscataway, NJ, USA).
  • Chemicals purchased from Sigma/ Aldrich Chemical Co include Chitosan (minimum 85% deacetylated), poly(vinylalcohol) (PVA), and D(+)-trehalose tin(II) 2-ethylhexanoate, D,L-lactide, toluene (99.8 %, anhydrous), and lectin from Bandeiraea Simpliciforia BS-I .
  • PLA-PEG-COOH was synthesized through ring opening polymerization of DL-lactide in anhydrous toluene using stannous octoate as catalyst.
  • DL-Lactide was recrystalized with ethyl acetate p ⁇ or to polymerization (using approximately 250 niL ethyl acetate to recrystallize 50 g DL-lactide).
  • DL-lactide (15 mmol) and COOH- PEG 340 Q-OH (0.1 mmol) in anhydrous toluene (10 mL) were heated to 120 ° C under N 2 .
  • Tin(II) 2-ethylhexanoate (30 mg) was added to the solution to initiate polymerization.
  • a 50 ⁇ l solution of the 125 I-Insulin solution (1-10 ⁇ Ci/mL reconstituted in pH 7.4 PBS) was emulsified in a 1 mL dichloromethane solution of 50 mg corresponding polymer (PLA-COOH, PLA-PEG-COOH) in using a probe sonicator (Sonic & Materials Inc, Danbury, CT, USA) at 1OW for 30s.
  • a probe sonicator Sonic & Materials Inc, Danbury, CT, USA
  • Organic solvent was either rapidly removed using rotary evaporator or by stirring at room temperature for 2.5h.
  • the NPs were isolated by centrifugation at 10000 rpm for 10 min at 10 0 C, washed once with double-distilled water, and used for study immediately. The yield of NPs was between 20 and 30%.
  • Drug encapsulated MPs were prepared using the water-in-oil-in-water (W/O/W) solvent evaporation procedure (double emulsion method).
  • 50 ⁇ l of the 125 I- Insulin solution (1-10 ⁇ Ci/mL in pH 7.4 PBS) was emulsified in a 1 mL dichloromethane solution of 50 mg corresponding polymer (PLA-COOH, PLA-PEG- COOH) using a probe sonicator at 1OW for 30s.
  • Humulin R-encapsulated NPs and MPs are same as that for making 125 I-insulin-encapsulated NPs and MPs (see above) except that 50 ⁇ L of 500 U/mL Humulin R was used instead of 125 I-insulin PBS solution.
  • NPs or MPs
  • a chitosan solution (20 mL, 0.2 wt% in distilled water, pH 5). After the suspension is allowed to stand for 10 min, the resulting suspension was centrifuged at 10000 rpm for 10 min.
  • the NP (or MPs) were washed with 2% trehalose solution, centrifuged, and stored at -20 0 C.
  • the chitosan-coated NP and MPs prepared for in vivo glucose reduction were washed with water instead of trehalose solution and used immediately.
  • Lectin from Bandeiraea simplicifolia was reconstituted with DI water.
  • LMW PLGA-COOH NP (20 mg) was activated with EDC/NHS and then reacted with lectin (0.2 mg) in the presence of excess DIEA (1 mg). The suspension was stirred for 4h at room temperature. The resulting NPs were washed with water, centrifuged twice, and stored in 2 mL water at -15 0 C.
  • the loading of 125 I-insulin in NPs and MPs was determined by analyzing the solution of known amount of NPs or MPs (2 mg NPs or MPs dissolved in 1 mL acetonitrile/water with 5 mL added Hionic-Fluro cocktail) using a Liquid Scintillation Analyzer (Packard Instrument Company, Downers grove, IL).
  • the loading of Humulin R was determined by measuring the actual amount of Humulin R using a BCA protein assay (Pierce Chemical Co., Rockford, IL).
  • the 125 I-labelled insulin was encapsulated into NPs/MPs using carboxylate terminated poly(lactic acid) (PLA-COOH) or poly(lactic acid)-co-poly(ethylene glycol) (PLA-PEG-COOH) by the double emulsion method.
  • the surface of the resulting NPs/MPs were negatively charged, which facilitates use of a positively charged mucoadhesive material (e.g., chitosan) coating.
  • NPs were typically in a range of 300-400 run, while MPs were in a range of 1-10 ⁇ m. Details for the synthesis of PLA-PEG-COOH and for the preparation and characterization NPs/MPs are given above.
  • NP 125 I-Insulin Encapsulated Nanoparticles
  • MP Zeta Potential and Microparticles
  • PLA-PEG-COOH MP 1-5 ⁇ m -35.70 + 1.07
  • Mice blood 200 ⁇ L was collected and decolored 6h after administration and analyzed by liquid scintillation counter (Tri-Carb, Packard).
  • PEGylated NPs exhibited a slightly lower systemic absorption with respect to non-PEGylated NPs for both chitosan-coated (4.79% for PLA-COOH NP and 4.41% for PLA-PEG-COOH NP) and uncoated systems (4.02% for PLA-COOH NP and 3.83% for PLA-PEG-COOH NP) ( Figure 4A).
  • the detected radioactivity in blood is a combined effect of the released (both active and denatured), encapsulated and decomposed insulins. It is desirable to study the availability of the free, active insulin to evaluate the effectiveness of and to further improve the polymer particles for oral insulin delivery.
  • bioavailability was measured by measuring glucose concentrations and by quantifying released insulin in blood. Plasma glucose levels were obtained by using the Ascensia Breeze Blood Glucose Monitoring System (Bayer) following the manufacturer's protocols. Since NPs show higher in-vivo absorption than MPs ( Figure 4B), we only focused on NPs in this study.
  • Humulin R consists of zinc-insulin crystals dissolved in a clear fluid. Humulin R has nothing added to change the speed or length of its action. It takes effect rapidly and has a relatively short duration of activity (about 4 hours) as compared with other insulins. Prolonged hypoglycemia obtained from a sustained release system can be attributed to the effectiveness of drug delivery vehicle.
  • Humulin R in mouse serum can be differentiated from mouse insulin using an appropriate assay, and thus can be accurately quantified.
  • BalB/C mice weighing 23-25 g, were fasted for 12-16 h. The initial glucose level of each mouse was measured.
  • Various amounts of Humulin R NPs or MPs in 200 ⁇ L water were administrated orally using gavage needles ' .
  • Control mice were administered with 200 ⁇ L water only. The glucose level of each mouse was monitored at scheduled times. In some experiments and at scheduled times, in addition to measuring blood glucose concentration, we collected blood samples (50 ⁇ L) in heparinized tubes.
  • PLA-PEG NPs generally are not as efficacious as PLGA-PEG- COOH NPs for reducing blood glucose (Figure 5).
  • Glucose bioavailibility after administration of PLGA-PEG-COOH NPs was 1.86 ⁇ 0.86 and 2.53 ⁇ 0.62 in the 50 U/kg and 100 U/kg groups, respectively.
  • the bioavailability of glucose delivered using of PLGA-PEG-COOH was 320%-440% higher than after delivery using PLA-PEG-COOH.
  • the increased bioavailability of insulin delivered with PLGA may be due to the accelerated drug release rate compared to PLA groups (Carino, et al., Nanosphere based oral insulin delivery. Journal of Controlled Release 2000, 65, 261-269).
  • Serum (5 ⁇ L) was transferred to a micro-well and diluted with 20 ⁇ L calibrator 0 of the Mercodia insulin ELISA kit (ALPCO Diagnostics, Inc). Enzyme conjugate (100 ⁇ L) was added to each well. The mixture was incubated at room temperature for Ih on a plate shaker. The reaction medium was aspirated and washed with 5 x 350 ⁇ L Wash Buffer (provided in the kit). The TMB substrate (200 ⁇ L) of the kit was added to the well and incubated for 15 min at room temperature. After adding 50 ⁇ L Stop Solution, the UV absorbance was measured at 450 nm. Insulin concentration was determined based on a standard curve generated from known concentration of insulin standard.
  • the AUC of insulin concentration (mU/kg) vs time (hour) of the IP administered insulin was 692.29 ⁇ 272.70 ml) .hr/L. 1 he bioavailability of IP administered insulin was 29.46 ⁇ 11.60 %.
  • the bioavailabilities of insulin- PLGA-PEG-COOH NP, chitosan-coated insulin-PLGA-PEG-COOH NP, and insulin- PLGA-PEG-COOH NP-Lectin bioconjugates were 1.22 ⁇ 0.38 %, 1.49 ⁇ 0.53%, and 1.87 ⁇ 0.65%, respectively.
  • Chitosan coating and lectin conjugation of PLGA-PEG- COOH NP enhanced the bioavailability by 22% and 53%, respectively.
  • the bioavailability of the insulin-PLGA-PEG-COOH NP (1.22 %) obtained by measuring insulin concentration was 54-107% lower than that determined by measuring glucose concentrations (compared to bioavailability of 1.86% and 2.53% in Table 4).
  • COOH NP-Lectin Conjugate a Calculated based on trapezoidal treatment of the serum Humulin R concentration (mU/L) vs time (hour) for both IV, IP and oral administration groups.
  • the release of Humulin from NPs and MPs was measured by incubating aliquots containing 2-5 mg of Humulin R-containing particles in 1.0 mL of 1 x??? PBS at 37°. Measurements were conducted in triplicate. The supernatant was collected after centrifugation of the particle suspension at 14000 g for 5 min and analyzed with a BCA protein assay. The amount of Humulin R was calculated based on a standard curve generated with Humulin R stock solution (See Figure S4).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core. The polymer may include covalently linked poly(ethylene glycol) chains, and the mucoadhesive coating may be selected to facilitate transfer of the particle through the intestinal mucosa. A molecular weight and cross-link density of the polymer may be selected such that the polymer core will decompose in a predetermined time interval. The fraction of the dose of the drug entering the system at circulation during the predetermined time interval may be between about 0.25% and about 25%. The composition may be formulated as a plurality of nanoparticles or microparticles that are combined with a pharmaceutically acceptable carrier to produce an edible or inhalable drug product.

Description

Coated Controlled Release Polymer Particles as Efficient Oral Delivery
Vehicles for Biopharmaceuticals
This application claims the priority of U.S. Provisional Application No. 60/625,001, filed November 4, 2004, the entire contents of which are incorporated herein by reference.
Field of the Invention
This invention pertains to drug delivery vehicles, and, more particularly, to controlled release particles coated with a mucoadhesive material.
Background of the Invention A vast pharmacopeia is available to treat conditions ranging from the annoyance of dry skin to life-threatening diseases. Many of these remedies can be administered orally, either through ingestion or inhalation, or through the skin as a patch or ointment. Others are susceptible to enzymatic degradation by proteases and other chemicals in the gastrointestinal (GI) tract or exhibit poor permeability through the skin or intestinal epithelial cells (enterocytes). Such drugs must be administered through less convenient methods, for example, by injection.
Unless a pharmaceutical is administered continuously, for example, using an intravenous drip, the serum levels of the drug will not be continuous. Serum levels will spike shortly after administration and then tail off in a non-linear fashion. While there may be an optimal serum concentration, a patient will only experience this optimum concentration briefly, as the concentration of the drug decreases from the initial spike. While the average concentration over time may be correct, the actual serum concentration of the drug will practically always be greater or less than optimal. Another factor that tends to impede a patient's receipt of the proper quantity of a drug is patient compliance. Many patients are unwilling or unable to comply with a physician's instructions describing how often to take a drug. It is inconvenient and confusing to take several drugs at different times during the day and painful to inject protein drugs such as insulin.
The use of controlled-release formulations to provide a consistent dose of a drug to a patient has been an active area of research for decades and has been fueled by the many recent developments in polymer science and the need to deliver more labile pharmaceutical agents such as nucleic acids, proteins, and peptides. Controlled release polymer systems can be designed to provide a drug level in the optimum range over a longer period of time than other drug delivery methods, thus increasing both the efficacy of the drug and patient compliance. Biodegradable particles have been developed as sustained release vehicles used in the administration of small molecule drugs as well as protein and peptide drugs and nucleic acids (Langer, Science, 249:1527-1533, 1990; Mulligan, Science, 260:926-932, 1993; Eldridge, MoI Immunol, 28:287-294, 1991; the entire teaching of each of the foregoing references is incorporated herein by reference). The drugs are typically encapsulated in a polymer matrix which is biodegradable and biocompatible. As the polymer is degraded or dissolved and/or as the drug diffuses out of the polymer, the drug is released into the body. Typically, polymers used in preparing these particles are polyesters such as poly(glycolide-co-lactide) (PLGA), polyglycolic acid, poly-β-hydroxybutyrate, and polyacrylic acid ester. These particles have the additional advantage of protecting the drug from degradation by the body.
Still, it is desirable to have controlled-release system that can be used for oral administration of substances that are not normally stable in the gastrointestinal tract or that are difficult to transport across the intestinal mucosa into the bloodstream. Oral delivery is expected to result in enhanced patient compliance, resulting in improved clinical outcomes, largely due to ease of drug administration as compared to subcutaneous or intravenous injection. An appropriate delivery system that can 1) encapsulate protein and other labile drugs, 2) protect the drugs while in transit through the gastrointestinal (GI) tract, 3) efficiently transport the drugs across the intestinal mucosa, and 4) efficiently release the drugs in the systemic circulation may result in high bioavailability of protein drugs after oral administration. Even for drugs that are stable in the GI tract, a delivery system that can transport them across the intestinal mucosa and release them directly into the bloodstream can enhance bioavailability.
Summary of the Invention
In one aspect, the invention is a composition for delivering an active agent to a patient. The composition includes a polymer core encapsulating a predetermined amount of the active agent and a mucoadhesive coating disposed about the core to form a coated particle. The polymer includes covalently linked poly(alkylene glycol) chains. The mucoadhesive coating is retained on the core through one or more of covalent interactions, electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions. A molecular weight and cross-link density of the biodegradable polymer is selected such that the polymer core will decompose over a predetermined time interval. The mucoadhesive coating is selected to facilitate transfer of the particle through the intestinal mucosa. The fraction of the predetermined amount entering the systemic circulation during the predetermined time interval is between about 0.25% and about 25%, for example, between about 5% and about 20% or between about 10% and about 15%.
The composition may further include a targeting agent disposed under the mucoadhesive coating and, optionally, an intermediate layer disposed between the targeting agent and the mucoadhesive coating. The intermediate layer may include a first material while the mucoadhesive coating includes a second material, and the first material and the second material may have opposing electrostatic charges at pH 2, but not at pH 7.4. The intermediate layer may include a biodegradable polymer, and the targeting agent may be disposed at a surface portion of the polymer core, an interior portion of the polymer core, or both. The targeting agent may be one or more of nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences, for example, RGD.
The core may include PEGylated poly (lactic acid). The coating may be a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions. The active agent may be a biomolecule, bioactive agent, small molecule, drug, protein, vaccine, or polynucleotide. The poly(alkylene glycol) may be carboxylated and may be selected from poly(ethylene glycol) and poly(propylene glycol). The poly(alkylene glycol) may have a molecular weight between about 100 and about 7000 Daltons, for example, between about 100 and about 1000 Daltons, between about 1000 Daltons and 3500 Daltons, between 3500 Daltons and about 7000 Daltons, or more. The coating may include one or more of chitosan, poly(lysine), poly(ethylene imine), lecithin, lectin, polycarboxylic acids, poly(acrylic acids), polysaccharides, hydrogels, monosaccharides, oligosaccharides, oligopeptides, polypeptides, and copolymers of these.
In another aspect, the invention is a composition for administering an active agent to a patient. The composition includes a plurality of particles, each particle including a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core to form a coated particle, and a pharmaceutically acceptable carrier combined with the plurality of particles. The pharmaceutically acceptable carrier is edible or inhalable. In another aspect, the invention is a method for administering an active agent to a patient. The method includes orally administering to the patient a composition comprising a plurality of particles. Each particle includes a polymer core encapsulating the active agent and a mucoadhesive coating disposed about the core to form a coated particle. The composition further includes a pharmaceutically acceptable edible carrier.
Definitions
"Bioavailability": The term "bioavailability", as used herein, refers to the rate at which and extent to which an active agent is absorbed or is otherwise available to a treatment site in the body. For active agents that are encapsulated in a biodegradable polymer or pharmaceutically acceptable carrier, or both, bioavailability also depends on the extent to which the active agent is released from the polymer and/or carrier into the bloodstream.
"Biomolecules": The term "biomolecules", as used herein, refers to molecules (e.g., proteins, amino acids, peptides, polynucleotides, nucleotides, carbohydrates, sugars, lipids, nucleoproteins, glycoproteins, lipoproteins, steroids, etc.) whether naturally-occurring or artificially created (e.g., by synthetic or recombinant methods) that are commonly found in cells and tissues. Specific classes of biomolecules include, but are not limited to, enzymes, receptors, neurotransmitters, hormones, cytokines, cell response modifiers such as growth factors and chemotactic factors, antibodies, vaccines, haptens, toxins, interferons, ribozymes, anti-sense agents, plasmids, DNA, and RNA.
"Biocompatible": The term "biocompatible", as used herein is intended to describe compounds that are not toxic to cells. Compounds are "biocompatible" if their addition to cells in vitro results in less than or equal to 20 % cell death, and their administration in vivo does not induce significant inflammation or other such significant adverse effects.
"Biodegradable": As used herein, "biodegradable" polymers are polymers that degrade fully (i.e., down to monomeric species) under physiological or endosomal conditions. In preferred embodiments, the polymers and polymer biodegradation byproducts are biocompatible. Biodegradable polymers are not necessarily hydrolytically degradable and may require enzymatic action to fully degrade.
"Decomposition": As used herein, "decomposition" is the process by which a material is broken down under physiological conditions into components that may be metabolized by the body. For example, biodegradable polymers are degraded to monomeric species. Non-biodegradable polymers may be dissolved and removed from the bloodstream by the kidneys. Alternatively, the material or its components may be metabolized by the liver.
"Endosomal conditions": The phrase "endosomal conditions", as used herein, relates to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered within endosomal vesicles. For most endosomal vesicles, the endosomal pH ranges from about 5.0 to 6.5.
"Physiological conditions": The phrase "physiological conditions", as used herein, relates to the range of chemical (e.g., pH, ionic strength) and biochemical (e.g., enzyme concentrations) conditions likely to be encountered in the intracellular and extracellular fluids of tissues. For most tissues, the physiological pH ranges from about 7.0 to 7.4.
"Polynucleotide", "nucleic acid", or "oligonucleotide": The terms "polynucleotide", "nucleic acid", or "oligonucleotide" refer to a polymer of nucleotides. The terms "polynucleotide", "nucleic acid", and "oligonucleotide", may be used interchangeably. Typically, a polynucleotide comprises at least two nucleotides. DNAs and RNAs are polynucleotides. The polymer may include natural nucleosides (i.e., adenosine, thymidine, guanosine, cytidine, uridine, deoxyadenosine, deoxythymidine, deoxyguanosine, and deoxycytidine), nucleoside analogs (e.g., 2- aminoadenosine, 2-thiothymidine, inosine, pyrrolo-pyrimidine, 3-methyl adenosine, C5-propynylcytidine, C5-propynyluridine, C5 bromouridine, C5 fluorouridine, C5 iodouridine, C5 methylcytidine, 7 deazaadenosine, 7 deazaguanosine, 8 oxoadenosine, 8 oxoguanosine, 0(6) methylguanine, and 2-thiocytidine), chemically modified bases, biologically modified bases (e.g., methylated bases), intercalated bases, modified sugars (e.g., 2'-fluororibose, ribose, 2'-deoxyribose, arabinose, and hexose), or modified phosphate groups (e.g., phosphorothioates and 5'-N phosphoramidite linkages). Enantiomers of natural or modified nucleosides may also be used. Nucleic acids also include nucleic acid-based therapeutic agents, for example, nucleic acid ligands, siRNA, short hairpin RNA, antisense oligonucleotides, ribozymes, aptamers, and SPIEGELMERS™, oligonucleotide ligands described in Wlotzka, et al., Proc. Nat'l. Acad. Sci. USA, 2002, 99(13):8898, the entire contents of which are incorporated herein by reference.
"Polypeptide", "peptide", or "protein": According to the present invention, a "polypeptide", "peptide", or "protein" comprises a string of at least three amino acids linked together by peptide bonds. The terms "polypeptide", "peptide", and "protein", may be used interchangeably. Peptide may refer to an individual peptide or a collection of peptides. Inventive peptides preferably contain only natural amino acids, although non natural amino acids (i.e., compounds that do not occur in nature but that can be incorporated into a polypeptide chain) and/or amino acid analogs as are known in the art may alternatively be employed. Also, one or more of the amino acids in a peptide may be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modification, etc. In one embodiment, the modifications of the peptide lead to a more stable peptide (e.g., greater half-life in vivo). These modifications may include cyclization of the peptide, the incorporation of D-amino acids, etc. None of the modifications should substantially interfere with the desired biological activity of the peptide. "Polysaccharide", "carbohydrate" or "oligosaccharide": The terms
"polysaccharide", "carbohydrate", or "oligosaccharide" refer to a polymer of sugars. The terms "polysaccharide", "carbohydrate", and "oligosaccharide", may be used interchangeably. Typically, a polysaccharide comprises at least two sugars. The polymer may include natural sugars (e.g., glucose, fructose, galactose, mannose, arabinose, ribose, and xylose) and/or modified sugars (e.g., 2'-fluororibose, T- deoxyribose, and hexose).
"Mucoadhesive": As used herein, the term "mucoadhesive" is used to indicate that a moiety has an affinity for a component of the intestinal wall. The affinity may be specific, for example, a specific affinity for a protein or sugar found in the membrane of a cell, for example, an M cell or intestinal epithelial cell, or nonspecific, for example, a tendency to non-covalently bind to the mucosa.
"Small molecule": As used herein, the term "small molecule" is used to refer to molecules, whether naturally-occurring or artificially created (e.g., via chemical synthesis) that have a relatively low molecular weight. In some embodiments, small molecules are monomeric and have a molecular weight of less than about 1500 g/mol. Preferred small molecules are biologically active in that they produce a local or systemic effect in animals, preferably mammals, more preferably humans. Small molecules include, but are not limited to, radionuclides and imaging agents. In certain embodiments, the small molecule is a drug. Preferably, though not necessarily, the drug is one that has already been deemed safe and effective for use by the appropriate governmental agency or body. For example, drugs for human use listed by the FDA under 21 C.F.R. §§ 330.5, 331 through 361, and 440 through 460; drugs for veterinary use listed by the FDA under 21 C.F.R. §§ 500 through 589, incorporated herein by reference, are all considered acceptable for use in accordance with the present invention. Known naturally-occurring small molecules include, but are not limited to, penicillin, erythromycin, taxol, cyclosporin, and rapamycin. Known synthetic small molecules include, but are not limited to, ampicillin, methicillin, sulfamethoxazole, and sulfonamides.
"Bioactive agents": As used herein, "bioactive agents" is used to refer to compounds or entities that alter, inhibit, activate, or otherwise affect biological or chemical events. For example, bioactive agents may include, but are not limited to, anti-AIDS substances, anti-cancer substances, antibiotics, immunosuppressants, anti-viral substances, enzyme inhibitors, including but not limited to protease and reverse transcriptase inhibitors, fusion inhibitors, neurotoxins, opioids, hypnotics, anti-histamines, lubricants, tranquilizers, anti-convulsants, muscle relaxants and anti-Parkinson substances, anti-spasmodics and muscle contractants including channel blockers, miotics and anti-cholinergics, anti-glaucoma compounds, anti-parasite and/or anti-protozoal compounds, modulators of cell-extracellular matrix interactions including cell growth inhibitors and anti-adhesion molecules, vasodilating agents, inhibitors of DNA, RNA or protein synthesis, anti-hypertensives, analgesics, anti-pyretics, steroidal and non-steroidal anti-inflammatory agents, anti-angiogenic factors, anti-secretory factors, anticoagulants and/or antithrombotic agents, local anesthetics, ophthalmics, prostaglandins, anti-depressants, anti-psychotic substances, anti-emetics, and imaging agents. In a certain embodiments, the bioactive agent is a drug. A more complete listing of bioactive agents and specific drugs suitable for use in the present invention may be found in "Pharmaceutical Substances: Syntheses, Patents, Applications" by Axel Kleemann and Jurgen Engel, Thieme Medical Publishing, 1999; the "Merck Index: An Encyclopedia of Chemicals, Drugs, and Biologicals", Edited by Susan Budavari et al, CRC Press, 1996, and the United States Pharmacopeia-25/National Formulary-20, published by the United States Pharmcopeial Convention, Inc., Rockville MD, 2001, all of which are incorporated herein by reference.
As used herein, the term "pharmaceutically active agent" refers collectively to biomolecules, small molecules, and bioactive agents.
Brief Description of the Drawing
The invention is described with reference to the several figures of the drawing, in which,
Figure 1 is a schematic diagram of a particle according to an embodiment of the invention.
Figures 2A&B are graphs showing the transport yields of nanoparticles (A) and micorparticles (B) across monolayers of Caco-2 cells with and without a mucoadhesive coating.
Figures 3A&B are graphs showing the absorption yields of nanoparticles (A) and micorparticles (B) into mice.
Figure 4A is a graph showing the whole blood absorption of 125I-insulin delivered to balb/C mice by PEGylated and non-PEGylated PLA nanoparticles.
Fibure 4B is a graph comparing the whole blood absorption of 125I-insulin delivered to balb/C mice by PEGylated PLA nanoparticles and microparticles Figure 5 is a graph illustrating the decrease in plasma glucose over time after administration of insulin encapsulated in PLA-PEG-COOH and PLGA-PEG-COOH nanoparticles.
Figure 6 is a graph illustrating the reduction in plasma glucose after intravenous administration of Humulin R (0.5U/kg) Figure 7 is a graph illustrating the linear relationship between absorbance and plasma insulin concentration
Figure 8 is a graph illustrating the serum insulin concentration with respect to time after intravenous and intraperitoneal administration of Humulin-R Figure 9 is a graph illustrating the serum insulin concentration with respect to time after administration of encapsulated Humulin with various surface coatings.
Detailed Description of Certain Preferred Embodiments
A delivery device for biopharmaceuticals and other substances that are not easily transported from the gastrointestinal tract to the circulatory system or that are not stable in the gastrointestinal tract includes a polymer encapsulating an active agent and a mucoadhesive surface.
In one embodiment, the device is a plurality of microparticles or nanoparticles 10 having a core 12 in which a pharmaceutical is encapsulated by a controlled-release polymer and a mucoadhesive coating 14 disposed about the core (Figure 1). The controlled-release polymer may be biodegradable, and the coating may be biodegradable as well. The coating is affixed to the core by covalent or non-covalent interactions. The coating may remain in place as the core material decomposes. Such particles may be ingested by a patient. The particles may be nanoparticles, having a size between about 10 and about 1000 nm, for example, between about 10 and aboutlOO nm, between 100 and about 500 nm, or between about 500 and about 1000 nm. Alternatively, the particles may be microparticles having a size between about 1 and about 100 micrometers, for example, between about 1 and about 10 micrometers, between about 10 and about 50 micrometers, or between about 50 and about 100 micrometers. The particles adhere to the intestinal lining and gradually pass through the lining into the circulatory system, where they gradually release the active agent at a rate determined by the decomposition rate of the core. Alternatively, the core material may also include a mucoadhesive, obviating a coating. Encapsulation Materials
Materials for use in encapsulating pharmaceuticals for use with the invention may be biodegradable. A variety of biodegradable polymers are well known to those skilled in the art. Exemplary synthetic polymers suitable for use with the invention include but are not limited to poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, poly(vinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(ethylene imine), poly(acrylic acid), poly(maleic anhydride), biodegradable polyurethanes and polysaccharides. U.S. Patents that describe the use of polyanhydrides for controlled delivery of substances include U.S. Pat. No. 4,857,311 to Domb and Langer, U.S. Pat. No. 4,888,176 to Langer, et al., and U.S. Pat. No. 4,789,724 to Domb and Langer.
Naturally-occurring polymers, such as polysaccharides and proteins, may also be employed. Exemplary polysaccharides include alginate, starches, dextrans, celluloses, chitin, chitosan, hyaluronic acid and its derivatives; exemplary proteins include collagen, albumin, and gelatin. Polysaccharides such as starches, dextrans, and celluloses may be unmodified or may be modified physically or chemically to affect one or more of their properties such as their characteristics in the hydrated state, their solubility, or their half-life in vivo.
In other embodiments, the polymer includes polyhydroxy acids such as polylactic acid (PLA), polyglycolic acid (PGA), their copolymers poly(lactic-co- glycolic acid) (PLGA), and mixtures of any of these. These polymers are among the synthetic polymers approved for human clinical use as surgical suture materials and in controlled release devices. They are degraded by hydrolysis to products that can be metabolized and excreted. Furthermore, copolymerization of PLA and PGA offers the advantage of a large spectrum of degradation rates from a few days to several years by simply varying the copolymer ratio of glycolic acid to lactic acid, which is more hydrophobic and less crystalline than PGA and degrades at a slower rate.
Non-biodegradable polymers may also be employed for use with the invention. Exemplary non-biodegradable, yet biocompatible polymers include polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly( vinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, nonbiodegradable polyurethanes, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilmes, polythiophene, and poly(ethylene oxide), Any of the above polymers may be functionalized with a poly(alkylene glycol), for example, poly(ethylene glycol) (PEG) or poly (propyleneglycol) (PPG), or may have a particular terminal functional group, e.g., poly(lactic acid) modified to have a terminal carboxyl group. Exemplary PEGylated polymers include but are not limited to PEGylated ρoly(lactic acid), PEGylated poly(lactic-co-glycolic acid), PEGylated poly(caρrolactone), PEGylated poly(ortho esters), PEGylated polylysine, and PEGylated poly(ethylene imine). Poly(alkylene glycols) are known to increase the bioavailability of many pharmacologically useful compounds, partly by increasing the gastrointestinal stability of derivatized compounds. Poly(alkylene glycols) chains may be as short as about 100 Daltons or have a molecular weight of about 1000, about 3000, about 5000, about 7000 Daltons, or more. The poly(alkylene glycol) chain may also be modified to have a charged endgroup or other group selected to engage in a particular interaction with the coating material. For example, carboxylated PEG will engage in electrostatic interactions with positively charged coating materials such as chitosan. Co-polymers, mixtures, and adducts of any of the above modified and unmodified polymers may also be employed. For example, amphiphilic block copolymers having hydrophobic regions and anionic or otherwise hydrophilic regions may be employed. Block co-polymers having regions that engage in different types of non-covalent or covalent interactions may also be employed. For example, a block co-polymer may have one block that is optimized to interact with an active agent being encapsulated and another block optimized to interact with the bioadhesive coating (see below). Alternatively or in addition, polymers may be chemically modified to have particular functional groups. For example, polymers may be functionalized with hydroxyl, amine, carboxy, maleimide, thiol, N-hydroxy- succinimide (NHS) esters, or azide groups. These groups may be used to render the polymer hydrophilic or to achieve particular interactions with coating materials as described below.
One skilled in the art will recognize that the molecular weight and the degree of cross-linking may be adjusted to control the decomposition rate of the polymer and thus the release rate of the pharmaceutical. Methods of controlling molecular weight and cross-linking to adjust release rates are well known to those skilled in the art.
A variety of methods of making particles in which active agents are encapsulated are well known to those skilled in the art. For example, a double emulsion technique may be used to combine a polymer and active agent in particles. Alternatively, particles may be prepared by spray-drying.
Coating materials
Positively charged biocompatible materials such as chitosan, poly(L-lysine), and poly(ethylene imines) are suitable for coating particles for use with the invention. Lectins may also be used to coat particles. Lectins may particularly target M cells in Peyer's patches in the intestine, enhancing the affinity of the particles for the intestinal wall. Lectins are produced by a wide variety of plants; one skilled in the art will recognize that not all lectins are appropriate for use in pharmaceutical compositions. A wide variety of lectins are available from Sigma- Aldrich, which also provides information on the toxicity and mutagenicity of commercially available lectins. One skilled in the art will recognize that lectins that are found in commonly eaten foods are more likely to be suitable for use with embodiments of the invention. Negatively charged materials may also be employed. Exemplary bioadhesive materials also include, without limitation, lecithin, polycarboxylic acids, poly(acrylic acids), polysaccharides, monosaccharides, oligosaccharides, oligopeptides, polypeptides, and co-polymers of two or more mucoadhesive materials. Alternatively or in addition, mucoadhesive or non-mucoadhesive polymers may be modified with mucoadhesive materials. For example, sugars may be covalently linked to poly aery lates. Polymers having regions adapted to bind the coating to the core material and regions adapted to be mucoadhesive may also be employed. For example, a block co-polymer of a polycation and a hydrogen bond donor can be used to coat a core containing a polymer that acts as a hydrogen bond receptor. Additional bioadhesive molecules that may be used with the invention include but are not limited to hydrophilic and amphiphilic polymers, hydrogels, and the polymers disclosed in U.S. Patents Nos. 6,217,908, 6,297,337; 6,514,535; and 6,284,235 the contents of which are incorporated herein by reference. Bioadhesive molecules may be PEGylated or otherwise modified as described above.
One skilled in the art will recognize that excessive cross-linking of the coating material may hinder release of the active agent from the core of the particle. The skilled artisan will also recognize that the effect of cross-linking may be easily tested by measuring the release of an active agent or a labeled analog from particles coated with materials having different degrees of cross-linking.
In another embodiment, the particles are provided with a double coating. For example, the particles may include a targeting agent that helps direct the particles to a specific tissue once they enter the blood stream. Exemplary targeting agents include nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences such as RGD. Nucleic acid aptamers selective for a particular target may be known from the literature or may be identified using any method known to those skilled in the art, for example, the methods disclosed in U.S. Patents Nos. 5,270,163, 5,475,096, and 6,114,120, the contents of which are incorporated herein by reference. Aptamers for certain tissues may also be obtained commercially, for example, from Archemix Corp. These targeting agents may be attached to the surface of the particle or may be attached to the polymer itself before the particles are formed. The particles are then coated with a negatively charged material, e.g., a negatively charged polymer. Exemplary polymers include carboxymethylcellulose, polyacrylic acid, polymethacrylic acid, polystyrenesulfonate, and polymers including carboxylate, sulfonate, sulfate, phosphate, or nitrate groups. A positively charged mucoadhesive material is then coated over the negatively charged material.
After the particle crosses the intestinal wall into the bloodstream, the environmental pH increases from about 2-3 to about 7.4. Depending on the pKa of the negative coating, it may become neutrally charged, reducing its affinity for the positively charged mucoadhesive coating. As a result, the mucoadhesive coating becomes dislodged from the particle. The negatively charged coating may also be biodegradable, for example, through hydrolysis or enzymatic mechanisms. In this embodiment, whether the pKa of the negatively charged coating is such that it will become neutrally charged after entering the bloodstream, the degradation of the coating will dislodge the outer mucoadhesive coating from the particle. In any of these embodiments, the two coatings protect both the agent being delivered and the targeting agent from degradation in the digestive system while allowing the targeting agent to be exposed at the surface of the particles after they enter the bloodstream.
Pharmaceutical compositions
The active agents to be incorporated in the controlled release polymer system of the present invention may be therapeutic, diagnostic, prophylactic or prognostic agents. Any chemical compound to be administered to an individual may be delivered using the conjugates of the invention. The active agent may be a small molecule, organometallic compound, nucleic acid, protein, peptide, metal, an isotopically labeled chemical compound, drug, vaccine, immunological agent, etc. Exemplary active agents include small molecules, biomolecules, and bioactive agents as defined herein. In one embodiment, the agents are organic compounds with pharmaceutical activity. In another embodiment of the invention, the agent is a small molecule that is a clinically used drug. In exemplary embodiments, the drug is an antibiotic, anti-viral agent, anesthetic, steroidal agent, anti-inflammatory agent, anti-neoplastic agent, antigen, vaccine, antibody, decongestant, antihypertensive, sedative, birth control agent, progestational agent, anti-cholinergic, analgesic, anti-depressant, anti- psychotic, adrenergic blocking agent, diuretic, cardiovascular active agent, vasoactive agent, non-steroidal anti-inflammatory agent, nutritional agent, etc. While many small molecule drugs are already available for oral administration, some are not sufficiently soluble to be orally administered and may benefit from the techniques described herein.
In another embodiment, the agent is a protein drug, such as an antibody, an antibody fragment, a recombinant antibody, a recombinant protein, a purified protein, a peptide, an amino acid and combinations thereof. Exemplary protein drugs include but are not limited to biologically active macromolecules such as enzyme inhibitors, colony-stimulating factors, plasminogen activators, polypeptide hormones, insulin, myelin basic protein, collagen S antigen, calcitonin, angiotensin, vasopressin, desmopressin, LH-RH (luteinizing hormone-releasing hormone), somatostatin, glucagon, somatomedin, oxytocin, gastrin, secretin, h-ANP (human atrial natriuretic polypeptide), ACTH (adrenocorticotropic hormone), MSH (melanocyte stimulating hormone), beta-endorphin, muramyl dipeptide, enkephalin, neurotensin, bombesin, VIP (vasoactive intestinal peptide), CCK-8 (cholecystokinin), PTH (parathyroid hormone), CGRP (calcitonin gene related peptide), endothelin, TRH (thyroid releasing hormone), interferons, cytokines, streptokinase, urokinase, and growth factors. Exemplary growth factors include but are not limited to activin A (ACT), retinoic acid (RA), epidermal growth factor, bone morphogenetic protein, platelet derived growth factor, hepatocyte growth factor, insulin-like growth factors (IGF) I and II, hematopoietic growth factors, peptide growth factors, erythropoietin, angiogenic factors, anti-angiogenic factors, interleukins, tumor necrosis factors, interferons, colony stimulating factors, t-PA (tissue plasminogen activator), G-CSF (granulocyte colony stimulating factor), heparin binding growth factor (HBGF), alpha or beta transforming growth factor (α- or β-TGF), fibroblastic growth factors, epidermal growth factor (EGF), vascular endothelium growth factor (VEGF), nerve growth factor (NGF) and muscle morphogenic factor (MMP). Also suitable for use with the invention are recombinantly-produced derivatives of therapeutically useful proteins, including deletion, insertion and substitution variants, which on the whole have similar or comparable pharmacological properties.
Gene therapy technology may also benefit from the techniques of the invention. Genetic material is typically not stable in the GI tract. Polymer encapsulation can protect genetic material and "escort" it through the GI tract and into the bloodstream. In one embodiment, the active agent delivered using the techniques of the invention is a nucleic acid based drug, such as DNA, RNA, modified DNA, modified RNA, antisense oligonucleotides, expression plasmid systems, nucleotides, modified nucleotides, nucleosides, modified nucleosides, nucleic acid ligands (e.g. aptamers), intact genes, a promoter complementary region, a repressor complementary region, an enhancer complementary region, and combinations thereof. A promoter complementary region, a repressor complementary region, or an enhancer complementary region can be fully complementary or partially complementary to the DNA promoter region, repressor region, an enhancer region of a gene for which it is desirable to modulate expression. For example, it may be at least 50% complementary, at least 60% complementary, at least 70% complementary, at least 80% complementary, at least 90% complementary, or at least 95% complementary.
Genetic material is acidic and will form electrostatic bonds with cationic polymers. If it is desirable to avoid strong ionic interactions, nucleic acid based drugs can be encapsulated with anionic polymers or other hydrophilic polymers that do not have cationic groups. For example, polymers modified with short poly(cytosine) tags may be used to encapsulate genetic material. Other examples include but are not limited to polysebacic anhydride (PSA) and poly(lactic acid). These polymers may be modified to carry a more negative charge, for example, a terminal carboxylic acid group can be added to poly(lactic acid).
In another embodiment, the controlled release polymer systems may deliver a diagnostic or prognostic agent used for long term diagnosis of a patient's health. For example, kidney function is determined by delivering an agent, such as creatinine, to the bloodstream that is cleared solely by the glomerulus and then measuring the concentration of the agent in the blood or urine over time. The controlled release particles of the invention can be used to provide a steady state concentration of the clearance agent in the bloodstream for an extended period of time, and periodic assays of the concentration of the agent in the patient's urine can be used to determine the rate of clearance of the agent by the kidneys. Alternative clearance agents, for example, agents that are cleared from the body through other mechanisms, e.g, by the liver or through other metabolic processes, may also be encapsulated and delivered using the controlled release polymer systems described herein.
Prophylactic agents that can be delivered to a patient by exploiting the invention include, but are not limited to, antibiotics and nutritional supplements. For example, the techniques of the invention may be used to deliver nutrients to patients experiencing a deficiency or who are unable to produce or store such substances themselves. For example, vitamin D may be delivered to patients who are unable to synthesize it.
Vaccines and antigens are additional prophylactic agents that may be administered to a patient using the techniques of the invention. Some vaccines require extended exposure to the immune system to stimulate the desired immune response. Micro- or nanoparticles containing a vaccine or antigen may be suspended in a fluid or charged into a capsule and ingested, allowing patients to receive their vaccine orally instead of as an injection. A single administration of a dose of particles produced according to the invention may substitute for multiple injections or reduce the number of administrations. Of course, fast-decomposing particles may be fabricated to encapsulate vaccines that do not require extended exposure. Formulation of the vaccine as a capsule, pill, or ingestible liquid may also improve the shelf life of the vaccine, easing delivery of vaccines to rural or impoverished areas. Vaccines may comprise isolated proteins or peptides, inactivated organisms and viruses, dead organisms and viruses, genetically altered organisms or viruses, and cell extracts. Prophylactic agents may be combined with interleukins, interferon, cytokines, and adjuvants such as cholera toxin, alum, Freund's adjuvant, etc. Prophylactic agents include antigens of such bacterial organisms as Streptococccus pneumoniae, Haemophilus influenzae, Staphylococcus aureus, Streptococcus pyrogenes, Corynebacterium diphtheriae, Listeria monocytogenes, Bacillus anthracis, Clostridium tetani, Clostridium botulinum, Clostridium perfringens, Neisseria meningitidis, Neisseria gonorrhoeae, Streptococcus mutans, Pseudomonas aeruginosa, Salmonella typhi, Haemophilus parainfluenzae, Bordetella pertussis, Francisella tularensis, Yersinia pestis, Vibrio cholerae, Legionella pneumophila, Mycobacterium tuberculosis, Mycobacterium leprae, Treponema pallidum, Leptospirosis interrogans, Borrelia burgdorferi, Camphylobacter jejuni, and the like; antigens of such viruses as smallpox, influenza A and B, respiratory syncytial virus, parainfluenza, measles, HIV, varicella-zoster, herpes simplex 1 and 2, cytomegalovirus, Epstein-Barr virus, rotavirus, rhinovirus, adenovirus, papillomavirus, poliovirus, mumps, rabies, rubella, coxsackieviruses, equine encephalitis, Japanese encephalitis, yellow fever, Rift Valley fever, hepatitis A, B, C, D, and E virus, and the like; antigens of fungal, protozoan, and parasitic organisms such as Cryptococcus neoformans, Histoplasma capsulatum, Candida albicans, Candida tropicalis, Nocardia asteroides, Rickettsia ricketsii, Rickettsia typhi, Mycoplasma pneumoniae, Chlamydial psittaci, Chlamydial trachomatis, Plasmodium falciparum, Trypanosoma brucei, Entamoeba histolytica, Toxoplasma gondii, Trichomonas vaginalis, Schistosoma mansoni, and the like. These antigens may be in the form of whole killed organisms, peptides, proteins, glycoproteins, carbohydrates, or combinations thereof. While practically any bioactive agent, small molecule, or drug may benefit from the teachings herein, certain pharmaceutical compositions will find particular utility in the inventive compositions. Proteins such as insulin that are not generally stable in the gastrointestinal system may be encapsulated using the techniques of the invention. For example, diabetics could swallow a capsule containing microparticles or nanoparticles having encapsulated insulin. The particles would adhere to the mucosa and pass through the mucosal layer into the blood stream, where they would gradually release insulin. Peptides and small molecules may be delivered in the same manner. Other biomolecules involved in metabolic disorders may also be delivered using the techniques of the invention. For example, phenylalanine hydroxylase and/or tyrosine may be administered to phenylketonurics. Nutritional and enzymatic supplements may be provided to patients with maple syrup urine disease. The techniques of the invention may be exploited to provided enzyme replacement therapy to treat a host of metabolic diseases including but not limited to Gaucher disease, Fabry disease, Niemann-Pick disease, cystic fibrosis, mucopolysaccharidosis, Tay- Sachs disease, Hurler syndrome, many forms of muscular dystrophy, including Pompe disease, and lysosomal storage disorders (see, for example, Sly, "Enzyme replacement therapy for lysosomal storage disorders: successful transition from concept to clinical practice," Mo Med. 2004 Mar-Apr;101(2):100-4; Desnick, et al, "Enzyme replacement and enhancement therapies: lessons from lysosomal disorders," Nat Rev Genet. 2003 Feb;4(2):157).
For patients who take a drug every day, the compositions of the invention can reduce the frequency with which patients have to take the drug. For example, a patient could take a pill once a week or once a month instead of daily. In one embodiment, controlled release particles produced using the invention may be used to deliver contraceptive drugs to patients. Instead of taking a pill every day, the formulations of the invention may be used to provide a weekly or monthly dose regimen. Estrogen replacement therapy may be administered in the same manner. For example, female reproductive hormones, for example, estrogen and progesterone, may be formulated as particles using the techniques of the invention. In one embodiment of the present invention, the agent to be delivered may be a mixture of agents. For example, an antibiotic may be combined with an inhibitor of the enzyme commonly produced by bacteria to inactivate the antibiotic (e.g., penicillin and clavulanic acid). In one embodiment, different active agents may be compounded into particles, and then mixtures of different particles may be combined with a delivery vehicle in specific ratios using the techniques described below to provide different combinations of active agents to patients. For example, cyclic contraceptives work by providing a different ratio of reproductive hormones to patients over the course of three weeks, simulating the manner in which the ratio of estrogen and other hormones vary over the course of a menstrual cycle. Rather than preparing particles with different ratios of estrogen and progesterone, different ratios of particles encapsulating estrogen and progesterone may be compounded into single dosage units.
The techniques of the invention provide improved bioavailability to the compounds delivered thereby. Less of the compound will be lost in the digestive tract than if it were delivered without the protection of the encapsulating material and the PEG tag. The mucoadhesive facilitates increased transfer of the active agent across the intestinal mucosa. Using the techniques of the invention, between 0.25 and 25%, for example, between 10 and 15%, of the active agent delivered in a dosage unit can be made available to the patient through release in the bloodstream. The bioavailability of the active agent may be determined using standard pharmacokinetic techniques known to those skilled in the art. For example, the concentration of the active agent in the bloodstream or of the agent or its derivatives in urine may be measured periodically and used to calculate AUC (area under the curve).
Formation of a Coated Particle Coatings may be immobilized on the particles using a variety of chemical interactions. For example, positively charged coatings such as chitosan will form electrostatic bonds with negatively charged PLA or PLGA. This interaction prevents the coating from being stripped off the particle as it passes into the bloodstream. Likewise, negatively charged coatings may be employed with positively charged cores.
The electrostatic interaction allows for easy fabrication of the particles and facilitates release of the active agent. Layer-by-layer deposition techniques may be used to coat the particles. For example, particles may be suspended in a solution containing the coating material, which then simply adsorbs onto the surface of the particles. The coating is not a thick or tight layer but rather allows the active agent to diffuse from the polymer core into the bloodstream. In addition, where enzymatic action is needed to decompose the core, the coating allows enzymes to diffuse from the blood into the particle. Even though the coating can remain intact as the active agent is released, it is itself susceptible to decomposition, and the particle can be fully metabolized. In addition to electrostatic interactions, other non-covalent interactions may also be used to immobilize a coating. Exemplary non-covalent interactions include but are not limited to the following:
1) Affinity Interactions: For example, biotin may be attached to the surface of the controlled release polymer core and streptavidin may be attached to the coating material; or conversely, biotin may be attached to the coating material and the streptavidin may be attached to the surface of the controlled release polymer core. The biotin group and streptavidin are typically attached to the controlled release polymer system or to the coating via a linker, such as an alkylene linker or a polyether linker. Biotin and streptavidin bind via affinity interactions, thereby retaining the coating on the controlled release polymer core.
2) Metal Coordination: For example, a polyhistidine may be attached to the coating material, and a nitrilotriacetic acid can be attached to the surface of the controlled release polymer core. A metal, such as Ni+2, will chelate the polyhistidine and the nitrilotriacetic acid, thereby binding the coating to the controlled release polymer core.
3) Physical Adsorption: For example, a hydrophobic tail, such as polymethacrylate or an alkyl group having at least about 10 carbons, may be attached to the coating material. The hydrophobic tail will adsorb onto the surface of a hydrophobic controlled release polymer, such as a polyorthoester, polysebacic anhydride, unmodified poly(lactic acid),or polycaprolactone, thereby binding the coating to the controlled release polymer core.
4) Host-Guest Interactions: For example, a macrocyclic host, such as cucurbituril or cyclodextrin, may be attached to the controlled release polymer or the surface of the controlled release polymer core and a guest group, such as an alkyl group, a polyethylene glycol, or a diaminoalkyl group, may be attached to the coating material; or conversely, the host group may be attached to the coating material and the guest group may be included in the controlled release polymer core. In one embodiment, the host and/or the guest molecule may be attached to the coating material or the controlled release polymer system via a linker, such as an alkylene linker or a polyether linker.
5) Hydrogen Bonding Interactions: For example, an oligonucleotide having a particular sequence may be attached to the surface of the controlled release polymer core, and an essentially complementary sequence may be attached to the coating material. The coating material will then bind to the controlled release polymer core via complementary base pairing with the oligonucleotide attached to the controlled release polymer system. Two oligonucleotides are essentially complimentary if about 80% of the nucleic acid bases on one oligonucleotide form hydrogen bonds via an oligonucleotide base pairing system, such as Watson-Crick base pairing, reverse Watson-Crick base pairing, Hoogsten base pairing, etc., with a base on the second oligonucleotide. Typically, it is desirable for an oligonucleotide sequence attached to the controlled release polymer system to form at least about 6 complementary base pairs with a complementary oligonucleotide attached to the nucleic acid ligand. For example, a poly(cytosine) tag may be attached to the controlled release polymer core and a poly(guanine) tag may be attached to the coating material. Indeed, it is not necessary to only surface treat the controlled release polymer; the entire polymer may be so modified. Some of the poly-C tags will end up on the surface of the core, and others will remain in the interior portions of the particle. In another embodiment, sugars may be used as a mucoadhesive coating. The hydroxyl groups on sugars such as glucose and galactose will hydrogen bond with polar moieties on polymers such as poly (vinyl alcohol). Sugar dimers or oligomers may be used as well.
The core and the coating may also be linked via covalent interactions. For example, PLGA may be modified with a carboxylate group and employed as a core material. Chitosan or another aminated coating material can be coupled to the core using a coupling reagent such as EDC or DCC. Alternatively, PLGA may be modified to have an activated NHS ester which can then be reacted with an amine group on the coating material. Either coating or core materials may be modified to include reactive groups such as hydroxyl, amine, carboxyl, maleimide, thiol, NHS ester, azide, or alkyne. Standard coupling reactions may then be used to couple the modified material to a second material having a complementary group (e.g., a carboxyl modified core coupled to an aminated coating material).
Administration of Inventive Compositions Once the inventive particles have been prepared, they may be combined with pharmaceutical acceptable carriers to form a pharmaceutical composition. While the composition may be injectable or administrable as a suppository, it is preferable that the composition be orally administrable, either through ingestion or as an inhalant. To this end, the particles produced using the techniques described herein may be sufficiently small to traverse the intestinal mucosa or the alveolar wall. Enhanced uptake may be achieved for larger particles by the use of mucoadhesive coatings, as described herein. The size of the particle may be optimized for stability and increased uptake. One skilled in the art will recognize that the optimum particle size may vary depending on the nature of the drug being delivered. The studies described below may be used to determine the optimal particle size.
As used herein, the term "pharmaceutically acceptable carrier" means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Remington 's Pharmaceutical Sciences Ed. by Gennaro, Mack Publishing, Easton, PA, 1995, discloses various carriers used in formulating pharmaceutical compositions and known techniques for the preparation thereof. Some examples of materials which can serve as pharmaceutically acceptable carriers include, but are not limited to, sugars such as lactose, glucose, and sucrose; starches such as com starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose, and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil; safflower oil; sesame oil; olive oil; corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; detergents such as TWEEN™ 80; buffering agents such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's solution; ethyl alcohol; and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate. Coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and/or antioxidants can also be present in the composition, according to the judgment of the formulator. The pharmaceutical compositions of the invention can be administered to a patient by any means known in the art including oral and parenteral routes. The term "patient", as used herein, refers to humans as well as non-humans, including, for example, mammals, birds, reptiles, amphibians, and fish. Preferably, the non-humans are mammals (e.g., a rodent, a mouse, a rat, a rabbit, a monkey, a dog, a cat, a primate, or a pig). Non-edible compositions may be administered by injection (e.g., intravenous, subcutaneous or intramuscular, intraperitoneal injection), rectally, vaginally, topically (as by powders, creams, ointments, or drops), or by inhalation (as by sprays).
Powders and sprays can contain, in addition to the inventive particles of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates, and polyamide powder, or mixtures thereof. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Pharmaceutical compositions for oral administration can be liquid or solid. Liquid dosage forms suitable for oral administration of inventive particles include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups, and elixirs. In addition to an encapsulated or unencapsulated particle, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents. As used herein, the term "adjuvant" refers to any compound which is a nonspecific modulator of the immune response. In certain preferred embodiments, the adjuvant stimulates the immune response. Any adjuvant may be used in accordance with the present invention. A large number of adjuvant compounds is known in the art (Allison Dev. Biol. Stand. 92:3-11, 1998; Unkeless et al. Annu. Rev. Immunol. 6 :251 -281 , 1998 ; and Phillips et al. Vaccine 10:151- 158,1992).
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the encapsulated or unencapsulated particle is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or (a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, (c) humectants such as glycerol, (d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, (e) solution retarding agents such as paraffin, (f) absorption accelerators such as quaternary ammonium compounds, (g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, (h) absorbents such as kaolin and bentonite clay, and (i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets, and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art.
It will be appreciated that the exact dosage of the inventive particle is chosen by the individual physician in view of the patient to be treated. In general, dosage and administration are adjusted to provide an effective amount of the desired active agent to the patient being treated. As used herein, the "effective amount" of a substance refers to the amount necessary to elicit the desired biological response. As will be appreciated by those of ordinary skill in the art, the effective amount of encapsulated active agent may vary depending on such factors as the desired biological endpoint, the active agent to be delivered, the target tissue, the route of administration, etc. For example, the effective amount of inventive particles containing an anti-cancer drug might be the amount that results in a reduction in tumor size by a desired amount over a desired period of time. Additional factors which may be taken into account include the severity of the disease state; age, weight and gender of the patient being treated; diet, time and frequency of administration; drug combinations; reaction sensitivities; and tolerance/response to therapy.
The particles of the invention are preferably compounded with a carrier in dosage unit form for ease of administration and uniformity of dosage. The expression "dosage unit form" as used herein refers to a physically discrete unit of conjugate appropriate for the patient to be treated. It will be understood, however, that the total daily usage of the compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. For any particle composition, the therapeutically effective dose can be estimated initially either in cell culture assays or in animal models, usually mice, rabbits, dogs, or pigs. The animal model is also used to achieve a desirable concentration range and route of administration. Such information can then be used to determine useful doses and routes for administration in humans. Therapeutic efficacy and toxicity of particle materials and the drugs delivered thereby can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., ED50 (the dose is therapeutically effective in 50% of the population) and LD50 (the dose is lethal to 50% of the population). The dose ratio of toxic to therapeutic effects is the therapeutic index, and it can be expressed as the ratio, LD5o/ED50. Pharmaceutical compositions which exhibit large therapeutic indices are preferred. The data obtained from cell culture assays and animal studies is used in formulating a range of dosage for human use. Examples
Example 1: In vitro and in vivo evaluation of insulin release from nano- or microspheres with or without bioadhesive polymer coats
Encapsulation of insulin in nano- or microspheres PoIy(D ,L-lactic acid) containing carboxylic end group (PLA-COOH, inherent viscosity = 0.15 — 0.25 corresponding to 1 Ik - 25k in molecular weight) was purchased from Birmingham Polymers, Inc. (Birmingham, AL). OH-PEG3400-COOH was custom synthesized by Nektar Therapeutics (San Carlos, CA5 USA). 125I-labeled insulin was purchased from Amersham Bioscience (Piscataway, NJ, USA). Chitosan (minimum 85% deacetylated), poly(vinylalcohol) (PVA), and D(+)-trehalose were also obtained from Sigma.
Poly(D,L-lactic acid)-ό/oc£-poly(ethylene glycol)-COOH (PLA-PEG3400- COOH) was synthesized by ring opening polymerization with minor modifications in anhydrous toluene using stannous octoate as catalyst. D,L-Lactide (1.6 g, 11.1 mmol) and COOH-PEG3400-OH (290 mg, 0.085 mmol) in anhydrous toluene (10 mL) containing anhydrous Na2SO4 (200 mg) were heated to reflux temperature at 120 0C, after which the polymerization was initiated by adding tin(II) 2-ethylhexanoate (20 mg, 0.049 mmol). After stirring for 6 h with reflux, the reaction mixture was cooled to room temperature. To this solution was added cold water (10 mL), and the resulting suspension was stirred vigorously at room temperature for 30 min to hydrolyze unxeacted lactide monomers. The resulting mixture was transferred to a separation funnel containing CHCl3 (50 mL) and water (30 mL). After layer separation, the organic layer was collected, dried using anhydrous MgSO4, filtered, and concentrated under reduced vacuum. Hexane was then added to the concentrated solution to precipitate the polymer product. Pure PLA-PEG340o-COOH was collected as a white solid. PLA-PEG34OO-COOH: 1H-NMR (400 MHz), δ = 5.28-5.11 (br, -OC- CH(CH3)O- in PLA), 3.62 (s, -CH2CH2O- in PEG), 1.57-1.45 (br, -OC-CHCH5O- in PLA); molecular weight (GPC): Mn = 10500 with MvZMn = 1.54 relative to monodisperse polystyrene standards. 1H NMR (400 MHz) spectra were recorded on a Bruker instrument (Avance DPX 400). Aqueous phase GPC was performed by American Polymer Standards (Mentor, OH) using Ultrahydrogels L and 120A columns in series (Waters Corporation, Milford, MA). Water (1% acetic acid, 0.3 M NaCl) was used as the eluent at a flow rate of 1.0 mL/min. Data were collected using a Knauer differential refractometer and processed using an IBM/PC GPC-PRO 3.13 software package (Viscotek Corporation, Houston, TX).
Drug encapsulated nanoparticles were prepared using the water-in-oil-in-water (W/O/W) solvent evaporation procedure (double emulsion method) employed elsewhere. In brief, 50 μl of the 125I-lableled Insulin solution (1 mg/mL in aqueous 2 wt % trehalose) was emulsified in a 1 mL solution of the polymer (PLA-COOH or PLA-PEG-COOH) (50 mg) in dichloromethane using a probe sonicator (1OW for 15- 20s). To this emulsion was then added 3 mL of aqueous PVA (1 % w/v), and the mixture was sonicated again for 20 s (10W) using the same probe sonicator. The resulting emulsion was poured into 50 mL of aqueous PVA (0.3 % w/v) with gentle stirring, after which organic solvent was rapidly removed using rotary evaporator. Finally, the 125I-Insulin encapsulated nanoparticles were isolated by centrifugation at 10,000 rpm for 10 min, washed 2 times with water, and preserved at -15 0C as emulsion form in aqueous trehalose (2% w/v, 2 mL).
Chitosan-coated nanoparticles were prepared as follows. The 125I-Insulin encapsulated nanoparticles (1 mL, ca. 10 mg) were added dropwise to chitosan solution (10 mL, 0.2 wt% in distilled water, pH 5.5) with gentle stirring. After 10 min, the resulting suspension was then centrifuged at 10,000 rpm for 10 min. The remained nanoparticles were washed with aqueous trehalose (2% w/v, 20 mL) and finally suspended in aqueous trehalose (2% w/v, 2 mL).
Characterization of Particles
Nanoparticles encapsulating 5I-labeled were prepared by the procedure above, centrifuged, and then the radioactivity in the supernatant was measured by liquid scintillation analyzer (Packard Instrument Company, Downers Grove, IL). The encapsulation efficiency was calculated by the difference between the total amount of radioactivity in the initial solution and the remained amount in the supernatant. lhe nanoparticles before and after chitosan coating were characterized using several standard analytical means. The size of the particles and zeta-potential (surface charge) were measured by Quasi-elastic laser light scattering (QELS) using a ZetaPALS dynamic light scattering detector (Brookhaven Instruments Corporation, 15 mW laser, incident beam = 676 nm). Samples (0.1 mL, ca. 1 mg) were diluted with 3 mL of distilled water. Particle sizes were measured at 25 °C. Correlation functions were collected at a scattering angle of 90°, and particle sizes were calculated using the MAS option of the company's particle sizing software (version 2.30) under the viscosity and refractive index of pure water at 25 °C. Particle sizes expressed as effective diameters assuming a log-normal distribution. Three measurements were made on each sample and results are reported as mean diameters. Electrophoretic mobilities were measured at 25 °C using BIC PALS zeta potential analysis software, and zeta potentials were calculated using the Smoluchowsky model. Surface morphology and size were characterized by high-resolution scanning electron microscopy (JEOL 6320FV). All samples were coated with 75 A Au/Pd prior to analysis. Atom composition of the nanoparticles was analyzed using a Kratos AXIS Ultra Imaging X-ray Photoelectron Spectrometer with a monochromatized Al K X-ray source and a 160 mm concentric hemispherical energy analyzer for acquisition of spectra and scanned images, lateral resolution down to 20 μm. The spot size was 300 by 700 μm.
Table 1 summarizes the size, zeta potential, and drug encapsulation efficiency of the nanoparticles. As a model protein drug, 125Iodine-labeled insulin was encapsulated by PLA-COOH and PLA-PEG-COOH polymer system with efficiency of 65 % and 71%, respectively. Both polymer particles showed large negative zeta potentials, indicating the presence of the negatively charged carboxylic acid group on the particle surface. In particular, a much larger negative charge was developed on the surface of PEGylated particles compared to PLA particles. This may be attributed to the presence of the hydrophilic PEG block interposed between PLA and COOH. Upon exposure to aqueous media, COOH is sequestered at the particle surface. Chitosan coating was carried out by simply adding the negatively charged particle's to chitosan solution at pH 5.5. Highly positive zeta potential values are observed after chitosan coating, suggesting successful coating of the cationic chitosan onto the negatively charged nanoparticles. As expected, there were slight increases in particle sizes after chitosan coating.
Table 1 : Particle size, zeta potential, and drag encapsulation efficiency of PLA-
COOH and PLA-PEG-COOH based nanoparticles encapsulating insulin
Polymer particles Mean Size (nm)a Zeta Potential Encapsulation efficiency (%)a
PLA-COOH 275 ± 16 -35 + 3 65 ± 7
PLA-COOH/ Chitosan 310 + 19 +55 + 7
PLA-PEG-COOH 249 ± 12 -50 + 3 71 ± 8
PLA-PEG-COOH/
265 ± 22 +59 + 5 Chitosan a Mean ± SD (n = 3).
The scanning electron microscopic images of the particles are shown in Figure 1. A majority of the PLA-COOH and PLA-PEG-COOH nanoparticles are approximately 200 to 300 nm, and there was no distinct discrepancy before and after chitosan coating, in agreement with the quasi-elastic laser scattering (QELS) data.
The presence of a chitosan layer on the particle surface was further confirmed by X-ray photoelectron spectroscopy (XPS). We compared high resolution carbon (Is) intensity. PLA contains three different types of carbons, namely, -C(=0)0 carbonyl, C-O ether, and C-C carbons, whereas the PEG chain contains only C-O ether carbons. Very similarly, chitosan is also composed of mostly C-O ether carbon. Therefore, it is expected that after chitosan coating, the ratio of C-O to -C(=0)0 carbons should increase. As shown in Table 2, the value increased by approximately 35% for PLA particles and 20% for PEGylated particles, respectively. These data also indicate that chitosan is coated onto the particle surface. Table 2: High resolution XPS C(Is) composition of nanoparticlesa
Composition (%)b
Nanoparticles C-C C(=O)O C-O C-O/C(=O)O
PLA-COOH 31.1 ± 0.7 32.8 ± 0.3 36.1 ± 0.5 1.10
PLA-COOH0 30.5 + 0.4 28.0 + 0.5 41.5 ± 0.2 1.48
PLA-PEG-COOH 42.2 ± 0.8 26.5 + 0.6 31.2 + 0.7 1.18
PLA-PEG-COOH0 40.5 ± 0.4 24.6 ± 0.3 35.0 ± 0.2 1.42 a55 take-off angle was taken from surface normal. bMean ± SD. cChitosan-coated equivalent.
Evaluation of particles in simulated digestive fluid Simulated gastric fluid (pH 1.2, pepsin 0.32% w/v, sodium chloride 0.2% w/v) and intestinal fluid (pH 7.5, pancreatin 1% w/v, monobasic potassium phosphate 0.68% w/v) were prepared by referring to US Pharmacopoeia (23rd edition, 1995). Pepsin from porcine stomach mucosa and pancreatin from porcine pancreases were purchased from Sigma (St Louis, USA). Chitosan-coated and uncoated nanoparticles were incubated in each digestive solution for 4 h. Degradation of PLA was determined by measuring lactate concentration in the suspension using a lactate detection kit. Briefly, each nanoparticle (5 mg) encapsulating FITC-labeled insulin (as a model protein) was incubated at 37 °C in simulated digestive fluid (5 mL) with gentle stirring using a magnetic bar. Aliquots (33 μL) were removed at appropriate time intervals and mixed with 967 μL of lactate detection kit (0.5 mL lactate dehydrogenase, 2 vials nicotinamide adenine dinucleotide, 12 mL glycine buffer). After incubation at 37 0C for 15 min, the absorbance of the solution was measured at 340 nm.
Particle stability was determined by measuring lactate concentration in solution after neutralization using a lactate detection kit. As shown in Table 3, in gastric fluid, 3% and 2% of the PLA in PLA-COOH and PLA-PEG-COOH particles, respectively, degraded. In intestinal fluid, the degradation percentage was ca. 15% and 10%, respectively. As expected, the presence of PEG increased stability as compared to simple PLA, presumably due to the enzyme repelling properties of PEG. The chitosan coating rendered the corresponding nanoparticles more stable than the uncoated equivalents in intestinal fluid (15% versus 9% degradation for PLA-COOH and 10% versus 6% degradation for PLA-PEG-COOH nanoparticles, respectively). In addition, when the chitosan-coated PLA-PEG-COOH nanoparticles were collected and analyzed after 4 h incubation in gastric fluid, the size and zeta potential of collected nanoparticles were unchanged, suggesting the chitosan coating layer remained stable on the particle surface (data not shown). Consequently, coexistence of PEG and chitosan coating layers largely increased particle stability over PLA nanoparticles in digestive fluids.
Table 3: Stability of the nanoparticles in simulated gastric and intestinal fluids
PLA converted to lactate (%)a
Nanoparticles Gastric fluid (4 h) Intestinal fluid (4 h)
PLA-COOH 3 + 0.9 15 ± 1.3
PLA-COOHb 2 + 0.5 9 + 2.2
PLA-PEG-COOH 2 + 0.3 10 + 1.5
PLA-PEG-COOHb 2 + 1.1 6 + 0.8 aMean ± SD. bChitosan-coated equivalent.
In vitro model: determination of uptake efficiency of chitosan-coated controlled release polymer particles across human intestinal epithelial cells (Caco-2) AU manipulations involving live cells or sterile materials were performed in a laminar flow hood using standard sterile technique. The Caco-2 cell line was purchased from the American Type Culture Collection (Manassas, VA) and grown at 37 0C, 5% CO2 in Dulbecco's modified Eagle's medium (DMEM), 90%; fetal bovine serum, 10%; penicillin, 100 units/mL; streptomycin, 100 μg/mL; apo-transferrin, 10 μg/mL. Costar transwells (12 well/plate) were obtained from Corning, Inc. (Acton, MA). The Caco-2 cells were seeded at 1.7 x 105 cells/mL in 12 well/plate transwells (Costar, pore size of 3μm) and grown for 12-24 days. Costar transwells had a membrane insert size of 12 mm and a pore size of 3 μm, with an apical chamber volume of 0.75 mL and a basal chamber volume of 2 mL. Cells generally reached confluence within 10 days. Transepithelial resistance measurements were made of monolayers and only cultures with greater than 250 ohms/cm2 were used for experiments representing a "tight monolayer" with closed gap junctions. 100 μL of each nanoparticle from stock solution (ca.lO mg/mL in aqueous 2% w/v trehalose) was mixed with 400 μL of cell culture medium and then, the mixture was loaded to each apical chamber. After 12 h, the radioactivity in the basal chamber was measured using a liquid scintillation analyzer to measure the transport efficiency of the particles across the Caco-2 monolayers. The transport efficiency was denoted as % total radioactivity obtained in the basal chamber. The results are summarized in Figure 2. First, in terms of chitosan coating effect, both non-PEGylated and PEGylated nanoparticles showed approximately 40% increased transport after chitosan coating. Enhanced transport by chitosan coating may be attributed to either increased interaction of positively charged chitosan with partially negatively charged epithelial cell layers or chitosan-facilitated paracellular transport. Although the mechanism by which chitosan can open tight junctions is not clearly demonstrated to date, it is currently accepted that it opens the junction reversibly so as to facilitate paracellular transport of macromolecules. Secondly, PEGylated polymer particles exhibited much higher (at least 60%) transport than non-PEGylated systems with and without chitosan coating. Therefore, the chitosan-coated PEGylated nanoparticle appears to have the most satisfactory transport profile in this experimental model.
In vivo: absorption and biodistribution of nanoparticles in mice
Nanoparticles (0.2 mL) encapsulating 125I-labeled insulin were fed to mice (n = 8) by a gavage method. Male BALA/c mice (10 weeks old, 22-25 g weight) were obtained from Taconic (Germantown, NY) and allowed access to food and water. At Ih after oral administration, half of the mice (n — 4) were sacrificed, then samples of blood (0.2 mL) were taken by cardiac puncture. The remaining mice (n = 4) were sacrificed at 6 h post oral administration and samples of blood were taken. Some organs and tissues were harvested by necropsy. The radioactivity in blood or in tissues was measured to calculate absorption yield into the body. The results are summarized in Figure 3. The absorption yield of insulin into blood was denoted as % original dose. The chitosan-coated particles exhibited approximately 80% increased insulin-absorption at Ih and 40% increased absorption when measured at 6h with respect to their uncoated equivalent. Much less absorption was observed for microparticles than for nanoparticles, but they both still exhibited enhanced insulin uptake after chitosan coating. Chitosan coating of nanoparticles resulted in at least 2 times higher absorption of insulin into the blood than corresponding microparticles. The absorption yield of chitosan-coated nanoparticles (14%) indicates an efficiency several times higher than reported literature values of 2- 3%.
Example 2: In vivo absorption of125I-insulin and Humulin R
General
Human insulin (Humulin R, 100 U/mL and 500 VImL, 100 unit = 3.5mg Humulin R) was purchased from www.drugstore.com and used as the stock soluion. Bovine zinc insulin was purchased from Sigma. A number of different polymers used in these studies were obtained from Absorbable Polymers International (Pelham, AL): low molecular- weight (LMW) poly(DL-lactic acid) with acid terminal groups (LMW PLA-COOH, inherent viscosity (IV) 0.20 dL/g,), high molecular-weight (HMW) poly(DL-lactic acid) with acid terminal groups (HMW PLA-COOH, IV 0.45 dL/g), LMW 50/50 poly(DL-lactide-co-glycolide) with acid terminal groups (LMW PLGA- COOH, IV 0.18 dL/g), HMW 50/50 poly(DL-lactide-co-glycolide) with acid terminal groups (HMW PLGA-COOH, IV 0.76 dL/g). NH2-PEG500o-COOH and HO- PEG5000-COOH were purchased from Nektar Therapeutics. 125I-labeled insulin was purchased from Amersham Bioscience (Piscataway, NJ, USA). Chemicals purchased from Sigma/ Aldrich Chemical Co include Chitosan (minimum 85% deacetylated), poly(vinylalcohol) (PVA), and D(+)-trehalose tin(II) 2-ethylhexanoate, D,L-lactide, toluene (99.8 %, anhydrous), and lectin from Bandeiraea Simpliciforia BS-I .
Synthesis of PLA-PEG-COOH via ring-opening polymerization
PLA-PEG-COOH was synthesized through ring opening polymerization of DL-lactide in anhydrous toluene using stannous octoate as catalyst. DL-Lactide was recrystalized with ethyl acetate pήor to polymerization (using approximately 250 niL ethyl acetate to recrystallize 50 g DL-lactide). DL-lactide (15 mmol) and COOH- PEG340Q-OH (0.1 mmol) in anhydrous toluene (10 mL) were heated to 120 ° C under N2. Tin(II) 2-ethylhexanoate (30 mg) was added to the solution to initiate polymerization. After stirring for 6-8h under N2 at 120 0C, the reaction mixture was cooled to room temperature and poured to cold methanol (60 mL). The precipitate was washed with methanol and dried under vacuum (yield 62%). 1H NMR (400 MHz) δ = 5.20 (m, -OC-CH(CH3)O-), 3.55 (s, -CH2CH2O-), 1.57-1.45 (br, -OC- CHCH3O-).
Synthesis of PLGA-PEG-COOH (or PLA-PEG-COOH) via conjugation methods
ΗMW DL-PLGA-COOΗ (0.99g) was dissolved in anhydrous methylene chloride (5 mL). N-Ηydroxysuccinimide (NΗS) (23 mg) and l-Ethyl-3-(3- dimethylaminopropyl)-carbodiimide (EDC) (42 mg) were added to the solution. After 3h solution was poured into 25 mL cold MeOH. The precipitate was washed with 3 χ25 mL MeOH and dried under vacuum (yield 100%). The white solid (335 mg) obtained was re-dissolved in chloroform (3.35 mL). A chloroform solution of NH2-PEG5OOO-COOH (32.5 mg in 320 μL chloroform) was added dropwisely to the activated PLGA solution. Diisopropylethylamine (DIEA, 3 eq., 2.52 mg) was added the mixtures. The solution was stirred under N2 overnight. The resulting PLGA- PEG-COOH was precipitated with cold MeOH and dried under vacuum (yield 95%). 1H NMR (400 MHz) δ = 5.18 (m, -OC-CH(CH3)O-), 4.79 (m, -OC-CH2O-), 3.61 (s, - CH2CH2O-), 3.41 (s, -CH2CH2O-), 1.56 (br, -OC-CHCH5O-). Preparation ofU3I-insulin~encapsulated nanoparticles (NPs) Drug encapsulated NPs were prepared using the water-in-oil-in-water (W/O/W) solvent evaporation procedure (double emulsion method). A 50 μl solution of the 125I-Insulin solution (1-10 μCi/mL reconstituted in pH 7.4 PBS) was emulsified in a 1 mL dichloromethane solution of 50 mg corresponding polymer (PLA-COOH, PLA-PEG-COOH) in using a probe sonicator (Sonic & Materials Inc, Danbury, CT, USA) at 1OW for 30s. To this emulsion was then added 3 mL of aqueous PVA (MW = 30-70 kDa, 1 % w/v) and the mixture was sonicated for 30s using the same probe sonicator at 1OW. The resulting emulsion was immediately poured into 50 mL of aqueous PVA (MW = 30-70 kDa, 0.3 % w/v) with gentle stirring. Organic solvent was either rapidly removed using rotary evaporator or by stirring at room temperature for 2.5h. The NPs were isolated by centrifugation at 10000 rpm for 10 min at 10 0C, washed once with double-distilled water, and used for study immediately. The yield of NPs was between 20 and 30%.
Preparation of125I-insulin-encapsulated microparticles (MPs)
Drug encapsulated MPs were prepared using the water-in-oil-in-water (W/O/W) solvent evaporation procedure (double emulsion method). 50 μl of the 125I- Insulin solution (1-10 μCi/mL in pH 7.4 PBS) was emulsified in a 1 mL dichloromethane solution of 50 mg corresponding polymer (PLA-COOH, PLA-PEG- COOH) using a probe sonicator at 1OW for 30s. The first emulsion was transferred to 50 mL of aqueous PVA (MW = 30-70 kDa, 1 % w/v) and homogenized at 8000 rpm for 1 minute. The resulting emulsion was immediately poured into 200 mL of aqueous PVA solution (MW = 30-70 kDa, 0.3 % w/v) with gentle stirring. Organic solvent was removed using rotary evaporator or by stirring at room temperature for 2.5h. The MPs were isolated by centrifugation at 10000 rpm for 10 min at 1O0C, washed once with double-distilled water, and lyophilized. The yield of MPs was between 60-80%. Preparation ofHumulin R-encapsulated NPs and MPs
The procedures for making Humulin R-encapsulated NPs and MPs are same as that for making 125I-insulin-encapsulated NPs and MPs (see above) except that 50μL of 500 U/mL Humulin R was used instead of 125I-insulin PBS solution.
Chitosan coating of NP and MPs
To a suspension of NPs (or MPs) (15-30 mg in 1 mL water) was added a chitosan solution (20 mL, 0.2 wt% in distilled water, pH 5). After the suspension is allowed to stand for 10 min, the resulting suspension was centrifuged at 10000 rpm for 10 min. The NP (or MPs) were washed with 2% trehalose solution, centrifuged, and stored at -20 0C. The chitosan-coated NP and MPs prepared for in vivo glucose reduction were washed with water instead of trehalose solution and used immediately.
NP modified with lectin
Lectin from Bandeiraea simplicifolia (Sigma) was reconstituted with DI water. LMW PLGA-COOH NP (20 mg) was activated with EDC/NHS and then reacted with lectin (0.2 mg) in the presence of excess DIEA (1 mg). The suspension was stirred for 4h at room temperature. The resulting NPs were washed with water, centrifuged twice, and stored in 2 mL water at -15 0C.
Characterization of the NPs and MPs
The size of the NPs and the zeta-potential of NPs and MPs were measured by Quasi-elastic laser light scattering (QELS) using a ZetaPALS dynamic light scattering detector (Brookhaven Instruments Corporation, 15 mW laser, incident beam = 676 nm). Particle sizes were measured at room temperature at a concentration of 0.5-1 mg/mL water. Three to five measurements were made on each sample. Results are reported as mean diameters. Electrophoretic mobilities were measured at 25 0C using BIC PALS zeta potential analysis software, and zeta potentials were calculated using the Smoluchowsky model. Surface morphology and size were characterized by scanning electron microscopy. Determination of drug loading
The loading of 125I-insulin in NPs and MPs was determined by analyzing the solution of known amount of NPs or MPs (2 mg NPs or MPs dissolved in 1 mL acetonitrile/water with 5 mL added Hionic-Fluro cocktail) using a Liquid Scintillation Analyzer (Packard Instrument Company, Downers grove, IL). The loading of Humulin R was determined by measuring the actual amount of Humulin R using a BCA protein assay (Pierce Chemical Co., Rockford, IL). Briefly, aliquots containing known amounts of particles (5-10 mg) dissolved in 2 ml Of CH2Cl2 were extracted with 2 ml buffer (1 x phosphate-buffered saline (PBS) and 0.05% sodium dodecyl sulfate (SDS)). Humulin R in buffer solution was quantified using BCA assay (Pierce) in triplicate.
In-vivo absorption of125I-insulin encapsulated PLA-based NPs and MPs
The 125I-labelled insulin was encapsulated into NPs/MPs using carboxylate terminated poly(lactic acid) (PLA-COOH) or poly(lactic acid)-co-poly(ethylene glycol) (PLA-PEG-COOH) by the double emulsion method. The surface of the resulting NPs/MPs were negatively charged, which facilitates use of a positively charged mucoadhesive material (e.g., chitosan) coating. NPs were typically in a range of 300-400 run, while MPs were in a range of 1-10 μm. Details for the synthesis of PLA-PEG-COOH and for the preparation and characterization NPs/MPs are given above.
125I-Insulin encapsulated PLA or PLA-PEG NPs and MPs (Table 3) were administered to mice (n = 4) orally by gavage. Each animal received 0.2 mL of the NP or MP suspension (approximately 0.2-0.5 μCi). Mice were euthanized at 6h by CO2 inhalation. Blood (200 μL) from each mouse was collected immediately in a glass scintillation vial by cardiac puncture. The blood was treated with 0.4 mL Solvable for Ih at 55 0C. Sample color turned into green. EDTA-di-sodium salt solution (0.04 mL) was added, followed by dropwise addition of 30% hydrogen peroxide (0.15 mL). The solution was allowed to stand for 15 to 30 minutes at room temperature to complete the reaction. The vial was incubated again at 55 - 60 0C for one hour. The color changed from green to pale yellow. After solution was cooled to room .temperature for about Ih, Hionic-Fluor (5 mL) was added to the mixture. The solution was then analyzed on a Liquid Scintillation Counter (Packard, IL). Table 3. Nanoparticle and Microparticle Characterization
125I-Insulin Encapsulated Nanoparticles (NP) Particle size Zeta Potential and Microparticles (MP) (nm)
PLA-COOH NP 332 + 2.5 -28.42 + 2.21
PLA-PEG-COOH NP 375 ± 6.2 -37.49 + 1.73
PLA-COOH NP/Chitosan 405 ± 18.6 53.06 ± 0.77
PLA-PEG-COOH NP/Chitosan 415 + 13.8 57.33 ± 0.90
PLA-PEG-COOH MP 1-5 μm -35.70 + 1.07
NPs/MPs (Table 3) were administered to Balb/C mice (average 25 g, N = 4) by oral gavage at 0.2-0.5 μCi per mouse. Mice blood (200 μL) was collected and decolored 6h after administration and analyzed by liquid scintillation counter (Tri-Carb, Packard). PEGylated NPs exhibited a slightly lower systemic absorption with respect to non-PEGylated NPs for both chitosan-coated (4.79% for PLA-COOH NP and 4.41% for PLA-PEG-COOH NP) and uncoated systems (4.02% for PLA-COOH NP and 3.83% for PLA-PEG-COOH NP) (Figure 4A). The absorption of NPs coated with chitosan was enhanced with respect to equivalent NPs without chitosan. The absorption of PLA-PEG-COOH NPs was increased by 133% as compared to PLA- PEG-COOH MPs (Figure 4B). This in-vivo absorption study showed that particle size significantly affects the absorption efficiency and smaller particles can be absorbed more efficiently.
Release of insulin from PLA-PEG-COOH and P LGA-P EG-COOH particles In the previous set of experiments we measured the amount of radioactivity (125I insulin encapsulated particles) in the plasma. However, we did not differentiate between released insulin and insulin that remained encapsulated. Since only the released insulin is therapeutically effective, it is desirable to evaluate the insulin release rate from particles prepared from various polymers. In this set of studies, we used particles generated from the PLA-PEG-COOH as before, in addition to particles generated from a poly(DL-lactide-co-glycolide)-PEG-COOH (PLGA-PEG-COOH) polymer system (the latter is expected to have a faster release kinetics). We studied the release of insulin from uncoated and chitosan-coated PLA-PEG-COOH or PLGA- PEG-COOH particles in PBS. 68% of insulin was released from uncoated PLGA- PEG-COOH NPs within 4h, while about 42% of insulin was released from uncoated PLA-PEG-COOH NPs. The insulin release rate from particles with chitosan surface- coatings was reduced by 10-15% in both the PLA-PEG-COOH and PLGA-PEG- COOH systems.
Oral efficacy ofHumulin R Encapsulated PLA-PEG-COOH and PLGA-PEG-
COOH Nanoparticles
The detected radioactivity in blood is a combined effect of the released (both active and denatured), encapsulated and decomposed insulins. It is desirable to study the availability of the free, active insulin to evaluate the effectiveness of and to further improve the polymer particles for oral insulin delivery. We determined bioavailability by measuring glucose concentrations and by quantifying released insulin in blood. Plasma glucose levels were obtained by using the Ascensia Breeze Blood Glucose Monitoring System (Bayer) following the manufacturer's protocols. Since NPs show higher in-vivo absorption than MPs (Figure 4B), we only focused on NPs in this study.
We chose Humulin R because:
1. Humulin R consists of zinc-insulin crystals dissolved in a clear fluid. Humulin R has nothing added to change the speed or length of its action. It takes effect rapidly and has a relatively short duration of activity (about 4 hours) as compared with other insulins. Prolonged hypoglycemia obtained from a sustained release system can be attributed to the effectiveness of drug delivery vehicle.
2. Humulin R in mouse serum can be differentiated from mouse insulin using an appropriate assay, and thus can be accurately quantified. We first chose to study the response of glucose concentration to the orally administered, Humulin R-encapsulated polymer NPs. BalB/C mice, weighing 23-25 g, were fasted for 12-16 h. The initial glucose level of each mouse was measured. Four mice were assigned to a group such that the mean values of the glucose concentrations of each group were roughly equal. Various amounts of Humulin R NPs or MPs in 200 μL water were administrated orally using gavage needles'. Control mice were administered with 200 μL water only. The glucose level of each mouse was monitored at scheduled times. In some experiments and at scheduled times, in addition to measuring blood glucose concentration, we collected blood samples (50 μL) in heparinized tubes.
We found that PLA-PEG NPs generally are not as efficacious as PLGA-PEG- COOH NPs for reducing blood glucose (Figure 5). PLGA-PEG-COOH NPs administered at 100 U/mg reduced glucose levels by 48.7 ± 12.9%, compared to 24.0 ± 5.93% after administration of the same dose using PLA-PEG-COOH NPs. Administration of PLGA-PEG-COOH and PLA-PEG-COOH NPs at 50 U/kg reduced serum glucose by 36.2 ± 7.5% and 16.7 ± 9.3%, respectively (Figure 5). The lowest glucose levels were observed 4 hours after administration in all tested groups except for the 50 U/kg dosed PLGA-PEG-COOH NP group, in which the lowest glucose level occurred 6 hours after administration. To determine the bioavailability, we measured the glucose concentrations after tail-vein intravenous (IV) administration of Humulin R alone at 0.5 U/kg (25-50 μL total, n=4) (Figure 6). A rapid decrease of glucose concentration was observed during the first hour, and the lowest glucose level was detected at t = 1 hour with a decrease of 45.4 ± 12.2%. The glucose concentration returned to the original level after 5 hours (Figure 6). Based on the percent of glucose level deviation from the fasting blood glucose level for the challenged mice (see Figure 6 for the Humulin IV administration group), we calculated the area under the curve (AUC) for the percent of the decreased blood glucose (%) vs time (hour) using the trapezoidal method for both IV and oral administration groups (Table 4). Glucose bioavailibility after the oral administration of Humulin encapsulated in PLA-PEG-COOH NPs was 0.34 ± 0.43 and 0.58 ± 0.28 for the 50 U/kg and 100 U/kg groups, respectively. Glucose bioavailibility after administration of PLGA-PEG-COOH NPs, however, was 1.86 ± 0.86 and 2.53 ± 0.62 in the 50 U/kg and 100 U/kg groups, respectively. Thus, the bioavailability of glucose delivered using of PLGA-PEG-COOH was 320%-440% higher than after delivery using PLA-PEG-COOH. Without being limited by any particular hypothesis, the increased bioavailability of insulin delivered with PLGA may be due to the accelerated drug release rate compared to PLA groups (Carino, et al., Nanosphere based oral insulin delivery. Journal of Controlled Release 2000, 65, 261-269).
Table 4 Determination of Bioavailibility of Orally Administered Humulin R Encapsulated PLA-PEG-COOH and PLGA-PEG-COOH Nanoparticles in Mice
Gp Route Substrate Dose Avg Weight AUCa Bioavailibility
(U/kg) of Mice (g) (%)
1 IV Humulin R 0.5 29.7 95.79 ± -
50.03
2 oral Humulin R-PLA- 50 27.5 76.45 ± 0.34 ± 0.43
PEG-COOH NP 94.60
3 oral Humulin R-PLA- 100 27 133.27 ± 0.58 ± 0.28
PEG-COOHNP 64.58
4 oral Humulin R-PLGA- 50 27.5 206.59 ± 1.86 ± 0.86
PEG-COOH NP 94.98
5 oral Humulin R-PLGA- 100 28 276.07± 2.53 ± 0.62
PEG-COOH NP 68.59 a Calculated based on trapezoidal treatment of the percent of decreased blood glucose
(%) vs time (hour) for both W and oral administration groups. b/= [AUCo-8h oral x (weight of mice/dose)orai]/ [AUCo-5hivx(weight of mice/dose)iv]
Besides determining bioavailability based on the blood glucose concentration, we also studied bioavailibility by directly measuring serum Humulin R using an ELISA insulin assay (Mercodic, ALPCO Diagnostics). This assay has very high specificity for the detection of Humulin R in mouse serum and shows no cross- reaction with mouse insulin. As shown in Figure 7, the concentration of Humulin R measured in mouse plasma is linear over a range typically used for quantification of absorbed Humulin R via oral administration. Blood (approximately 20 μL) samples were collected into Startedt serum gel microtubes and allowed to clot for 30 minutes. The tubes were then centrifuged for 3 min at 10, 000 x g. Serum (5 μL) was transferred to a micro-well and diluted with 20 μL calibrator 0 of the Mercodia insulin ELISA kit (ALPCO Diagnostics, Inc). Enzyme conjugate (100 μL) was added to each well. The mixture was incubated at room temperature for Ih on a plate shaker. The reaction medium was aspirated and washed with 5 x 350 μL Wash Buffer (provided in the kit). The TMB substrate (200 μL) of the kit was added to the well and incubated for 15 min at room temperature. After adding 50 μL Stop Solution, the UV absorbance was measured at 450 nm. Insulin concentration was determined based on a standard curve generated from known concentration of insulin standard. When serum was administered at 2 U/kg via tail- vein intravenous injection, the serum concentration decreased drastically from 3203.21 ± 143.65 mU/L to 124.18 ± 30.90 mU/L at t = Ih and to 14.17 ± 3.08 mU/L at t = 2h (Figure 8). Less than
0.5% of administered insulin remained in blood 2h after administration. The AUC of insulin concentration (mU/kg) vs time (hour) was 1175.89 ± 125.51 mU.hr/L (Table 5).
Since the encapsulation of insulin during double emulsion may denature and thus deactivate the loaded insulin, the bioactivity of some Humulin R encapsulated MPs were tested using intraperitoneal administration before testing for oral activity. Balb/c mice were fasted overnight (about 12-16h). Humulin R and Humulin R- magnetite-PLGA-MP were injected intraperitoneally to one and three mice, respectively. Blood (1 drop, roughly 3 μL) was collected from tail vein through puncture using 26G needle and analyzed with Ascensia Breeze Blood Glucose Monitoring System. The serum concentration of the intraperitoneally (IP) administered Humulin (4 U/kg) reached its highest level (541.85 ± 46.92 mU/L) at t = 30 minutes, and decreased to 36.32 ± 6.92 mU/L at t = 7h (Figure 8). The AUC of insulin concentration (mU/kg) vs time (hour) of the IP administered insulin was 692.29 ± 272.70 ml) .hr/L. 1 he bioavailability of IP administered insulin was 29.46 ± 11.60 %.
After oral administration of insulin-PLGA-PEG-COOH NP, chitosan-coated, insulin-PLGA-PEG-COOH NP, and insulin-PLGA-PEG-COOH NP-Lectin bioconjugates, the highest insulin concentrations were 267.08 ± 10.07 mU/kg (t=2h), 188.04 ± 46.75 mU/kg (f=4h), and 391.87 ± 68.43 mU/kg (t=2h), respectively (Figure 9). By t=20.5h, serum insulin concentrations decreased to 15.21 ± 7.97 mU/kg, 8.05 ± 14.46 mU/kg, 39.48 ± 37.76 mU/kg, respectively. The bioavailabilities of insulin- PLGA-PEG-COOH NP, chitosan-coated insulin-PLGA-PEG-COOH NP, and insulin- PLGA-PEG-COOH NP-Lectin bioconjugates were 1.22 ± 0.38 %, 1.49 ± 0.53%, and 1.87 ± 0.65%, respectively. Chitosan coating and lectin conjugation of PLGA-PEG- COOH NP enhanced the bioavailability by 22% and 53%, respectively. The bioavailability of the insulin-PLGA-PEG-COOH NP (1.22 %) obtained by measuring insulin concentration was 54-107% lower than that determined by measuring glucose concentrations (compared to bioavailability of 1.86% and 2.53% in Table 4).
Table 5 Determination of Bioavailability of Orally Administered Humulin R Encapsulated PLGA-PEG-COOH Nanoparticles with Various Surface Modifications
Gp Route Substrate Dose AUC Bioavailability
(U/kg) (mU.hr/L) (Jf
6 IV Humulin R 2 1175.89 ± 125.51 -
7 IP Humulin R 4 692.29 ± 272.70 29.43 ± 11.60
8 oral Humulin R-PLGA-PEG- 200 1435.63 ± 445.84 1.22 ± 0.38
COOH NP
9 oral Humulin R-PLGA-PEG- 200 1754.87 ± 629.15 1.49 ± 0.54
COOH NP/Chitosan
10 oral Humulin R-PLGA-PEG- 200 2194.26± 759.69 1.87 ± 0.65
COOH NP-Lectin Conjugate a Calculated based on trapezoidal treatment of the serum Humulin R concentration (mU/L) vs time (hour) for both IV, IP and oral administration groups. Vorai = (AUC0-20.5h Or3IZdOSeOr3Iy(AUC0-7I1 IvZdOSe1V)-ZiP = (AUC0-7h ipZdoseip)Z(AUCo-7h ivZdoseiv). Mice were grouped to make average body weight to be 3Og in each group.
Humulin R release study
The release of Humulin from NPs and MPs was measured by incubating aliquots containing 2-5 mg of Humulin R-containing particles in 1.0 mL of 1 x??? PBS at 37°. Measurements were conducted in triplicate. The supernatant was collected after centrifugation of the particle suspension at 14000 g for 5 min and analyzed with a BCA protein assay. The amount of Humulin R was calculated based on a standard curve generated with Humulin R stock solution (See Figure S4).
Other embodiments of the invention will be apparent to those skilled in the art from a consideration of the specification or practice of the invention disclosed herein. It is intended that the specification and examples be considered as exemplary only, with the true scope and spirit of the invention being indicated by the following claims. What is claimed is:

Claims

1. A composition for delivering an active agent to a patient, comprising: a polymer core encapsulating a predetermined amount of the active agent; and a mucoadhesive coating disposed about the core to form a coated particle, wherein the polymer is derivatized with a poly(alkylene glycol), the mucoadhesive coating is retained on the core through one or more of covalent interactions, electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions, a molecular weight and cross-link density of the polymer is selected such that the polymer core will decompose in a predetermined time interval, the mucoadhesive coating is selected to facilitate transfer of the particle through the intestinal mucosa, and a fraction of the predetermined amount of the active agent entering the systemic circulation during the predetermined time interval is between about 0.25% and about 25%.
2. The composition of claim 1 , further comprising a targeting agent disposed under the mucoadhesive coating.
3. The composition of claim 2, further comprising an intermediate layer disposed between the targeting agent and the mucoadhesive coating.
4. The composition of claim 3, wherein the intermediate layer comprises a first material and the mucoadhesive coating comprises a second material, wherein the first material and the second material have opposing electrostatic charges at pH 2.
5. The composition of claim 4, wherein the first material and the second material do not have opposing electrostatic charges at pH 7.4.
6. The composition of claim 3, wherein the intermediate layer comprises a biodegradable polymer.
7. The composition of claim 2, wherein the targeting agent is disposed at a surface portion of the polymer core.
8. The composition of claim 2, wherein the targeting agent is disposed at a surface portion of the polymer core and is also disposed at an interior portion of the polymer core.
9. The composition of claim 2, wherein the targeting agent is selected from nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences.
10. The composition of claim 1, wherein the fraction of the dose of the drug entering the systemic circulation during the predetermined time interval is between about 5% and about 20%.
11. The composition of claim 1 , wherein the fraction of the dose of the drug entering the systemic circulation during the predetermined time interval is between about 10% and about 15%.
12. The composition of claim 1 , wherein the mucoadhesive coating is retained on the core though electrostatic interactions.
13. The composition of claim 1, wherein the core comprises PEGylated poly(lactic acid).
14. The composition of claim 1, wherein the poly(alkylene glycol) is carboxylated.
15. The composition of claim 1 wherein the poly(alkylene glycol) is selected from poly(ethylene glycol) and poly(propylene glycol).
16. The composition of claim 1, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 7000 Daltons.
17. The composition of claim 16, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 1000 Daltons.
18. The composition of claim 16, wherein the poly(alkylene glycol) has a molecular weight between about 1000 and about 3500 Daltons.
19. The composition of claim 16, wherein the poly(alkylene glycol) has a molecular weight between about 3500 and 7000 Daltons.
20. The composition of claim 1, wherein the polymer is a biodegradable polymer or a non-biodegradable polymer.
21. The composition of claim 20, wherein the biodegradable polymer is selected from poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(lactic acid), poly(glycolic acid), poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, polyvinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(ethylene imine), poly(acrylic acid), poly(maleic anhydride), biodegradable polyurethanes, polysaccharides, PEG-functionalized derivatives of the above, co-polymers of the above, adducts of the above, and mixtures of the above.
22. The composition of claim 20, wherein the non-biodegradable polymer is selected from polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(vinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, non-biodegradable polyurethanes, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilines, polythiophene, poly(ethylene oxide), PEG-functionalized derivatives of the above, co-polymers of the above, adducts of the above, and mixtures of the above.
23 The composition of claim 1, wherein the coating comprises chitosan, poly(lysine), poly(ethylene imine), lecithin, lectin, polycarboxylic acids, poly(acrylic acids), polysaccharides, hydrogels, monosaccharides, oligosaccharides, oligopeptides, polypeptides, co-polymers of the above, or any combination of the above.
24 The composition of claim 1, wherein the coating comprises chitosan, lectin, or both.
25 The composition of claim 1, wherein the coating is a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions.
26 The composition of claim 1, wherein the active agent is a biomolecule, bioactive agent, small molecule, drug, protein, vaccine, or polynucleotide.
27 The composition of claim 26, wherein the active agent is a vaccine.
28 The composition of claim 26, wherein the active agent is a protein.
29. The composition of claim 28, wherein the active agent is insulin.
30. A composition for administering an active agent to a patient, comprising: a plurality of particles, each particle comprising a polymer core encapsulating a predetermined amount of the active agent and a mucoadhesive coating disposed about the core to form a coated particle; and a pharmaceutically acceptable carrier combined with the plurality of particles, wherein the pharmaceutically acceptable carrier is edible or inhalable, wherein: the mucoadhesive coating is retained on the core through one or more of covalent interactions, electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions, a molecular weight and cross-link density of the biodegradable polymer is selected such that the polymer core will decompose in vivo in a predetermined time interval, and a fraction of the predetermined amount of the bioactive agent entering the systemic circulation during the predetermined time interval is between about 0.25% and about 25%.
31. The composition of claim 30, wherein each particle further comprises a targeting agent disposed under the mucoadhesive coating.
32. The composition of claim 31 , wherein each particle further comprises an intermediate layer disposed between the targeting agent and the mucoadhesive coating.
33. The composition of claim 32, wherein the intermediate layer comprises a first material and the mucoadhesive coating comprises a second material, wherein the first material and the second material have opposing electrostatic charges at pH 2.
34. The composition of claim 33, wherein the first material and the second material do not have opposing electrostatic charges at pH 7.4.
35. The composition of claim 32, wherein the intermediate layer comprises a biodegradable polymer.
36. The composition of claim 31, wherein the targeting agent is disposed at a surface portion of the polymer core.
37. The composition of claim 31, wherein the targeting agent is disposed at a surface portion of the polymer core and is also disposed at an interior portion of the polymer core.
38. The composition of claim 31, wherein the targeting agent is selected from nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences.
39. The composition of claim 30, wherein the fraction of the dose of the drug entering the systemic circulation during the predetermined time interval is between about 5% and about 20%.
40. The composition of claim 30, wherein the fraction of the dose of the drug entering the systemic circulation during the predetermined time interval is between about 10% and about 15%.
41. The composition of claim 30, wherein the mucoadhesive coating is retained on the core though electrostatic interactions.
42. The composition of claim 30, wherein the polymer is derivatized with a poly (alky lene glycol).
43. The composition of claim 42 wherein the poly(alkylene glycol) is selected from poly(ethylene glycol) and poly(propylene glycol).
44. The composition of claim 30, wherein the core comprises PEGylated poly (lactic acid).
45. The composition of claim 42, wherein the poly(alkylene glycol) is carboxylated.
46. The composition of claim 42, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 7000 Daltons.
47. The composition of claim 46, wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 1000 Daltons.
48. The composition of claim 46, wherein the poly(alkylene glycol) has a molecular weight between about 1000 and about 3500 Daltons.
49. The composition of claim 46, wherein the poly(alkylene glycol) has a molecular weight between about 3500 and 7000 Daltons.
50. The composition of claim 30, wherein the polymer is a biodegradable polymer or a non-biodegradable polymer.
51. The composition of claim 50, wherein the biodegradable polymer is selected from poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, poly(vinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(ethylene imine), poly(acrylic acid), poly(maleic anhydride), biodegradable polyurethanes, polysaccharides, PEG-functionalized derivatives of the above, co-polymers of the above, adducts of the above, and mixtures of the above.
52. The composition of claim 50, wherein the non-biodegradable polymer is selected from polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, poly(vinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, non-biodegradable polyurethanes, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilines, polythiophene, poly(ethylene oxide), PEG-functionalized derivatives of the above, co-polymers of the above, adducts of the above, and mixtures of the above.
53 The composition of claim 30, wherein the coating comprises chitosan, poly(lysine), poly(ethylene imine), lecithin, lectin, polycarboxylic acids, ρoly(acrylic acids), polysaccharides, hydrogels, monosaccharides, oligosaccharides, oligopeptides, polypeptides, co-polymers of the above, or any combination of the above.
54 The composition of claim 30, wherein the coating comprises chitosan, lectin, or both.
55 The composition of claim 30, wherein the coating is a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions.
56 The composition of claim 30, wherein the active agent is a biomolecule, bioactive agent, small molecule, drug, protein, vaccine, or polynucleotide.
57 The composition of claim 56, wherein the active agent is a vaccine.
58 The composition of claim 56, wherein the active agent is a protein.
59. The composition of claim 58, wherein the active agent is insulin.
60. A method for administering an active agent to a patient, comprising: orally or nasally administering to the patient a composition comprising: A) a plurality of particles, each particle comprising: a polymer core encapsulating a predetermined amount of the active agent; and a mucoadhesive coating disposed about the core to form a coated particle; and B) a pharmaceutically acceptable carrier, wherein the pharmaceutically acceptable carrier is edible or inhalable, wherein the mucoadhesive coating is retained on the core through one or more of covalent interactions, electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions, a molecular weight and cross-link density of the polymer is selected such that the polymer core will decompose in vivo in a predetermined time interval, and a fraction of the predetermined amount of the bioactive agent entering the systemic circulation during the predetermined time interval is between about 0.25% and about 25%.
61. The method of claim 60, wherein each particle further comprises a targeting agent disposed under the mucoadhesive coating.
62. The method of claim 61 , wherein each particle further comprises an intermediate layer disposed between the targeting agent and the mucoadhesive coating.
63. The method of claim 62, wherein the intermediate layer comprises a first material and the mucoadhesive coating comprises a second material, wherein the first material and the second material have opposing electrostatic charges at pH 2.
64. The method of claim 63, wherein the first material and the second material do not have opposing electrostatic charges at pH 7.4.
65. The method of claim 62, wherein the intermediate layer comprises a biodegradable polymer.
66. The method of claim 61, wherein the targeting agent is disposed at a surface portion of the polymer core.
67. The method of claim 61, wherein the targeting agent is disposed at a surface portion of the polymer core and is also disposed at an interior portion of the polymer core.
68. The method of claim 61, wherein the targeting agent is selected from nucleic acid aptamers, growth factors, hormones, cytokines, interleukins, antibodies, integrins, fibronectin receptors, p-glycoprotein receptors, and cell binding sequences.
69. The method of claim 60, wherein the fraction of the dose of the drug entering the systemic circulation during the predetermined time interval is between about 5% and about 20%.
70. The method of claim 60, wherein the fraction of the dose of the drug entering the systemic circulation during the predetermined time interval is between about 10% and about 15%.
71. The method of claim 60, wherein the polymer is derivatized with a poly(alkylene glycol).
72. The method of claim 71, wherein the poly(alkylene glycol) is selected from poly(ethylene glycol) and poly(propylene glycol).
73. The method of claim 71, wherein the core comprises PEGylated poly(lactic acid).
74. The method of claim 71, wherein the poly(alkylene glycol) is carboxylated.
75. The method of claim 71 , wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 7000 Daltons.
76. The method of claim 71 , wherein the poly(alkylene glycol) has a molecular weight between about 100 and about 1000 Daltons.
77. The method of claim 71 , wherein the poly(alkylene glycol) has a molecular weight between about 1000 and about 3500 Daltons.
78. The method of claim 71, wherein the poly(alkylene glycol) has a molecular weight between about 3500 and 7000 Daltons.
79. The method of claim 60, wherein the mucoadhesive coating is retained on the core though electrostatic interactions.
80. The method of claim 60, wherein the core comprises PEGylated poly(lactic acid).
81. The method of claim 60, wherein the polymer is a biodegradable polymer or a non-biodegradable polymer.
82. The method of claim 81, wherein the biodegradable polymer is selected from poly(arylates), poly(anhydrides), poly(hydroxy acids), polyesters, poly(ortho esters), polycarbonates, poly(propylene fumerates), poly(caprolactones), polyamides, polyphosphazenes, polyamino acids, polyethers, polyacetals, polylactides, polyhydroxyalkanoates, polyglycolides, polyketals, polyesteramides, poly(dioxanones), polyhydroxybutyrates, polyhydroxyvalyrates, polycarbonates, polyorthocarbonates, polyvinyl pyrrolidone), biodegradable polycyanoacrylates, polyalkylene oxalates, polyalkylene succinates, poly(malic acid), poly(methyl vinyl ether), poly(ethylene imine), poly(acrylic acid), poly(maleic anhydride), biodegradable polyurethanes, polysaccharides, PEG-functionalized derivatives of the above, co-polymers of the above, adducts of the above, and mixtures of the above.
83. The method of claim 81 , wherein the non-biodegradable polymer is selected from polystyrene, polyesters, non-biodegradable polyurethanes, polyureas, polyvinyl alcohol), polyamides, poly(tetrafluoroethylene), poly(ethylene vinyl acetate), polypropylene, polyacrylate, non-biodegradable polycyanoacrylates, non-biodegradable polyurethanes, polymethacrylate, poly(methyl methacrylate), polyethylene, polypyrrole, polyanilines, polythiophene, poly(ethylene oxide), PEG-functionalized derivatives of the above, co-polymers of the above, adducts of the above, and mixtures of the above.
84. The method of claim 60, wherein the coating comprises chitosan, poly(lysine), poly(ethylene imine), lecithin, lectin, polycarboxylic acids, poly(acrylic acids), polysaccharides, hydrogels, monosaccharides, oligosaccharides, oligopeptides, polypeptides, co-polymers of the above, or any combination of the above.
85. The method of claim 60, wherein the coating comprises lectin, chitosan, or both.
86. The method of claim 60, wherein the coating is a block co-polymer having a mucoadhesive block and a block that is adapted to participate in an interaction selected from electrostatic interactions, affinity interactions, metal coordination, physical adsorption, host-guest interactions, and hydrogen bonding interactions.
87. The method of claim 60, wherein the active agent is a biomolecule, bioactive agent, small molecule, drug, protein, vaccine, or polynucleotide.
88. The method of claim 87, wherein the active agent is a vaccine.
89. The method of claim 87, wherein the active agent is a protein.
90. The method of claim 87, wherein the active agent is insulin.
PCT/US2005/040100 2004-11-04 2005-11-04 Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals WO2007001448A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US11/666,908 US9492400B2 (en) 2004-11-04 2005-11-04 Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US15/349,681 US20170112776A1 (en) 2004-11-04 2016-11-11 Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62500104P 2004-11-04 2004-11-04
US60/625,001 2004-11-04

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US11/666,908 A-371-Of-International US9492400B2 (en) 2004-11-04 2005-11-04 Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US15/349,681 Division US20170112776A1 (en) 2004-11-04 2016-11-11 Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals

Publications (2)

Publication Number Publication Date
WO2007001448A2 true WO2007001448A2 (en) 2007-01-04
WO2007001448A3 WO2007001448A3 (en) 2009-04-23

Family

ID=37595609

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2005/040100 WO2007001448A2 (en) 2004-11-04 2005-11-04 Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals

Country Status (2)

Country Link
US (2) US9492400B2 (en)
WO (1) WO2007001448A2 (en)

Cited By (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1962867A2 (en) * 2005-12-06 2008-09-03 Tyco Healthcare Group, LP Biocompatible surgical compositions
WO2009148598A1 (en) * 2008-06-05 2009-12-10 President And Fellows Of Harvard College Polymersomes, colloidosomes, liposomes, and other species associated with fluidic droplets
US7910129B2 (en) 2005-12-06 2011-03-22 Tyco Healthcare Group Lp Carbodiimide crosslinking of functionalized polyethylene glycols
EP2308473A1 (en) * 2008-07-01 2011-04-13 Nitto Denko Corporation Pharmaceutical composition containing surface-coated microparticles
US7998466B2 (en) 2005-12-06 2011-08-16 Tyco Healthcare Group Lp Biocompatible tissue sealants and adhesives
US8044234B2 (en) 2005-05-05 2011-10-25 Tyco Healthcare Group Lp Bioabsorbable surgical composition
US8263704B2 (en) 2008-04-23 2012-09-11 Tyco Healthcare Group Lp Bioabsorbable surgical composition
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8449714B2 (en) 2005-12-08 2013-05-28 Covidien Lp Biocompatible surgical compositions
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8652487B2 (en) 2011-04-29 2014-02-18 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for inducing regulatory B cells
US8709483B2 (en) 2006-03-31 2014-04-29 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8748094B2 (en) 2008-12-19 2014-06-10 President And Fellows Of Harvard College Particle-assisted nucleic acid sequencing
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
WO2014169256A3 (en) * 2013-04-11 2014-12-11 Vanderbilt University Polyplexes
US9017948B2 (en) 2007-03-07 2015-04-28 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9039273B2 (en) 2005-03-04 2015-05-26 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
US9056289B2 (en) 2009-10-27 2015-06-16 President And Fellows Of Harvard College Droplet creation techniques
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9080014B2 (en) 2006-05-15 2015-07-14 Massachusetts Institute Of Technology Polymers for functional particles
US9238206B2 (en) 2011-05-23 2016-01-19 President And Fellows Of Harvard College Control of emulsions, including multiple emulsions
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US9388465B2 (en) 2013-02-08 2016-07-12 10X Genomics, Inc. Polynucleotide barcode generation
US9410201B2 (en) 2012-12-14 2016-08-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2016153920A1 (en) * 2015-03-20 2016-09-29 Memorial Sloan Kettering Cancer Center Mesoscale nanoparticles for selective targeting to the kidney and methods of their therapeutic use
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9707252B2 (en) 2005-02-09 2017-07-18 Covidien Lp Synthetic sealants
US9737614B2 (en) 2014-04-17 2017-08-22 Memorial Sloan Kettering Cancer Center Fucoidan nanogels and methods of their use and manufacture
CN107121554A (en) * 2009-09-02 2017-09-01 新泽西鲁特格斯州立大学 Treat the composition and method of neurogenic pain
US9797010B2 (en) 2007-12-21 2017-10-24 President And Fellows Of Harvard College Systems and methods for nucleic acid sequencing
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
CN107582527A (en) * 2017-10-10 2018-01-16 雷笑天 A kind of enteral administration bioadhesive microspheres preparation and preparation method thereof
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
EP3395957A1 (en) * 2011-04-25 2018-10-31 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
US10195571B2 (en) 2011-07-06 2019-02-05 President And Fellows Of Harvard College Multiple emulsions and techniques for the formation of multiple emulsions
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10300136B2 (en) 2013-12-16 2019-05-28 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10471016B2 (en) 2013-11-08 2019-11-12 President And Fellows Of Harvard College Microparticles, methods for their preparation and use
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
WO2020028909A1 (en) * 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
CN110964204A (en) * 2018-09-29 2020-04-07 南方医科大学 PLGA microspheres of charge-loaded positive micelle/insulin compound and preparation method thereof
US10650912B2 (en) 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
US10765755B1 (en) * 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US10874997B2 (en) 2009-09-02 2020-12-29 President And Fellows Of Harvard College Multiple emulsions created using jetting and other techniques
US10874622B2 (en) 2015-06-24 2020-12-29 Board Of Regents, The University Of Texas System Dual assembly nanoparticles
US10933129B2 (en) 2011-07-29 2021-03-02 Selecta Biosciences, Inc. Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US11123297B2 (en) 2015-10-13 2021-09-21 President And Fellows Of Harvard College Systems and methods for making and using gel microspheres
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11401550B2 (en) 2008-09-19 2022-08-02 President And Fellows Of Harvard College Creation of libraries of droplets and related species
US11541017B2 (en) 2013-12-16 2023-01-03 Massachusetts Institute Of Technology Fortified micronutrient salt formulations
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US20230126744A1 (en) * 2021-10-25 2023-04-27 The Secant Group, Llc. Polymeric delivery systems
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening
US12163191B2 (en) 2014-06-26 2024-12-10 10X Genomics, Inc. Analysis of nucleic acid sequences
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US8778384B2 (en) 2008-03-24 2014-07-15 Advanced Bionutrition Corporation Compositions and methods for encapsulating vaccines for the oral vaccination and boostering of fish and other animals
ES2661038T3 (en) * 2008-03-24 2018-03-27 Intervet International B.V. Encapsulated vaccines for oral and booster vaccination of fish and other animals
JP5804453B2 (en) * 2009-05-14 2015-11-04 国立大学法人 東京大学 Crystalline polyol fine particles and preparation method thereof
CA2771863A1 (en) * 2009-08-26 2011-03-17 Selecta Biosciences, Inc. Compositions that induce t cell help
US8865220B2 (en) * 2010-06-14 2014-10-21 Kaohsiung Medical University Method for controlled release of parathyroid hormone from encapsulated poly(lactic-glycolic)acid microspheres
EP2768488A4 (en) 2011-10-19 2015-04-15 Rp Scherer Technologies Llc Two phase pharmaceutical delivery system
JP6396288B2 (en) 2012-04-23 2018-09-26 ナノプロティアジェン， リミテッド Polymer nanoparticles and process for their preparation
EP3068223B1 (en) * 2013-11-12 2020-01-01 University of Utah Research Foundation Glycol chitin based thermosensitive hydrogel for vaginal delivery of progesterone
EP3076952A4 (en) * 2013-12-06 2017-09-20 Advanced BioNutrition Corporation Composition for oral delivery of bioactive agents
US11918695B2 (en) * 2014-05-09 2024-03-05 Yale University Topical formulation of hyperbranched polymer-coated particles
US10272019B2 (en) 2014-05-09 2019-04-30 Yale University Topical formulation of hyperbranched polyglycerol-coated particles thereof
CA2951707A1 (en) 2014-06-10 2015-12-17 Massachusetts Institute Of Technology Method for gene editing
WO2016025871A2 (en) 2014-08-14 2016-02-18 Secant Medical, Inc. Composition, methods and devices useful for manufacturing of implantable articles
US11596605B2 (en) * 2016-08-01 2023-03-07 The Brigham And Women's Hospital, Inc. Particles for delivery of proteins and peptides
KR20190082263A (en) 2016-11-02 2019-07-09 나노프로테아젠 Polymer nanoparticles
KR102753928B1 (en) 2017-03-11 2025-01-14 셀렉타 바이오사이언시즈, 인크. Methods and compositions relating to combination therapy using synthetic nanocarriers comprising anti-inflammatory agents and immunosuppressants
US10835489B2 (en) * 2018-03-09 2020-11-17 University Of Saskatchewan Modified release formulations of mycophenolate mofetil
EP3803866A4 (en) 2018-05-24 2022-03-16 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
EP3801378A4 (en) 2018-05-24 2022-02-23 Celanese EVA Performance Polymers LLC IMPLANTABLE DEVICE FOR THE DELAYED RELEASE OF A MACROMOLECULAR DRUG COMPOUND
JP2021524841A (en) 2018-05-24 2021-09-16 セラニーズ・イーブイエイ・パフォーマンス・ポリマーズ・エルエルシー Implantable device for sustained release of macromolecular drug compounds
CN108743971B (en) * 2018-06-11 2021-04-13 西南大学 Preparation method and application of drug-loaded polypyrrole nanoparticles
BR112021003897A2 (en) 2018-08-30 2021-05-25 Tenaya Therapeutics, Inc. reprogramming of cardiac cells with myocarin and asci1
GB201818517D0 (en) * 2018-11-13 2018-12-26 Univ Liverpool John Moores Nanoparticles and uses thereof
US20230137971A1 (en) 2019-07-11 2023-05-04 Tenaya Therapeutics Inc. Cardiac cell reprogramming with micrornas and other factors
WO2023164487A1 (en) * 2022-02-22 2023-08-31 Brown University Compositions and methods to achieve systemic uptake of particles following oral or mucosal administration
AU2023227803A1 (en) * 2022-03-04 2024-09-05 2508 Biosciences Llc Compositions and methods to promote brain health
WO2023214285A1 (en) * 2022-05-03 2023-11-09 Alek Itsekson Compositions comprising female reproductive hormones and methods for using thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs

Family Cites Families (391)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766774A (en) 1972-02-18 1973-10-23 H Clark Apparatus and method for measuring blood characteristics
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
USRE33405E (en) 1979-12-28 1990-10-23 Research Corporation Technologies, Inc. Purified human prostate antigen
US4446122A (en) 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
US4946929A (en) 1983-03-22 1990-08-07 Massachusetts Institute Of Technology Bioerodible articles useful as implants and prostheses having predictable degradation rates
US4818542A (en) * 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
US4795436A (en) * 1983-11-14 1989-01-03 Bio-Mimetics, Inc. Bioadhesive composition and method of treatment therewith
US4638045A (en) * 1985-02-19 1987-01-20 Massachusetts Institute Of Technology Non-peptide polyamino acid bioerodible polymers
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4631211A (en) 1985-03-25 1986-12-23 Scripps Clinic & Research Foundation Means for sequential solid phase organic synthesis and methods using the same
GB8601100D0 (en) * 1986-01-17 1986-02-19 Cosmas Damian Ltd Drug delivery system
US4806621A (en) * 1986-01-21 1989-02-21 Massachusetts Institute Of Technology Biocompatible, bioerodible, hydrophobic, implantable polyimino carbonate article
US4970299A (en) 1986-07-03 1990-11-13 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies selective for prostate cancer
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US6024983A (en) 1986-10-24 2000-02-15 Southern Research Institute Composition for delivering bioactive agents for immune response and its preparation
US5736372A (en) * 1986-11-20 1998-04-07 Massachusetts Institute Of Technology Biodegradable synthetic polymeric fibrous matrix containing chondrocyte for in vivo production of a cartilaginous structure
CA1340581C (en) 1986-11-20 1999-06-08 Joseph P. Vacanti Chimeric neomorphogenesis of organs by controlled cellular implantation using artificial matrices
US5804178A (en) 1986-11-20 1998-09-08 Massachusetts Institute Of Technology Implantation of cell-matrix structure adjacent mesentery, omentum or peritoneum tissue
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4886499A (en) 1986-12-18 1989-12-12 Hoffmann-La Roche Inc. Portable injection appliance
US5174930A (en) 1986-12-31 1992-12-29 Centre National De La Recherche Scientifique (Cnrs) Process for the preparation of dispersible colloidal systems of amphiphilic lipids in the form of oligolamellar liposomes of submicron dimensions
FR2608988B1 (en) 1986-12-31 1991-01-11 Centre Nat Rech Scient PROCESS FOR THE PREPARATION OF COLLOIDAL DISPERSIBLE SYSTEMS OF A SUBSTANCE, IN THE FORM OF NANOPARTICLES
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4903649A (en) 1987-03-12 1990-02-27 Brunswick Corporation Fuel supply system with pneumatic amplifier
US4902615A (en) * 1987-03-27 1990-02-20 Biosciences Corporation Of Texas Detection of human cancer cells with antibodies to human cancer nucleolar antigen p120
DE3812289C2 (en) 1987-04-20 1995-06-08 Mitsubishi Electric Corp Idle speed control device for an internal combustion engine
US4839416A (en) 1987-06-09 1989-06-13 Ampad Corporation Low tack microsphere adhesive
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5069936A (en) 1987-06-25 1991-12-03 Yen Richard C K Manufacturing protein microspheres
US5019379A (en) 1987-07-31 1991-05-28 Massachusetts Institute Of Technology Unsaturated polyanhydrides
US5200181A (en) * 1988-01-11 1993-04-06 Massachusetts Institute Of Technology Oral bilirubin therapy
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
US5162504A (en) 1988-06-03 1992-11-10 Cytogen Corporation Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients
JPH0249596A (en) 1988-08-09 1990-02-19 Masamichi Ueda Monoclonal antibody specifically reacting with surface of human prostatic epithelial cells
US4959219A (en) 1988-08-15 1990-09-25 Fisons Corporation Coating barriers comprising ethyl cellulose
FR2638359A1 (en) 1988-11-03 1990-05-04 Tino Dalto SYRINGE GUIDE WITH ADJUSTMENT OF DEPTH DEPTH OF NEEDLE IN SKIN
DE3872260T2 (en) 1988-12-09 1992-12-24 Bosch Gmbh Robert METHOD FOR ACCELERATING ACCELERATION IN FUEL INJECTION SYSTEMS.
US5334497A (en) 1988-12-13 1994-08-02 Hideki Inaba Method of feeding a substrate into tubular bioreactor
US4976968A (en) 1989-02-24 1990-12-11 Clinical Technologies Associates, Inc. Anhydrous delivery systems for pharmacological agents
US5010167A (en) * 1989-03-31 1991-04-23 Massachusetts Institute Of Technology Poly(amide-and imide-co-anhydride) for biological application
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
DE69025334T2 (en) 1989-11-06 1996-08-01 Alkermes Inc PRODUCTION PROCESS FOR PROTEIN MICROSPHERES
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US6399754B1 (en) 1991-12-24 2002-06-04 Isis Pharmaceuticals, Inc. Sugar modified oligonucleotides
US6005087A (en) 1995-06-06 1999-12-21 Isis Pharmaceuticals, Inc. 2'-modified oligonucleotides
US5240963A (en) 1990-01-19 1993-08-31 Nova Pharmaceutical Corporation Branched polyanhydrides
US5496938A (en) * 1990-06-11 1996-03-05 Nexstar Pharmaceuticals, Inc. Nucleic acid ligands to HIV-RT and HIV-1 rev
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
US6280932B1 (en) 1990-06-11 2001-08-28 Gilead Sciences, Inc. High affinity nucleic acid ligands to lectins
US5874218A (en) * 1990-06-11 1999-02-23 Nexstar Pharmaceuticals, Inc. Method for detecting a target compound in a substance using a nucleic acid ligand
US6001577A (en) 1998-06-08 1999-12-14 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5789163A (en) 1990-06-11 1998-08-04 Nexstar Pharmaceuticals, Inc. Enzyme linked oligonucleotide assays (ELONAS)
ATE318832T1 (en) 1990-06-11 2006-03-15 Gilead Sciences Inc METHOD FOR USING NUCLEIC ACID LIGANDS
US5853984A (en) 1990-06-11 1998-12-29 Nexstar Pharmaceuticals, Inc. Use of nucleic acid ligands in flow cytometry
US5567588A (en) 1990-06-11 1996-10-22 University Research Corporation Systematic evolution of ligands by exponential enrichment: Solution SELEX
US6716580B2 (en) 1990-06-11 2004-04-06 Somalogic, Inc. Method for the automated generation of nucleic acid ligands
US5763177A (en) 1990-06-11 1998-06-09 Nexstar Pharmaceuticals, Inc. Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5660985A (en) 1990-06-11 1997-08-26 Nexstar Pharmaceuticals, Inc. High affinity nucleic acid ligands containing modified nucleotides
US6699474B1 (en) * 1990-08-20 2004-03-02 Erich Hugo Cerny Vaccine and immunserum against drugs of abuse
US5190521A (en) * 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5175296A (en) 1991-03-01 1992-12-29 Minnesota Mining And Manufacturing Company Imidazo[4,5-c]quinolin-4-amines and processes for their preparation
US5389640A (en) * 1991-03-01 1995-02-14 Minnesota Mining And Manufacturing Company 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
US5403750A (en) * 1991-03-06 1995-04-04 W. R. Grace & Co.-Conn. Biocompatible, low protein adsorption affinity matrix
IT1250421B (en) * 1991-05-30 1995-04-07 Recordati Chem Pharm CONTROLLED RELEASE PHARMACEUTICAL COMPOSITION WITH BIO-ADHESIVE PROPERTIES.
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
GB9118204D0 (en) * 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (en) 1991-09-13 1991-09-13 Kabi Pharmacia Ab INJECTION NEEDLE ARRANGEMENT
US5811447A (en) * 1993-01-28 1998-09-22 Neorx Corporation Therapeutic inhibitor of vascular smooth muscle cells
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105325A (en) 1992-04-16 1996-11-14 Minnesota Mining & Mfg Immunogen/vaccine adjuvant composition
US6235313B1 (en) 1992-04-24 2001-05-22 Brown University Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US6197346B1 (en) * 1992-04-24 2001-03-06 Brown Universtiy Research Foundation Bioadhesive microspheres and their use as drug delivery and imaging systems
US5383851A (en) * 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
KR940003548U (en) 1992-08-14 1994-02-21 김형술 Laundry dryer
US6608201B2 (en) 1992-08-28 2003-08-19 3M Innovative Properties Company Process for preparing 1-substituted, 2-substituted 1H-imidazo[4,5-c]quinolin-4-amines
FR2695563B1 (en) * 1992-09-11 1994-12-02 Pasteur Institut Microparticles carrying antigens and their use for the induction of humoral or cellular responses.
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5399665A (en) * 1992-11-05 1995-03-21 Massachusetts Institute Of Technology Biodegradable polymers for cell transplantation
AU679041B2 (en) 1993-01-11 1997-06-19 Dana-Farber Cancer Institute Inducing cytotoxic T lymphocyte responses
US5512600A (en) 1993-01-15 1996-04-30 Massachusetts Institute Of Technology Preparation of bonded fiber structures for cell implantation
US5514378A (en) 1993-02-01 1996-05-07 Massachusetts Institute Of Technology Biocompatible polymer membranes and methods of preparation of three dimensional membrane structures
US5820879A (en) 1993-02-12 1998-10-13 Access Pharmaceuticals, Inc. Method of delivering a lipid-coated condensed-phase microparticle composition
DE59403734D1 (en) 1993-03-17 1997-09-18 Silica Gel Gmbh SUPERPARAMAGNETIC PARTICLES, METHOD FOR THE PRODUCTION AND USE THEREOF
US5342781A (en) 1993-07-15 1994-08-30 Su Wei Wen W External-loop perfusion air-lift bioreactor
US5565215A (en) * 1993-07-23 1996-10-15 Massachusettes Institute Of Technology Biodegradable injectable particles for imaging
US5543158A (en) 1993-07-23 1996-08-06 Massachusetts Institute Of Technology Biodegradable injectable nanoparticles
EP0712421A1 (en) 1993-07-23 1996-05-22 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5744155A (en) 1993-08-13 1998-04-28 Friedman; Doron Bioadhesive emulsion preparations for enhanced drug delivery
US6458539B1 (en) 1993-09-17 2002-10-01 Somalogic, Inc. Photoselection of nucleic acid ligands
US5798340A (en) 1993-09-17 1998-08-25 Gilead Sciences, Inc. Nucleotide analogs
US5500161A (en) * 1993-09-21 1996-03-19 Massachusetts Institute Of Technology And Virus Research Institute Method for making hydrophobic polymeric microparticles
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
US5596091A (en) * 1994-03-18 1997-01-21 The Regents Of The University Of California Antisense oligonucleotides comprising 5-aminoalkyl pyrimidine nucleotides
GB9412273D0 (en) * 1994-06-18 1994-08-10 Univ Nottingham Administration means
US6007845A (en) 1994-07-22 1999-12-28 Massachusetts Institute Of Technology Nanoparticles and microparticles of non-linear hydrophilic-hydrophobic multiblock copolymers
US5716404A (en) * 1994-12-16 1998-02-10 Massachusetts Institute Of Technology Breast tissue engineering
US5599302A (en) * 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US6030613A (en) * 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
US5786204A (en) 1995-01-20 1998-07-28 Human Genome Sciences, Inc. Human prostatic specific reductase
US5686113A (en) 1995-03-21 1997-11-11 Temple University Of The Commonwealth System Of Higher Education Microcapsules of predetermined peptide(s) specificity (ies), their preparation and uses
US5876727A (en) * 1995-03-31 1999-03-02 Immulogic Pharmaceutical Corporation Hapten-carrier conjugates for use in drug-abuse therapy and methods for preparation of same
US6123727A (en) 1995-05-01 2000-09-26 Massachusetts Institute Of Technology Tissue engineered tendons and ligaments
US6902743B1 (en) 1995-05-22 2005-06-07 The United States Of America As Represented By The Secretary Of The Army Therapeutic treatment and prevention of infections with a bioactive material(s) encapuslated within a biodegradable-bio-compatable polymeric matrix
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US20020150578A1 (en) 1995-06-05 2002-10-17 Human Genome Sciences, Inc. Human prostatic specific reductase
US5843732A (en) 1995-06-06 1998-12-01 Nexstar Pharmaceuticals, Inc. Method and apparatus for determining consensus secondary structures for nucleic acid sequences
US7422902B1 (en) 1995-06-07 2008-09-09 The University Of British Columbia Lipid-nucleic acid particles prepared via a hydrophobic lipid-nucleic acid complex intermediate and use for gene transfer
US5879712A (en) * 1995-06-07 1999-03-09 Sri International Method for producing drug-loaded microparticles and an ICAM-1 dosage form so produced
AU5931896A (en) 1995-06-07 1996-12-30 Advanced Tissue Sciences, Inc. Apparatus and method for sterilizing, seeding, culturing, st oring, shipping, and testing replacement cartilage tissue co nstructs
WO1997004747A1 (en) 1995-07-27 1997-02-13 Dunn James M Drug delivery systems for macromolecular drugs
US6096344A (en) 1995-07-28 2000-08-01 Advanced Polymer Systems, Inc. Bioerodible porous compositions
US5622699A (en) 1995-09-11 1997-04-22 La Jolla Cancer Research Foundation Method of identifying molecules that home to a selected organ in vivo
US6395770B1 (en) 1995-10-26 2002-05-28 Baker Norton Pharmaceuticals, Inc. Method and compositions for administering taxanes orally to human patients
US6095148A (en) 1995-11-03 2000-08-01 Children's Medical Center Corporation Neuronal stimulation using electrically conducting polymers
FR2742357B1 (en) 1995-12-19 1998-01-09 Rhone Poulenc Rorer Sa STABILIZED AND FILTRABLE NANOPARTICLES UNDER STERILE CONDITIONS
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
US5902599A (en) 1996-02-20 1999-05-11 Massachusetts Institute Of Technology Biodegradable polymer networks for use in orthopedic and dental applications
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6136311A (en) * 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US20020106647A1 (en) 1996-07-24 2002-08-08 Segal Andrew H. Nucleic acid compositions and methods of introducing nucleic acids into cells
US5922695A (en) 1996-07-26 1999-07-13 Gilead Sciences, Inc. Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability
US6605713B1 (en) 1996-08-30 2003-08-12 Jens Peter Furste Mirror-symmetrical selection and evolution of nucleic acids
US6043224A (en) * 1996-09-05 2000-03-28 The Massachusetts Institute Of Technology Compositions and methods for treatment of neurological disorders and neurodegenerative diseases
US6368598B1 (en) 1996-09-16 2002-04-09 Jcrt Radiation Oncology Support Services, Inc. Drug complex for treatment of metastatic prostate cancer
US6120666A (en) 1996-09-26 2000-09-19 Ut-Battelle, Llc Microfabricated device and method for multiplexed electrokinetic focusing of fluid streams and a transport cytometry method using same
ATE367159T1 (en) 1996-10-25 2007-08-15 Minnesota Mining & Mfg COMPOUNDS THAT ALTER THE IMMUNE RESPONSE FOR THE TREATMENT OF TH2-MEDIATED AND RELATED DISEASES
US7759520B2 (en) * 1996-11-27 2010-07-20 University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6995284B2 (en) * 2000-08-24 2006-02-07 The University Of Tennessee Research Foundation Synthesis of selective androgen receptor modulators
US6492554B2 (en) 2000-08-24 2002-12-10 The University Of Tennessee Research Corporation Selective androgen receptor modulators and methods of use thereof
US7518013B2 (en) 2000-08-24 2009-04-14 University Of Tennessee Research Foundation Selective androgen receptor modulators
US7205437B2 (en) 1996-11-27 2007-04-17 University Of Tennessee Research Foundation Selective androgen receptor modulators
US6127533A (en) 1997-02-14 2000-10-03 Isis Pharmaceuticals, Inc. 2'-O-aminooxy-modified oligonucleotides
EP1019071A4 (en) 1997-05-15 2003-07-30 Cytogen Corp Random peptides that bind to gastro-intestinal tract (git) transport receptors and related methods
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
GB9713980D0 (en) 1997-07-03 1997-09-10 Danbiosyst Uk New conjugates
US5837752A (en) 1997-07-17 1998-11-17 Massachusetts Institute Of Technology Semi-interpenetrating polymer networks
US6190913B1 (en) * 1997-08-12 2001-02-20 Vijay Singh Method for culturing cells using wave-induced agitation
US7001996B1 (en) 1997-08-21 2006-02-21 The United States Of America As Represented By The Secretary Of The Army Enzymatic template polymerization
US6451527B1 (en) 1997-08-29 2002-09-17 Selective Genetics, Inc. Methods using genetic package display for selecting internalizing ligands for gene delivery
US20040136961A1 (en) 1997-10-09 2004-07-15 Ales Prokop Nanoparticulate composition for efficient gene transfer
DE19745950A1 (en) 1997-10-17 1999-04-22 Dds Drug Delivery Service Ges Drug carrier particle for site specific drug delivery, especially to CNS
AU1095799A (en) 1997-10-17 1999-05-10 Philip L. Fuchs Folic acid derivatives
AU734476B2 (en) * 1997-11-05 2001-06-14 Baylor College Of Medicine Sequences for targeting metastatic cells
US6254890B1 (en) 1997-12-12 2001-07-03 Massachusetts Institute Of Technology Sub-100nm biodegradable polymer spheres capable of transporting and releasing nucleic acids
US6242246B1 (en) 1997-12-15 2001-06-05 Somalogic, Inc. Nucleic acid ligand diagnostic Biochip
US6506559B1 (en) * 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
IT1298087B1 (en) 1998-01-08 1999-12-20 Fiderm S R L DEVICE FOR CHECKING THE PENETRATION DEPTH OF A NEEDLE, IN PARTICULAR APPLICABLE TO A SYRINGE FOR INJECTIONS
US6686446B2 (en) * 1998-03-19 2004-02-03 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
US6506577B1 (en) * 1998-03-19 2003-01-14 The Regents Of The University Of California Synthesis and crosslinking of catechol containing copolypeptides
US6632922B1 (en) 1998-03-19 2003-10-14 The Regents Of The University Of California Methods and compositions for controlled polypeptide synthesis
WO1999055715A2 (en) 1998-04-28 1999-11-04 Galenica Pharmaceuticals, Inc. Polysaccharide-antigen conjugates
SE9801923D0 (en) 1998-05-29 1998-05-29 Independent Pharmaceutical Ab Nicotine vaccine
DE19827164A1 (en) * 1998-06-18 1999-12-23 Merck Patent Gmbh Catalytic titanium (IV) oxide mediated geminal symmetrical dialkylation of carboxamides
US6265608B1 (en) 1998-06-30 2001-07-24 Eastman Chemical Company Method of purifying aromatic dicarboxylic acids
US6395718B1 (en) 1998-07-06 2002-05-28 Guilford Pharmaceuticals Inc. Pharmaceutical compositions and methods of inhibiting angiogenesis using naaladase inhibitors
US6429200B1 (en) 1998-07-17 2002-08-06 Mirus Corporation Reverse micelles for delivery of nucleic acids
DE19839214C1 (en) 1998-08-28 2000-05-25 Aventis Res & Tech Gmbh & Co Process for the production of spherical microparticles with a smooth surface which consist wholly or partly of at least one water-insoluble linear polysaccharide, and microparticles obtainable by this process and their use
CN1325115C (en) 1998-10-05 2007-07-11 法麦克萨有限公司 Methods for therapeutic vaccination
AU6419899A (en) 1998-10-09 2000-05-01 Regents Of The University Of Michigan, The Hydrogels and water soluble polymeric carriers for drug delivery
US6428814B1 (en) 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US6232082B1 (en) 1998-12-01 2001-05-15 Nabi Hapten-carrier conjugates for treating and preventing nicotine addiction
US6403779B1 (en) 1999-01-08 2002-06-11 Isis Pharmaceuticals, Inc. Regioselective synthesis of 2′-O-modified nucleosides
PL349773A1 (en) 1999-01-08 2002-09-09 3M Innovative Properties Co Formulations comprising imiquimod or other immune response modifiers for treating mucosal conditions
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030054360A1 (en) * 1999-01-19 2003-03-20 Larry Gold Method and apparatus for the automated generation of nucleic acid ligands
DE19956568A1 (en) 1999-01-30 2000-08-17 Roland Kreutzer Method and medicament for inhibiting the expression of a given gene
JP2002536640A (en) 1999-02-03 2002-10-29 アクララ バイオサイエンシーズ， インコーポレイテッド Multi-channel control for microfluidic introduction
US6558951B1 (en) 1999-02-11 2003-05-06 3M Innovative Properties Company Maturation of dendritic cells with immune response modifying compounds
US6110462A (en) 1999-03-03 2000-08-29 The Scripps Research Institute Enzymatic DNA molecules that contain modified nucleotides
GB9905136D0 (en) 1999-03-06 1999-04-28 Danbiosyst Uk Surface modification of lamellar particles
ES2254167T3 (en) 1999-04-08 2006-06-16 The Johns Hopkins University SPECIFIC INDUCTION OF PERIPHERAL IMMUNOLOGICAL TOLERANCE ANTIGENS.
US6943235B1 (en) * 1999-04-12 2005-09-13 Agensys, Inc. Transmembrane protein expressed in prostate cancer
US6444782B1 (en) 1999-04-26 2002-09-03 Eastman Chemical Company Process for making pre-gels for a cross-linked branched polyester
US6528499B1 (en) * 2000-04-27 2003-03-04 Georgetown University Ligands for metabotropic glutamate receptors and inhibitors of NAALADase
US20020102613A1 (en) 1999-05-18 2002-08-01 Hoogenboom Hendricus Renerus Jacobus Mattheus Novel Fab fragment libraries and methods for their use
AU780474B2 (en) 1999-06-16 2005-03-24 Boston Biomedical Research Institute Incorporated Immunological control of beta-amyloid levels in vivo
US6506887B1 (en) 1999-07-29 2003-01-14 Somalogic, Incorporated Conditional-selex
DE60045201D1 (en) * 1999-08-12 2010-12-16 Agensys Inc C-type lectin transmembrane antigen expressed in human prostate cancer, and uses of this antigen
US20020009466A1 (en) * 1999-08-31 2002-01-24 David J. Brayden Oral vaccine compositions
US7429639B2 (en) 1999-09-29 2008-09-30 Ludwig Institute For Cancer Research SSX-2 peptides presented by HLA class II molecules
CA2321321A1 (en) 1999-09-30 2001-03-30 Isotis B.V. Polymers loaded with bioactive agents
US6790631B1 (en) 1999-10-05 2004-09-14 Agensys, Inc. G protein-coupled receptor up-regulated in prostate cancer and uses thereof
US7030228B1 (en) 1999-11-15 2006-04-18 Miltenyi Biotec Gmbh Antigen-binding fragments specific for dendritic cells, compositions and methods of use thereof antigens recognized thereby and cells obtained thereby
AU2463701A (en) 1999-12-29 2001-07-09 Nanodelivery, Inc. Drug delivery system exhibiting permeability control
WO2001051665A2 (en) 2000-01-13 2001-07-19 Nanosphere Inc. Nanoparticles having oligonucleotides attached thereto and uses therefor
US20050020525A1 (en) * 2002-02-20 2005-01-27 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
US8202979B2 (en) 2002-02-20 2012-06-19 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid
US20050032733A1 (en) * 2001-05-18 2005-02-10 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (SiNA)
US7534417B2 (en) 2000-02-24 2009-05-19 Agensys, Inc. 103P2D6: tissue specific protein highly expressed in various cancers
SE0000933D0 (en) 2000-03-21 2000-03-21 Independent Pharmaceutica Ab Method of producing 6-substituted (S) -nicotine derivatives and intermediate compounds
NZ522045A (en) 2000-03-30 2007-05-31 Whitehead Biomedical Inst RNA sequence-specific mediators of RNA interference
US7217770B2 (en) 2000-05-17 2007-05-15 Samyang Corporation Stable polymeric micelle-type drug composition and method for the preparation thereof
US6610713B2 (en) 2000-05-23 2003-08-26 North Shore - Long Island Jewish Research Institute Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US20020151004A1 (en) 2000-07-24 2002-10-17 Roger Craig Delivery vehicles and methods for using the same
US6838484B2 (en) * 2000-08-24 2005-01-04 University Of Tennessee Research Foundation Formulations comprising selective androgen receptor modulators
US20040260108A1 (en) 2001-06-25 2004-12-23 Dalton James T. Metabolites of selective androgen receptor modulators and methods of use thereof
US7026500B2 (en) * 2000-08-24 2006-04-11 University Of Tennessee Research Foundation Halogenated selective androgen receptor modulators and methods of use thereof
US20020173495A1 (en) 2000-08-24 2002-11-21 Dalton James T. Selective androgen receptor modulators and methods of use thereof
US20030232792A1 (en) 2000-08-24 2003-12-18 Dalton James T. Selective androgen receptor modulators and methods of use thereof
ES2321933T3 (en) 2000-08-24 2009-06-15 University Of Tennessee Research Foundation SELECTIVE MODULATORS OF THE ANDROGEN RECEIVER AND METHODS OF USE OF THE SAME.
US6998500B2 (en) * 2000-08-24 2006-02-14 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
US6503538B1 (en) 2000-08-30 2003-01-07 Cornell Research Foundation, Inc. Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US6376190B1 (en) 2000-09-22 2002-04-23 Somalogic, Inc. Modified SELEX processes without purified protein
US20040067196A1 (en) 2000-10-11 2004-04-08 Brunke Karen J. Targeted therapeutic lipid constructs
CA2425605A1 (en) 2000-10-16 2002-04-25 Gilead Sciences, Inc. Nucleic acid ligands to the prostate specific membrane antigen
US6589562B1 (en) 2000-10-25 2003-07-08 Salvona L.L.C. Multicomponent biodegradable bioadhesive controlled release system for oral care products
SI1407044T2 (en) 2000-12-01 2018-03-30 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Small RNA molecules that mediate RNA interference
US6623761B2 (en) 2000-12-22 2003-09-23 Hassan Emadeldin M. Method of making nanoparticles of substantially water insoluble materials
TWI246524B (en) 2001-01-19 2006-01-01 Shearwater Corp Multi-arm block copolymers as drug delivery vehicles
DE60214134T2 (en) 2001-02-07 2007-07-19 Beth Israel Deaconess Medical Center, Boston MODIFIED PSMA LIGANDS AND THEIR USE
US7097837B2 (en) 2001-02-19 2006-08-29 Pharmexa A/S Synthetic vaccine agents
US7326564B2 (en) 2001-02-20 2008-02-05 St. Jude Medical, Inc. Flow system for medical device evaluation and production
ES2234723T3 (en) 2001-03-22 2005-07-01 Cognis Iberia, S.L. NANOCAPSULES
WO2002076394A2 (en) 2001-03-22 2002-10-03 The Ohio State University Research Foundation Enzyme-based anti-cancer compositions and methods
WO2002076469A1 (en) 2001-03-27 2002-10-03 Baylor College Of Medicine A novel technology of intracellular delivery of dna oligonucleotides to improve drug activity
CA2747159A1 (en) 2001-05-07 2002-11-07 Queen's University At Kingston Biodegradable elastomer and method of preparing same
US20030175950A1 (en) 2001-05-29 2003-09-18 Mcswiggen James A. RNA interference mediated inhibition of HIV gene expression using short interfering RNA
EP2545937A1 (en) 2001-06-05 2013-01-16 The Regents Of The University Of Michigan Nanoemulsion vaccines
EP1264603B8 (en) 2001-06-10 2010-03-03 Noxxon Pharma AG Use of L-polynucleotides for in vivo imaging
US20030022868A1 (en) * 2001-06-25 2003-01-30 Dalton James T. Selective androgen receptor modulators and methods of use thereof
AU2775402A (en) * 2001-06-29 2003-01-02 Medimolecular Pty Ltd Nucleic acid ligands to complex targets
US7863014B2 (en) 2001-07-02 2011-01-04 Oriental Yeast Co., Ltd. Process for preparing nicotinamide adenine dinucleotide phosphate(NADP)
BR0103887C1 (en) 2001-07-17 2005-11-08 Univ Minas Gerais Immunogenic compositions containing biodegradable microspheres encapsulating antigens, gene vectors and adjuvants
EP1279404A1 (en) 2001-07-26 2003-01-29 Istituto Superiore di Sanità Use of HIV-1 tat, fragments or derivatives thereof, to target or to activate antigen-presenting cells, to deliver cargo molecules for vaccination or to treat other diseases
CA2456328C (en) 2001-08-07 2015-05-26 Dynavax Technologies Corporation Complexes of a short cpg-containing oligonucleotide bound to the surface of a solid phase microcarrier and methods for use thereof
ATE500315T1 (en) 2001-08-16 2011-03-15 Statoil Asa METHOD OF FERRYING
US20060004042A1 (en) * 2001-08-23 2006-01-05 Dalton James T Formulations comprising selective androgen receptor modulators
US6818732B2 (en) 2001-08-30 2004-11-16 The Regents Of The University Of California Transition metal initiators for controlled poly (beta-peptide) synthesis from beta-lactam monomers
DE60234375D1 (en) 2001-09-14 2009-12-24 Cytos Biotechnology Ag PACKAGING IMMUNSTIMULATING CpG IN VIRUS LIKE PARTICLES: PREPARATION METHOD AND USE
WO2003028657A2 (en) 2001-10-03 2003-04-10 The Johns Hopkins University Compositions for oral gene therapy and methods of using same
US20030134810A1 (en) 2001-10-09 2003-07-17 Chris Springate Methods and compositions comprising biocompatible materials useful for the administration of therapeutic agents
BRPI0213226B1 (en) 2001-10-10 2016-03-01 Pf Medicament process of preparing a pharmaceutical composition in the form of extended release microspheres of a water soluble active ingredient, and, microspheres
CN1303155C (en) 2001-10-18 2007-03-07 株式会社三养社 Polymeric michelle composition with improved stability
JP4425536B2 (en) 2001-10-30 2010-03-03 株式会社吉野工業所 Container, thermoforming apparatus and thermoforming method thereof
US6881746B2 (en) * 2001-12-03 2005-04-19 Novo Nordick A/S Glucagon antagonists/inverse agonists
AU2002363998A1 (en) 2001-12-15 2003-06-30 Spherics, Inc. Bioadhesive drug delivery system with enhanced gastric retention
US20030235619A1 (en) 2001-12-21 2003-12-25 Christine Allen Polymer-lipid delivery vehicles
US7148250B2 (en) 2001-12-28 2006-12-12 Guilford Pharmaceuticals Inc. Indoles as NAALADase inhibitors
US7408079B2 (en) * 2002-01-10 2008-08-05 The Johns Hopkins University Imaging agents and methods of imaging NAALADase or PSMA
US6720008B2 (en) 2002-01-22 2004-04-13 Pr Pharmaceuticals, Inc. Composition and method for the encapsulation of water-soluble molecules into nanoparticles
US8088388B2 (en) 2002-02-14 2012-01-03 United Biomedical, Inc. Stabilized synthetic immunogen delivery system
US20030232013A1 (en) 2002-02-22 2003-12-18 Gary Sieckman Therapeutic and diagnostic targeting of cancers cells with tumor homing peptides
CA2476769A1 (en) 2002-02-22 2003-09-04 Insert Therapeutics, Inc. Carbohydrate-modified polymers, compositions and uses related thereto
US7344700B2 (en) * 2002-02-28 2008-03-18 University Of Tennessee Research Corporation Radiolabeled selective androgen receptor modulators and their use in prostate cancer imaging and therapy
AU2003217303A1 (en) 2002-02-28 2003-09-16 University Of Tennessee Research Foundation Haloacetamide and azide substituted compounds and methods of use thereof
ES2528764T3 (en) 2002-02-28 2015-02-12 University Of Tennessee Research Foundation Multi-substituted selective androgen receptor modulators and methods of use thereof
US7803970B2 (en) * 2002-02-28 2010-09-28 University Of Tennessee Research Foundation Multi-substitued selective androgen receptor modulators and methods of use thereof
AU2003217912A1 (en) 2002-03-01 2003-09-16 Xencor Antibody optimization
US20030228603A1 (en) 2002-04-05 2003-12-11 Cload Sharon T. Compositions selective for caffeine or aspartame and methods of using same
US20060165987A1 (en) 2002-04-05 2006-07-27 Patrice Hildgen Stealthy polymeric biodegradable nanospheres and uses thereof
US7285289B2 (en) * 2002-04-12 2007-10-23 Nagy Jon O Nanoparticle vaccines
EP1499895B1 (en) 2002-04-22 2008-05-07 University Of Florida Functionalized nanoparticles and methods of use
JP2003342168A (en) * 2002-05-24 2003-12-03 Nano Career Kk Method for producing polymer micelle preparation containing drug for injection
US6819165B2 (en) 2002-05-30 2004-11-16 Analog Devices, Inc. Voltage regulator with dynamically boosted bias current
US20050214378A1 (en) 2002-06-11 2005-09-29 Ethypharm Stealth lipid nanocapsules, methods for the preparation thereof and use thereof as a carrier for active principle(s)
US7741371B2 (en) 2002-06-17 2010-06-22 University Of Tennessee Research Foundation Selective androgen receptor modulators and methods of use thereof
WO2003106401A1 (en) 2002-06-17 2003-12-24 University Of Tennessee Research Foundation N-bridged selective androgen receptor modulators and methods of use thereof
EP1552002A4 (en) * 2002-06-18 2006-02-08 Archemix Corp Aptamer-toxin molecules and methods for using same
US7767803B2 (en) * 2002-06-18 2010-08-03 Archemix Corp. Stabilized aptamers to PSMA and their use as prostate cancer therapeutics
US20040092470A1 (en) 2002-06-18 2004-05-13 Leonard Sherry A. Dry powder oligonucleotide formualtion, preparation and its uses
EP1523334A2 (en) 2002-07-18 2005-04-20 Cytos Biotechnology AG Hapten-carrier conjugates and uses thereof
WO2004032829A2 (en) 2002-08-15 2004-04-22 3M Innovative Properties Company Immunostimulatory compositions and methods of stimulating an immune response
US6875605B1 (en) 2002-08-21 2005-04-05 Florida State University Research Foundation, Inc. Modular cell culture bioreactor and associated methods
US7488792B2 (en) * 2002-08-28 2009-02-10 Burnham Institute For Medical Research Collagen-binding molecules that selectively home to tumor vasculature and methods of using same
EP1556506A1 (en) 2002-09-19 2005-07-27 The Chancellor, Masters And Scholars Of The University Of Oxford Molecular arrays and single molecule detection
US7008411B1 (en) * 2002-09-30 2006-03-07 Advanced Cardiovascular Systems, Inc. Method and apparatus for treating vulnerable plaque
AU2003287077B2 (en) 2002-10-15 2007-09-20 University Of Tennessee Research Foundation Methylene-bridged selective androgen receptor modulators and methods of use thereof
US20040087810A1 (en) * 2002-10-23 2004-05-06 Dalton James T. Irreversible selective androgen receptor modulators and methods of use thereof
EP1578419A4 (en) 2002-12-30 2008-11-12 3M Innovative Properties Co Immunostimulatory combinations
WO2004062612A2 (en) 2003-01-13 2004-07-29 Gtx Inc. Large-scale synthesis of selective androgen receptor modulators
US20040156846A1 (en) 2003-02-06 2004-08-12 Triton Biosystems, Inc. Therapy via targeted delivery of nanoscale particles using L6 antibodies
WO2004071459A2 (en) 2003-02-13 2004-08-26 3M Innovative Properties Company Methods and compositions related to irm compounds and toll-like receptor 8
US8575110B2 (en) 2003-02-17 2013-11-05 Alpha-O Peptides G Peptidic nanoparticles as drug delivery and antigen display systems
US20040167103A1 (en) 2003-02-24 2004-08-26 Dalton James T. Haloacetamide and azide substituted compounds and methods of use thereof
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US9028863B2 (en) 2003-04-25 2015-05-12 The Penn State Research Foundation Method and system for systemic delivery of growth arresting, lipid-derived bioactive compounds
US20050008572A1 (en) 2003-04-29 2005-01-13 Ales Prokop Nanoparticular tumor targeting and therapy
US7731967B2 (en) 2003-04-30 2010-06-08 Novartis Vaccines And Diagnostics, Inc. Compositions for inducing immune responses
WO2004103159A2 (en) 2003-05-14 2004-12-02 The Board Of Trustees Of The Leland Stanford Junior University Methods for modulating endometrium
GB0312309D0 (en) 2003-05-29 2003-07-02 Gaslini Children S Hospital G Targeted liposome
US20060239907A1 (en) 2003-06-03 2006-10-26 The Trustees Of The University Of Pennsylvania Stealthy nano agents
US7727969B2 (en) 2003-06-06 2010-06-01 Massachusetts Institute Of Technology Controlled release nanoparticle having bound oligonucleotide for targeted delivery
US7149574B2 (en) 2003-06-09 2006-12-12 Palo Alto Investors Treatment of conditions through electrical modulation of the autonomic nervous system
PL1635863T3 (en) 2003-06-17 2011-01-31 Mannkind Corp Compositions to elicit, enhance and sustain immune responses against mhc class i-restricted epitopes, for prophylactic or therapeutic purposes
US7336744B2 (en) * 2003-06-25 2008-02-26 Interdigital Technology Corporation Digital baseband receiver including a cross-talk compensation module for suppressing interference between real and imaginary signal component paths
WO2005012407A2 (en) 2003-06-30 2005-02-10 Canji, Inc. Polymer encapsulation of adenoviruses
US20050256071A1 (en) 2003-07-15 2005-11-17 California Institute Of Technology Inhibitor nucleic acids
AU2004257373B2 (en) 2003-07-16 2011-03-24 Arbutus Biopharma Corporation Lipid encapsulated interfering RNA
US7362068B2 (en) * 2003-07-23 2008-04-22 Asmo Co., Ltd. Closing member control system
CN1860363B (en) 2003-08-28 2011-12-28 赛路拉公司 Methods and apparatus for sorting cells using an optical switch in a microfluidic channel network
WO2005021730A2 (en) 2003-09-02 2005-03-10 University Of North Carolina At Chapel Hill Biodegradable polymer-ligand conjugates and their uses in isolation of cellular subpopulations and in cryopreservation, culture and transplantation of cells
JP5097400B2 (en) * 2003-09-03 2012-12-12 デンドリセラピューティクス、インク． Combined vaccine
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
US7744861B2 (en) 2003-09-17 2010-06-29 Nektar Therapeutics Multi-arm polymer prodrugs
CA2558916C (en) 2003-10-20 2009-09-22 William Marsh Rice University Method to fabricate microcapsules from polymers and charged nanoparticles
US8129506B2 (en) 2003-10-24 2012-03-06 Genzyme Corporation Modulation of the interaction of MUC1 with MUC1 ligands
EP1687663A4 (en) 2003-10-28 2010-03-31 Arryx Inc System and method for manipulating and processing materials using holographic optical trapping
WO2005055949A2 (en) 2003-12-09 2005-06-23 The Children's Hospital Of Philadelphia Sustained release preparations composed of biocompatible complex microparticles
KR101376715B1 (en) * 2003-12-19 2014-03-27 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
US7846412B2 (en) 2003-12-22 2010-12-07 Emory University Bioconjugated nanostructures, methods of fabrication thereof, and methods of use thereof
WO2005062977A2 (en) 2003-12-23 2005-07-14 The Regents Of The University Of California Prostate cancer specific internalizing human antibodies
WO2005065418A2 (en) 2003-12-31 2005-07-21 Board Of Regents, The University Of Texas System Compositions and methods of use of targeting peptides for diagnosis and therapy
US8957034B2 (en) 2004-01-28 2015-02-17 Johns Hopkins University Drugs and gene carrier particles that rapidly move through mucous barriers
US20070053845A1 (en) * 2004-03-02 2007-03-08 Shiladitya Sengupta Nanocell drug delivery system
WO2005110438A2 (en) 2004-04-15 2005-11-24 Massachusetts Institute Of Technology Methods and products related to the intracellular delivery of polysaccharides
US20050239134A1 (en) 2004-04-21 2005-10-27 Board Of Regents, The University Of Texas System Combinatorial selection of phosphorothioate single-stranded DNA aptamers for TGF-beta-1 protein
AU2005325262B2 (en) 2004-04-27 2011-08-11 Alnylam Pharmaceuticals, Inc. Single-stranded and double-stranded oligonucleotides comprising a 2-arylpropyl moiety
ES2246695B1 (en) 2004-04-29 2007-05-01 Instituto Cientifico Y Tecnologico De Navarra, S.A. STIMULATING COMPOSITION OF THE IMMUNE RESPONSE THAT INCLUDES NANOPARTICLES BASED ON A COPYLIMER OF METHYL VINYL ETER AND MALEIC ANHYDRIDE.
AU2005244851B2 (en) 2004-05-12 2010-08-26 Baxter Healthcare S.A. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US8821859B2 (en) 2004-05-19 2014-09-02 Agency For Science, Technology And Research Methods and articles for the delivery of therapeutic agents
CN100475837C (en) 2004-06-11 2009-04-08 北京键凯科技有限公司 Branched polyglycol-amino acid oligopeptide and active derivative and medicinal composition thereof
US20080124400A1 (en) 2004-06-24 2008-05-29 Angiotech International Ag Microparticles With High Loadings Of A Bioactive Agent
AU2005326322B2 (en) * 2004-07-01 2009-02-05 Yale University Targeted and high density drug loaded polymeric materials
US20060258628A1 (en) 2004-07-20 2006-11-16 Steiner Mitchell S Compositions comprising 5-alpha reductase inhibitors, and SARMs and methods of use thereof
AU2005267028A1 (en) * 2004-07-22 2006-02-02 Genentech, Inc. Method of treating Sjogren's syndrome
KR100604976B1 (en) 2004-09-03 2006-07-28 학교법인연세대학교 Water-soluble nanoparticles stabilized with multifunctional ligands
WO2005111192A1 (en) 2004-09-22 2005-11-24 Catchmabs Bv Bioreactor assembly comprising at least one tray-like rocking platform
AU2005291058B2 (en) 2004-10-01 2011-09-29 Midatech Limited Nanoparticles comprising antigens and adjuvants and immunogenic structure
US20090004118A1 (en) * 2004-10-07 2009-01-01 Shuming Nie Multifunctional Nanoparticle Conjugates And Their Use
WO2007001448A2 (en) 2004-11-04 2007-01-04 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
EP2332985A3 (en) 2004-11-12 2012-01-25 Xencor, Inc. Fc variants with altered binding to FcRn
US20060111271A1 (en) 2004-11-24 2006-05-25 Cerny Erich H Active and passive immunization against pharmacologically active hapten molecules using a synthetic carrier compound composed of similar elements
WO2006066158A2 (en) 2004-12-14 2006-06-22 Alnylam Pharmaceuticals, Inc. Rnai modulation of mll-af4 and uses thereof
WO2006090924A1 (en) 2005-02-28 2006-08-31 The University Of Tokyo Block copolymer having peptide ligand
WO2006093991A1 (en) 2005-03-02 2006-09-08 The Cleveland Clinic Foundation Compounds which bind psma and uses thereof
US20090105172A1 (en) 2005-03-07 2009-04-23 Diener John L Stabilized Aptamers to PSMA and Their Use as Prostate Cancer Therapeutics
US20090110633A1 (en) 2005-03-14 2009-04-30 Shiladitya Sengupta Nanocells for Diagnosis and Treatment of Diseases and Disorders
US7785612B2 (en) 2005-04-20 2010-08-31 Taiho Pharmaceutical Co., Ltd. Polyamino acid for use as adjuvant
KR101418367B1 (en) 2005-05-04 2014-07-25 녹손 파르마 아게 HMGA-Binding Nucleic acids
US8088908B2 (en) 2005-05-10 2012-01-03 City Of Hope Humanized anti-prostate stem cell antigen monoclonal antibody
WO2006133271A2 (en) 2005-06-06 2006-12-14 The General Hospital Corporation Compositions and methods relating to target-specific photodynamic therapy
WO2006138463A2 (en) 2005-06-17 2006-12-28 Nektar Therapeutics Al, Corporation Polymer-based compositions and conjugates of non-steroidal anti-inflammatory drugs
UA94412C2 (en) * 2005-07-11 2011-05-10 Уайет Glutamate aggrecanase inhibitors
AU2006280600B2 (en) 2005-08-17 2012-01-19 Bioneer Corporation Sirna-hydrophilic polymer conjugates for intracellular delivery of siRNA and method thereof
US20090156480A1 (en) 2005-08-25 2009-06-18 Mitsuru Akashi Biodegradable nanoparticle having t-cell recognizable epitope peptide immobilized thereon or encapsulated therein
JP2009508936A (en) 2005-09-20 2009-03-05 イッサム リサーチ ディベロップメント カンパニー Nanoparticles for targeted delivery of active agents
EP1951299B1 (en) 2005-11-04 2012-01-04 Novartis Vaccines and Diagnostics S.r.l. Influenza vaccines including combinations of particulate adjuvants and immunopotentiators
NZ569741A (en) 2005-12-14 2012-02-24 Cytos Biotechnology Ag Immunostimulatory nucleic acid packaged particles for the treatment of hypersensitivity
WO2007070682A2 (en) 2005-12-15 2007-06-21 Massachusetts Institute Of Technology System for screening particles
EP1971372B1 (en) 2005-12-19 2018-11-14 PharmaIN Corporation Hydrophobic core carrier compositions for delivery of therapeutic agents, methods of making and using the same
US20070233534A1 (en) 2006-01-06 2007-10-04 Marware Inc. Project management system and method
WO2007084797A1 (en) 2006-01-23 2007-07-26 Abbott Laboratories Chemically modified polycation polymer for sirna delivery
US8021689B2 (en) 2006-02-21 2011-09-20 Ecole Polytechnique Federale de Lausanne (“EPFL”) Nanoparticles for immunotherapy
US20100189657A1 (en) 2006-03-20 2010-07-29 The General Hospital Corporation Intramolecularly quenched fluorochrome conjugates and methods of use
US20070225213A1 (en) 2006-03-23 2007-09-27 Kosak Matthew K Nucleic acid carriers for delivery of therapeutic agents
ES2776100T3 (en) 2006-03-31 2020-07-29 Massachusetts Inst Technology System for targeted delivery of therapeutic agents
WO2008051291A2 (en) 2006-04-11 2008-05-02 Ordway Research Institute Nanoparticle and polymer formulations for thyroid hormone analogs, antagonists, and formulations thereof
US20100247653A1 (en) 2006-04-11 2010-09-30 Hans Lautenschlager Nanoparticles containing nicotine and/or cotinine, dispersions, and use thereof
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP2019691B1 (en) 2006-05-15 2020-08-12 Massachusetts Institute of Technology Polymers for functional particles
US20110052697A1 (en) * 2006-05-17 2011-03-03 Gwangju Institute Of Science & Technology Aptamer-Directed Drug Delivery
US9381477B2 (en) * 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US20090117549A1 (en) 2006-07-18 2009-05-07 Weihong Tan Aptamer-based methods for identifying cellular biomarkers
JP4936312B2 (en) 2006-07-20 2012-05-23 株式会社島津製作所 Novel amphiphile, drug delivery system and molecular imaging system using the same
US20100144845A1 (en) 2006-08-04 2010-06-10 Massachusetts Institute Of Technology Oligonucleotide systems for targeted intracellular delivery
WO2008019366A2 (en) 2006-08-07 2008-02-14 Ludwig Institute For Cancer Research Methods and compositions for increased priming of t-cells through cross-presentation of exogenous antigens
US20080057103A1 (en) * 2006-08-21 2008-03-06 Wouter Roorda Methods of using medical devices for controlled drug release
JPWO2008041703A1 (en) 2006-10-02 2010-02-04 国立大学法人大阪大学 Influenza vaccine and influenza vaccine
CA2702340C (en) 2006-10-12 2014-12-16 The University Of Queensland Compositions and methods for modulating immune responses
ES2684322T3 (en) 2006-11-08 2018-10-02 Molecular Insight Pharmaceuticals, Inc. Heterodimers of glutamic acid
US20100303723A1 (en) 2006-11-20 2010-12-02 Massachusetts Institute Of Technology Drug delivery systems using fc fragments
EP2099496A2 (en) 2006-12-08 2009-09-16 Massachusetts Institute of Technology Delivery of nanoparticles and/or agents to cells
US9217129B2 (en) 2007-02-09 2015-12-22 Massachusetts Institute Of Technology Oscillating cell culture bioreactor
US20090074828A1 (en) * 2007-04-04 2009-03-19 Massachusetts Institute Of Technology Poly(amino acid) targeting moieties
WO2008124634A1 (en) 2007-04-04 2008-10-16 Massachusetts Institute Of Technology Polymer-encapsulated reverse micelles
US20080311045A1 (en) 2007-06-06 2008-12-18 Biovaluation & Analysis, Inc. Polymersomes for Use in Acoustically Mediated Intracellular Drug Delivery in vivo
HUE034775T2 (en) * 2007-09-28 2018-02-28 Pfizer Cancer Cell Targeting Using Nanoparticles
CN101861165A (en) 2007-10-12 2010-10-13 麻省理工学院 Vaccine Nanotechnology
EP2235043A2 (en) 2008-02-01 2010-10-06 Alpha-O Peptides AG Self-assembling peptide nanoparticles useful as vaccines
EP2106806A1 (en) 2008-03-31 2009-10-07 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Nanoparticles for targeted delivery of active agents to the lung
US8318211B2 (en) 2008-06-16 2012-11-27 Bind Biosciences, Inc. Therapeutic polymeric nanoparticles comprising vinca alkaloids and methods of making and using same
HUE047004T2 (en) 2008-06-16 2020-04-28 Pfizer Drug loaded polymeric nanoparticles and methods of making and using same
WO2010005726A2 (en) 2008-06-16 2010-01-14 Bind Biosciences Inc. Therapeutic polymeric nanoparticles with mtor inhibitors and methods of making and using same
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US8277812B2 (en) 2008-10-12 2012-10-02 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IgG humoral response without T-cell antigen
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
WO2010068866A2 (en) 2008-12-12 2010-06-17 Bind Biosciences Therapeutic particles suitable for parenteral administration and methods of making and using same
WO2010075072A2 (en) 2008-12-15 2010-07-01 Bind Biosciences Long circulating nanoparticles for sustained release of therapeutic agents
WO2010114770A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-agent conjugates, particles, compositions, and related methods of use
WO2010114768A1 (en) 2009-03-30 2010-10-07 Cerulean Pharma Inc. Polymer-epothilone conjugates, particles, compositions, and related methods of use
EP2509634B1 (en) 2009-12-11 2019-03-06 Pfizer Inc Stable formulations for lyophilizing therapeutic particles

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050249799A1 (en) * 2004-03-03 2005-11-10 Spherics, Inc. Polymeric drug delivery system for hydrophobic drugs

Cited By (216)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9492400B2 (en) 2004-11-04 2016-11-15 Massachusetts Institute Of Technology Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
US9707252B2 (en) 2005-02-09 2017-07-18 Covidien Lp Synthetic sealants
US9039273B2 (en) 2005-03-04 2015-05-26 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
US10316873B2 (en) 2005-03-04 2019-06-11 President And Fellows Of Harvard College Method and apparatus for forming multiple emulsions
US8044234B2 (en) 2005-05-05 2011-10-25 Tyco Healthcare Group Lp Bioabsorbable surgical composition
US7998466B2 (en) 2005-12-06 2011-08-16 Tyco Healthcare Group Lp Biocompatible tissue sealants and adhesives
US7947263B2 (en) 2005-12-06 2011-05-24 Tyco Healthcare Group Lp Biocompatible surgical compositions
US7910129B2 (en) 2005-12-06 2011-03-22 Tyco Healthcare Group Lp Carbodiimide crosslinking of functionalized polyethylene glycols
EP1962867A4 (en) * 2005-12-06 2010-08-04 Tyco Healthcare Biocompatible surgical compositions
EP1962867A2 (en) * 2005-12-06 2008-09-03 Tyco Healthcare Group, LP Biocompatible surgical compositions
US8790488B2 (en) 2005-12-08 2014-07-29 Covidien Lp Biocompatible surgical compositions
US8449714B2 (en) 2005-12-08 2013-05-28 Covidien Lp Biocompatible surgical compositions
US9267937B2 (en) 2005-12-15 2016-02-23 Massachusetts Institute Of Technology System for screening particles
US8709483B2 (en) 2006-03-31 2014-04-29 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US8802153B2 (en) 2006-03-31 2014-08-12 Massachusetts Institute Of Technology System for targeted delivery of therapeutic agents
US9080014B2 (en) 2006-05-15 2015-07-14 Massachusetts Institute Of Technology Polymers for functional particles
US9688812B2 (en) 2006-05-15 2017-06-27 Massachusetts Institute Of Technology Polymers for functional particles
US9381477B2 (en) 2006-06-23 2016-07-05 Massachusetts Institute Of Technology Microfluidic synthesis of organic nanoparticles
US10941430B2 (en) 2007-03-07 2021-03-09 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9029085B2 (en) 2007-03-07 2015-05-12 President And Fellows Of Harvard College Assays and other reactions involving droplets
US10221437B2 (en) 2007-03-07 2019-03-05 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9850526B2 (en) 2007-03-07 2017-12-26 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9068210B2 (en) 2007-03-07 2015-06-30 President And Fellows Of Harvard College Assay and other reactions involving droplets
US10738337B2 (en) 2007-03-07 2020-08-11 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9816121B2 (en) 2007-03-07 2017-11-14 President And Fellows Of Harvard College Assays and other reactions involving droplets
US10683524B2 (en) 2007-03-07 2020-06-16 President And Fellows Of Harvard College Assays and other reactions involving droplets
US10508294B2 (en) 2007-03-07 2019-12-17 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9017948B2 (en) 2007-03-07 2015-04-28 President And Fellows Of Harvard College Assays and other reactions involving droplets
US9333179B2 (en) 2007-04-04 2016-05-10 Massachusetts Institute Of Technology Amphiphilic compound assisted nanoparticles for targeted delivery
US9526702B2 (en) 2007-10-12 2016-12-27 Massachusetts Institute Of Technology Vaccine nanotechnology
US9474717B2 (en) 2007-10-12 2016-10-25 Massachusetts Institute Of Technology Vaccine nanotechnology
US11547667B2 (en) 2007-10-12 2023-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US9539210B2 (en) 2007-10-12 2017-01-10 Massachusetts Institute Of Technology Vaccine nanotechnology
US10736848B2 (en) 2007-10-12 2020-08-11 Massachusetts Institute Of Technology Vaccine nanotechnology
US9797010B2 (en) 2007-12-21 2017-10-24 President And Fellows Of Harvard College Systems and methods for nucleic acid sequencing
US10633701B2 (en) 2007-12-21 2020-04-28 President And Fellows Of Harvard College Systems and methods for nucleic acid sequencing
US8263704B2 (en) 2008-04-23 2012-09-11 Tyco Healthcare Group Lp Bioabsorbable surgical composition
WO2009148598A1 (en) * 2008-06-05 2009-12-10 President And Fellows Of Harvard College Polymersomes, colloidosomes, liposomes, and other species associated with fluidic droplets
EP2308473A4 (en) * 2008-07-01 2013-01-09 Nitto Denko Corp Pharmaceutical composition containing surface-coated microparticles
EP2308473A1 (en) * 2008-07-01 2011-04-13 Nitto Denko Corporation Pharmaceutical composition containing surface-coated microparticles
US12116631B2 (en) 2008-09-19 2024-10-15 President And Fellows Of Harvard College Creation of libraries of droplets and related species
US11401550B2 (en) 2008-09-19 2022-08-02 President And Fellows Of Harvard College Creation of libraries of droplets and related species
US9233072B2 (en) 2008-10-12 2016-01-12 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8343497B2 (en) 2008-10-12 2013-01-01 The Brigham And Women's Hospital, Inc. Targeting of antigen presenting cells with immunonanotherapeutics
US8637028B2 (en) 2008-10-12 2014-01-28 President And Fellows Of Harvard College Adjuvant incorporation in immunonanotherapeutics
US8932595B2 (en) 2008-10-12 2015-01-13 Massachusetts Institute Of Technology Nicotine immunonanotherapeutics
US9439859B2 (en) 2008-10-12 2016-09-13 Massachusetts Institute Of Technology Adjuvant incorporation in immunoanotherapeutics
US8343498B2 (en) 2008-10-12 2013-01-01 Massachusetts Institute Of Technology Adjuvant incorporation in immunonanotherapeutics
US8906381B2 (en) 2008-10-12 2014-12-09 Massachusetts Institute Of Technology Immunonanotherapeutics that provide IGG humoral response without T-cell antigen
US8591905B2 (en) 2008-10-12 2013-11-26 The Brigham And Women's Hospital, Inc. Nicotine immunonanotherapeutics
US9308280B2 (en) 2008-10-12 2016-04-12 Massachusetts Institute Of Technology Targeting of antigen presenting cells with immunonanotherapeutics
US8562998B2 (en) 2008-10-12 2013-10-22 President And Fellows Of Harvard College Targeting of antigen presenting cells with immunonanotherapeutics
US10457977B2 (en) 2008-12-19 2019-10-29 President And Fellows Of Harvard College Particle-assisted nucleic acid sequencing
US8748094B2 (en) 2008-12-19 2014-06-10 President And Fellows Of Harvard College Particle-assisted nucleic acid sequencing
US9884112B2 (en) 2009-05-27 2018-02-06 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US9006254B2 (en) 2009-05-27 2015-04-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
US8629151B2 (en) 2009-05-27 2014-01-14 Selecta Biosciences, Inc. Immunomodulatory agent-polymeric compounds
CN107121554A (en) * 2009-09-02 2017-09-01 新泽西鲁特格斯州立大学 Treat the composition and method of neurogenic pain
US10874997B2 (en) 2009-09-02 2020-12-29 President And Fellows Of Harvard College Multiple emulsions created using jetting and other techniques
US11000849B2 (en) 2009-10-27 2021-05-11 President And Fellows Of Harvard College Droplet creation techniques
US12121898B2 (en) 2009-10-27 2024-10-22 President And Fellows Of Harvard College Droplet creation techniques
US9056289B2 (en) 2009-10-27 2015-06-16 President And Fellows Of Harvard College Droplet creation techniques
US9839911B2 (en) 2009-10-27 2017-12-12 President And Fellows Of Harvard College Droplet creation techniques
US9066978B2 (en) 2010-05-26 2015-06-30 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9764031B2 (en) 2010-05-26 2017-09-19 Selecta Biosciences, Inc. Dose selection of adjuvanted synthetic nanocarriers
US9994443B2 (en) 2010-11-05 2018-06-12 Selecta Biosciences, Inc. Modified nicotinic compounds and related methods
US10190115B2 (en) 2011-04-25 2019-01-29 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US11939573B2 (en) 2011-04-25 2024-03-26 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
EP3395957A1 (en) * 2011-04-25 2018-10-31 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US10760073B2 (en) 2011-04-25 2020-09-01 Bio-Rad Laboratories, Inc. Methods and compositions for nucleic acid analysis
US11717569B2 (en) 2011-04-29 2023-08-08 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
US10420835B2 (en) 2011-04-29 2019-09-24 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US9295718B2 (en) 2011-04-29 2016-03-29 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce immune responses to therapeutic proteins
US9289476B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US9987354B2 (en) 2011-04-29 2018-06-05 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for antigen-specific deletion of T effector cells
US9289477B2 (en) 2011-04-29 2016-03-22 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers to reduce cytotoxic T lymphocyte responses
US9993548B2 (en) 2011-04-29 2018-06-12 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for inducing regulatory B cells
US10004802B2 (en) 2011-04-29 2018-06-26 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
US8652487B2 (en) 2011-04-29 2014-02-18 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for inducing regulatory B cells
US9265815B2 (en) 2011-04-29 2016-02-23 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers
US10039822B2 (en) 2011-04-29 2018-08-07 Selecta Biosciences, Inc. Method for providing polymeric synthetic nanocarriers for generating antigen-specific tolerance immune responses
US11779641B2 (en) 2011-04-29 2023-10-10 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for allergy therapy
US10441651B2 (en) 2011-04-29 2019-10-15 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for generating CD8+ regulatory T cells
US9238206B2 (en) 2011-05-23 2016-01-19 President And Fellows Of Harvard College Control of emulsions, including multiple emulsions
US9573099B2 (en) 2011-05-23 2017-02-21 President And Fellows Of Harvard College Control of emulsions, including multiple emulsions
US10195571B2 (en) 2011-07-06 2019-02-05 President And Fellows Of Harvard College Multiple emulsions and techniques for the formation of multiple emulsions
US10933129B2 (en) 2011-07-29 2021-03-02 Selecta Biosciences, Inc. Methods for administering synthetic nanocarriers that generate humoral and cytotoxic T lymphocyte responses
WO2013124867A1 (en) * 2012-02-21 2013-08-29 Amrita Vishwa Vidyapeetham University Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules
US11021749B2 (en) 2012-08-14 2021-06-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10669583B2 (en) 2012-08-14 2020-06-02 10X Genomics, Inc. Method and systems for processing polynucleotides
US10752950B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10752949B2 (en) 2012-08-14 2020-08-25 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9695468B2 (en) 2012-08-14 2017-07-04 10X Genomics, Inc. Methods for droplet-based sample preparation
US10221442B2 (en) 2012-08-14 2019-03-05 10X Genomics, Inc. Compositions and methods for sample processing
US11035002B2 (en) 2012-08-14 2021-06-15 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11078522B2 (en) 2012-08-14 2021-08-03 10X Genomics, Inc. Capsule array devices and methods of use
US11359239B2 (en) 2012-08-14 2022-06-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10626458B2 (en) 2012-08-14 2020-04-21 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9689024B2 (en) 2012-08-14 2017-06-27 10X Genomics, Inc. Methods for droplet-based sample preparation
US10273541B2 (en) 2012-08-14 2019-04-30 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10597718B2 (en) 2012-08-14 2020-03-24 10X Genomics, Inc. Methods and systems for sample processing polynucleotides
US10584381B2 (en) 2012-08-14 2020-03-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11441179B2 (en) 2012-08-14 2022-09-13 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323279B2 (en) 2012-08-14 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12098423B2 (en) 2012-08-14 2024-09-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12037634B2 (en) 2012-08-14 2024-07-16 10X Genomics, Inc. Capsule array devices and methods of use
US11591637B2 (en) 2012-08-14 2023-02-28 10X Genomics, Inc. Compositions and methods for sample processing
US10450607B2 (en) 2012-08-14 2019-10-22 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10053723B2 (en) 2012-08-14 2018-08-21 10X Genomics, Inc. Capsule array devices and methods of use
US10400280B2 (en) 2012-08-14 2019-09-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11473138B2 (en) 2012-12-14 2022-10-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9856530B2 (en) 2012-12-14 2018-01-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9410201B2 (en) 2012-12-14 2016-08-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10676789B2 (en) 2012-12-14 2020-06-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9701998B2 (en) 2012-12-14 2017-07-11 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9567631B2 (en) 2012-12-14 2017-02-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10533221B2 (en) 2012-12-14 2020-01-14 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10227648B2 (en) 2012-12-14 2019-03-12 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10253364B2 (en) 2012-12-14 2019-04-09 10X Genomics, Inc. Method and systems for processing polynucleotides
US10612090B2 (en) 2012-12-14 2020-04-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11421274B2 (en) 2012-12-14 2022-08-23 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10150964B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US9388465B2 (en) 2013-02-08 2016-07-12 10X Genomics, Inc. Polynucleotide barcode generation
US9644204B2 (en) 2013-02-08 2017-05-09 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10150963B2 (en) 2013-02-08 2018-12-11 10X Genomics, Inc. Partitioning and processing of analytes and other species
US11193121B2 (en) 2013-02-08 2021-12-07 10X Genomics, Inc. Partitioning and processing of analytes and other species
US10143700B2 (en) 2013-02-19 2018-12-04 Amrita Vishwa Vidyapeetham Nanoparticle formulations for delivering multiple therapeutic agents
US10835549B2 (en) 2013-04-11 2020-11-17 Vanderbilt University Polyplexes
WO2014169256A3 (en) * 2013-04-11 2014-12-11 Vanderbilt University Polyplexes
US12249402B2 (en) 2013-08-30 2025-03-11 10X Genomics, Inc. Sequencing methods
US10395758B2 (en) 2013-08-30 2019-08-27 10X Genomics, Inc. Sequencing methods
US12131805B2 (en) 2013-08-30 2024-10-29 10X Genomics, Inc. Sequencing methods
US10471016B2 (en) 2013-11-08 2019-11-12 President And Fellows Of Harvard College Microparticles, methods for their preparation and use
US10765755B1 (en) * 2013-11-20 2020-09-08 University Of South Florida Preparation and characterization of methylene blue nanoparticles for Alzheimer's disease and other tauopathies
US11541017B2 (en) 2013-12-16 2023-01-03 Massachusetts Institute Of Technology Fortified micronutrient salt formulations
US10300136B2 (en) 2013-12-16 2019-05-28 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
US10960073B2 (en) 2013-12-16 2021-03-30 Tokitae Llc Micromolded or 3-D printed pulsatile release vaccine formulations
US11975069B2 (en) 2013-12-16 2024-05-07 Massachusetts Institute Of Technology Micromolded or 3-D printed pulsatile release vaccine formulations
US9824068B2 (en) 2013-12-16 2017-11-21 10X Genomics, Inc. Methods and apparatus for sorting data
US10137449B2 (en) 2014-04-10 2018-11-27 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9694361B2 (en) 2014-04-10 2017-07-04 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10150117B2 (en) 2014-04-10 2018-12-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US12005454B2 (en) 2014-04-10 2024-06-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10343166B2 (en) 2014-04-10 2019-07-09 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US10071377B2 (en) 2014-04-10 2018-09-11 10X Genomics, Inc. Fluidic devices, systems, and methods for encapsulating and partitioning reagents, and applications of same
US9737614B2 (en) 2014-04-17 2017-08-22 Memorial Sloan Kettering Cancer Center Fucoidan nanogels and methods of their use and manufacture
US10030267B2 (en) 2014-06-26 2018-07-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US9951386B2 (en) 2014-06-26 2018-04-24 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10208343B2 (en) 2014-06-26 2019-02-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10839939B2 (en) 2014-06-26 2020-11-17 10X Genomics, Inc. Processes and systems for nucleic acid sequence assembly
US12163191B2 (en) 2014-06-26 2024-12-10 10X Genomics, Inc. Analysis of nucleic acid sequences
US11133084B2 (en) 2014-06-26 2021-09-28 10X Genomics, Inc. Systems and methods for nucleic acid sequence assembly
US10480028B2 (en) 2014-06-26 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11713457B2 (en) 2014-06-26 2023-08-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10041116B2 (en) 2014-06-26 2018-08-07 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10337061B2 (en) 2014-06-26 2019-07-02 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10344329B2 (en) 2014-06-26 2019-07-09 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11629344B2 (en) 2014-06-26 2023-04-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10760124B2 (en) 2014-06-26 2020-09-01 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10457986B2 (en) 2014-06-26 2019-10-29 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11739368B2 (en) 2014-10-29 2023-08-29 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US10287623B2 (en) 2014-10-29 2019-05-14 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequencing
US11135584B2 (en) 2014-11-05 2021-10-05 10X Genomics, Inc. Instrument systems for integrated sample processing
US10245587B2 (en) 2014-11-05 2019-04-02 10X Genomics, Inc. Instrument systems for integrated sample processing
US9975122B2 (en) 2014-11-05 2018-05-22 10X Genomics, Inc. Instrument systems for integrated sample processing
US10557158B2 (en) 2015-01-12 2020-02-11 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US11414688B2 (en) 2015-01-12 2022-08-16 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10221436B2 (en) 2015-01-12 2019-03-05 10X Genomics, Inc. Processes and systems for preparation of nucleic acid sequencing libraries and libraries prepared using same
US10650912B2 (en) 2015-01-13 2020-05-12 10X Genomics, Inc. Systems and methods for visualizing structural variation and phasing information
US10854315B2 (en) 2015-02-09 2020-12-01 10X Genomics, Inc. Systems and methods for determining structural variation and phasing using variant call data
US10697000B2 (en) 2015-02-24 2020-06-30 10X Genomics, Inc. Partition processing methods and systems
US11274343B2 (en) 2015-02-24 2022-03-15 10X Genomics, Inc. Methods and compositions for targeted nucleic acid sequence coverage
US11603554B2 (en) 2015-02-24 2023-03-14 10X Genomics, Inc. Partition processing methods and systems
WO2016153920A1 (en) * 2015-03-20 2016-09-29 Memorial Sloan Kettering Cancer Center Mesoscale nanoparticles for selective targeting to the kidney and methods of their therapeutic use
US11173152B1 (en) 2015-05-20 2021-11-16 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
US10758520B1 (en) 2015-05-20 2020-09-01 University Of South Florida Glutathione-coated nanoparticles for delivery of MKT-077 across the blood-brain barrier
US10874622B2 (en) 2015-06-24 2020-12-29 Board Of Regents, The University Of Texas System Dual assembly nanoparticles
US11123297B2 (en) 2015-10-13 2021-09-21 President And Fellows Of Harvard College Systems and methods for making and using gel microspheres
US11473125B2 (en) 2015-12-04 2022-10-18 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US10774370B2 (en) 2015-12-04 2020-09-15 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11873528B2 (en) 2015-12-04 2024-01-16 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11624085B2 (en) 2015-12-04 2023-04-11 10X Genomics, Inc. Methods and compositions for nucleic acid analysis
US11081208B2 (en) 2016-02-11 2021-08-03 10X Genomics, Inc. Systems, methods, and media for de novo assembly of whole genome sequence data
US12138628B2 (en) 2016-05-13 2024-11-12 10X Genomics, Inc. Microfluidic systems and methods of use
US11084036B2 (en) 2016-05-13 2021-08-10 10X Genomics, Inc. Microfluidic systems and methods of use
US10011872B1 (en) 2016-12-22 2018-07-03 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10793905B2 (en) 2016-12-22 2020-10-06 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10550429B2 (en) 2016-12-22 2020-02-04 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10480029B2 (en) 2016-12-22 2019-11-19 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10815525B2 (en) 2016-12-22 2020-10-27 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10858702B2 (en) 2016-12-22 2020-12-08 10X Genomics, Inc. Methods and systems for processing polynucleotides
US10323278B2 (en) 2016-12-22 2019-06-18 10X Genomics, Inc. Methods and systems for processing polynucleotides
US12084716B2 (en) 2016-12-22 2024-09-10 10X Genomics, Inc. Methods and systems for processing polynucleotides
US11180805B2 (en) 2016-12-22 2021-11-23 10X Genomics, Inc Methods and systems for processing polynucleotides
US11193122B2 (en) 2017-01-30 2021-12-07 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US12264411B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for analysis
US12264316B2 (en) 2017-01-30 2025-04-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US10428326B2 (en) 2017-01-30 2019-10-01 10X Genomics, Inc. Methods and systems for droplet-based single cell barcoding
US11898206B2 (en) 2017-05-19 2024-02-13 10X Genomics, Inc. Systems and methods for clonotype screening
US10844372B2 (en) 2017-05-26 2020-11-24 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10927370B2 (en) 2017-05-26 2021-02-23 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11773389B2 (en) 2017-05-26 2023-10-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11198866B2 (en) 2017-05-26 2021-12-14 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US10400235B2 (en) 2017-05-26 2019-09-03 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
US11155810B2 (en) 2017-05-26 2021-10-26 10X Genomics, Inc. Single cell analysis of transposase accessible chromatin
CN107582527A (en) * 2017-10-10 2018-01-16 雷笑天 A kind of enteral administration bioadhesive microspheres preparation and preparation method thereof
US11884962B2 (en) 2017-11-15 2024-01-30 10X Genomics, Inc. Functionalized gel beads
US10745742B2 (en) 2017-11-15 2020-08-18 10X Genomics, Inc. Functionalized gel beads
US10876147B2 (en) 2017-11-15 2020-12-29 10X Genomics, Inc. Functionalized gel beads
US10829815B2 (en) 2017-11-17 2020-11-10 10X Genomics, Inc. Methods and systems for associating physical and genetic properties of biological particles
US11155881B2 (en) 2018-04-06 2021-10-26 10X Genomics, Inc. Systems and methods for quality control in single cell processing
WO2020028909A1 (en) * 2018-08-03 2020-02-06 Brown University Oral formulations with increased uptake
CN110964204A (en) * 2018-09-29 2020-04-07 南方医科大学 PLGA microspheres of charge-loaded positive micelle/insulin compound and preparation method thereof
CN110964204B (en) * 2018-09-29 2021-03-12 南方医科大学 PLGA microspheres of charge-loaded positive micelle/insulin compound and preparation method thereof
US20230126744A1 (en) * 2021-10-25 2023-04-27 The Secant Group, Llc. Polymeric delivery systems
US20230125499A1 (en) * 2021-10-25 2023-04-27 The Secant Group, Llc Polymeric delivery systems

Also Published As

Publication number Publication date
US20170112776A1 (en) 2017-04-27
US9492400B2 (en) 2016-11-15
WO2007001448A3 (en) 2009-04-23
US20080268063A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US9492400B2 (en) Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals
JP5384831B2 (en) Nanoparticles for protein drug delivery
Dailey et al. The role of branched polyesters and their modifications in the development of modern drug delivery vehicles
US20200078304A1 (en) Compositions and methods relating to reduced mucoadhesion
Bala et al. PLGA nanoparticles in drug delivery: the state of the art
US6706289B2 (en) Methods and compositions for enhanced delivery of bioactive molecules
Uhrich et al. Polymeric systems for controlled drug release
US7550441B2 (en) Controlled release polymer nanoparticle containing bound nucleic acid ligand for targeting
US6221397B1 (en) Surface cross-linked particles suitable for controlled delivery
EP2308473A1 (en) Pharmaceutical composition containing surface-coated microparticles
CN102970864A (en) A pharmaceutical composition of nanoparticles
AU2002220002A1 (en) Methods and compositions for enhanced delivery of bioactive molecules
CN102014880A (en) Therapeutic calcium phosphate particles and methods of making and using same
Vaidya et al. Bioconjugation of polymers: a novel platform for targeted drug delivery
US8449915B1 (en) Pharmaceutical composition of nanoparticles
CN103656653A (en) Polyelectrolyte compound based on hyaluronic acid drug-loading nano particles, preparation method and application thereof
Davis Drug delivery systems
CN112469397B (en) Nanoparticles comprising bioresorbable polyester, hydrophilic polymer and acylated human lactoferrin derived peptide
WO2006105367A2 (en) Magnetically-labeled microparticles for oral drug delivery
Jain et al. Particulate systems of PLA and its copolymers
Agnihotri et al. Protein and peptide delivery through chitin, chitosan, and starch
Sarmento et al. Polymer-based delivery systems for oral delivery of peptides and proteins
Bhayana et al. Block Co-polymers: Vital Aspects and Applications in Drug Delivery
Maher et al. 2.1 Nanostructures overcoming the intestinal barrier: Physiological considerations and mechanistic issues

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05858302

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 11666908

Country of ref document: US

OSZAR »